

# Cellular Stress Responses, The Hormesis Paradigm, and Vitagenes: Novel Targets for Therapeutic Intervention in Neurodegenerative Disorders

Vittorio Calabrese,<sup>1</sup> Carolin Cornelius,<sup>1</sup> Alben T. Dinkova-Kostova,<sup>2,3</sup>  
Edward J. Calabrese,<sup>4</sup> and Mark P. Mattson<sup>5</sup>

## Abstract

Despite the capacity of chaperones and other homeostatic components to restore folding equilibrium, cells appear poorly adapted for chronic oxidative stress that increases in cancer and in metabolic and neurodegenerative diseases. Modulation of endogenous cellular defense mechanisms represents an innovative approach to therapeutic intervention in diseases causing chronic tissue damage, such as in neurodegeneration. This article introduces the concept of hormesis and its applications to the field of neuroprotection. It is argued that the hormetic dose response provides the central underpinning of neuroprotective responses, providing a framework for explaining the common quantitative features of their dose–response relationships, their mechanistic foundations, and their relationship to the concept of biological plasticity, as well as providing a key insight for improving the accuracy of the therapeutic dose of pharmaceutical agents within the highly heterogeneous human population. This article describes in mechanistic detail how hormetic dose responses are mediated for endogenous cellular defense pathways, including sirtuin and Nrf2 and related pathways that integrate adaptive stress responses in the prevention of neurodegenerative diseases. Particular attention is given to the emerging role of nitric oxide, carbon monoxide, and hydrogen sulfide gases in hormetic-based neuroprotection and their relationship to membrane radical dynamics and mitochondrial redox signaling. *Antioxid. Redox Signal.* 13, 1763–1811.

---

I. Introduction	1764
II. Hormesis	1764
III. Membrane Radical Dynamics	1766
IV. Lipid Peroxidation and Sphingomyelin Metabolism	1767
V. Plasma Membrane Redox System	1767
VI. Membrane-Related Hormesis Mechanisms	1768
VII. Mitochondria: A Hub of Cellular Redox Processes	1768
VIII. Hormesis, Mitochondria, and Neuroprotection	1769
IX. Proteotoxicity, Cellular Stress Response, and the Vitagene Network	1769
X. Sirtuins and the Integration of Adaptive Stress Responses in Neurons	1772
XI. The Kelch-Like ECH-Associated Protein 1/Nrf2/Antioxidant Response Element Pathway	1774
XII. Hormetic Phytochemicals and the Neuroprotective Effects of Pharmacological Activators of the Keap1/Nrf2/ARE Pathway	1779
A. Tert-butylhydroquinone	1779

---

Reviewing Editors: Narayan Bhat, Jin-Song Bian, Susan Browne, Enrique Cadenas, Paola Chiarugi, Jeffrey Keller, Daniel Linseman, Pamela Maher, Mark Smith, Russell Swerdlow, and Bobby Thomas

---

<sup>1</sup>Department of Chemistry, University of Catania, Catania, Italy.

<sup>2</sup>The Biomedical Research Institute, University of Dundee, Scotland, United Kingdom.

<sup>3</sup>Division of Clinical Pharmacology, Departments of Medicine and Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

<sup>4</sup>Environmental Health Sciences Division, School of Public Health, University of Massachusetts, Amherst, Massachusetts.

<sup>5</sup>National Institute on Aging Intramural Research Program, Baltimore, Maryland.

B. Sulforaphane	1780
C. Dimethyl fumarate	1781
D. Diallyl trisulfide	1781
E. Celastrol	1781
F. Curcumin	1781
G. Ferulic acid	1782
XIII. Heme Oxygenases	1782
XIV. Adaptive ER Stress Responses: Calcium and Protein Chaperones	1784
XV. Hsps and Neuroprotection	1786
A. Neuroprotective effects of extracellular Hsps	1788
XVI. Neuro Gas Biology and the Roles of CO, NO, and Hydrogen Sulfide in Brain Physiopathology	1788
A. Carbon monoxide	1788
B. NO and NO synthases	1792
C. Hydrogen sulfide	1793
D. H <sub>2</sub> S and suspended animation	1794
E. Functional interrelation of NO, CO, and H <sub>2</sub> S gases and their relevance to hormesis	1794
XVII. Future Directions	1796

## I. Introduction


THE ADAPTATION AND SURVIVAL of cells and organisms requires the ability to sense proteotoxic insults and to coordinate protective cellular stress response pathways and chaperone networks related to protein quality control (310). The toxic effects that stem from the misassembly or aggregation of proteins or peptides, in any cell type, are collectively termed proteotoxicity, whereas neurotoxicity is a term that refers to general toxic effects observed in neurons. To understand the relevance of proteotoxicity to neurotoxicity and to neurodegeneration is important, a comprehensive understanding of the mechanisms that lead to the development of neurodegenerative diseases. To date, these mechanisms are poorly understood; however, it is clear that protein aggregation is tightly linked to the emergence and development of neurodegenerative diseases. Molecular chaperones are known to disrupt aggregates and this represents the basis of the therapeutic potential of heat shock proteins (Hsps), which prevent protein misfolding and aggregation. However, despite the abundance and apparent capacity of chaperones and other components of homeostasis to restore folding equilibrium, the cell appears poorly adapted for chronic proteotoxic stress that increases in cancer and in metabolic and neurodegenerative diseases (311). In these conditions, a decline in biosynthetic and repair activities that compromises the integrity of the proteome is strongly influenced by protective genes called vitagenes that control aging, thus linking stress and protein homeostasis with the health and life span of the organism (99, 100). The disruption of protein folding quality control results in the accumulation of a nonnative protein species that can form oligomers, aggregates, and inclusions indicative of neurodegenerative disease (312). Pharmacological modulation of cellular stress response pathways has emerging implications for the treatment of human diseases, including neurodegenerative disorders, cardiovascular disease, and cancer (102).

A critical key to successful medical intervention is getting the dose right. Achieving this goal can be extremely challenging due to human interindividual variation as affected by age, gender, diet, exercise, genetic factors, and health status. Getting the dose right can also be affected by exposure to other drugs as well as factors such as circadian rhythms. For in-

stance, it has been shown that exercise promotes longevity and ameliorates type 2 diabetes mellitus and insulin resistance. However, exercise also increases mitochondrial formation of presumably harmful reactive oxygen species (ROS). Consistent with the concept of mitohormesis, exercise-induced oxidative stress ameliorates insulin resistance and causes an adaptive response promoting endogenous antioxidant defense capacity. Importantly, recent finding indicates that supplementation with antioxidants may preclude these health-promoting effects of exercise in humans (372). Another issue that can affect clinical success is the nature of the dose response in and adjacent to the therapeutic zone (58, 60). Over the past decade considerable advances have been made in the understanding of the nature of the dose response, especially in the low-dose zone (88, 116, 204, 280, 291, 292, 398). These findings challenge previous concepts of the dose response, suggesting that the commonly accepted threshold and linear dose-response models upon which society has based its toxicological and pharmacological predications for drug and chemical effects often fail to provide reliable estimates of responses in the low-dose zone, that is, below the threshold (55, 61, 69–71, 90, 91). Failure to accurately predict the effects of drugs and chemicals can lead to failed clinical trials, inadequate patient care, and potentially harmful governmental regulations (40, 73, 135, 143). While traditional dose-response models have failed to accurately predict responses in the low-dose zone in large-scale studies, the hormetic dose response performed extremely well, lending considerable support to other studies (56, 57, 65, 66, 73–86, 92) that have suggested that the process of drug development and chemical hazard/risk assessment could be improved in significant ways by a consideration of the hormetic dose response in the design, execution, and analysis of toxicological and pharmacological investigations. Consequently, this article will introduce the hormetic dose-response concept, including its scientific foundations, toxicological and pharmacological implications, and its applications to the field of neuroprotection and their mechanistic foundations.

## II. Hormesis

Hormesis is a dose-response phenomenon characterized by a low-dose stimulation and a high-dose inhibition (Fig. 1).



**FIG. 1.** Dose–response curve depicting the quantitative features of hormesis. NOAEL, No Observed Adverse Effect Level; ZEP, zero equivalent point.

It may be graphically represented by either an inverted U-shaped dose response or by a J- or U-shaped dose response. The term hormesis was first presented in the published literature in 1943 by Southam and Ehrlich, who reported that low doses of extracts from the red cedar tree enhanced the proliferation of fungi with the overall shape of the dose response being biphasic. However, credit for experimentally demonstrating the occurrence of hormesis goes to Hugo Schulz (396), who reported biphasic dose responses in yeast after exposure to a large number of toxic agents. The work of Schulz inspired a large number of investigators in diverse fields to assess whether such low-dose effects may be a general feature of biological systems. In fact, similar types of dose–response observations were subsequently reported by numerous researchers assessing chemicals (49) and radiation (41, 50–53, 246, 307, 313, 367, 381, 397, 431, 432) with investigators adopting different names such as the Arndt-Schulz Law, Huppe’s Rule, and other terms to describe these similar dose–response phenomena (368). Despite the rather substantial historical literature concerning hormetic dose responses, this concept had a difficult time being incorporated into routine safety assessment and pharmacological investigations, principally because it (a) required more rigorous evaluation in the low-dose zone, (b) failure of investigators to understand its clinical significance, (c) failure to appreciate the quantitative features of the hormetic dose response, (d) failure to understand the limitations of its implications for commercial applications in agriculture as well as medicine, (e) because of the predominant interest in responses at relatively high doses during most of the 20th century, and (f) the continuing, yet inappropriate, tendency to associate the concept of hormesis with the medical practice of homeopathy (64, 89, 91). However, from the late 1970s (423, 433) there has been a growing interest in hormetic-like biphasic dose responses across the broad spectrum of biomedical sciences. This resurgence of interest resulted from a variety of factors, including the capacity to measure progressively lower doses of drugs and chemicals, the adoption of cell culture methods, which has permitted more efficient testing of numerous doses and the need to reexamine the validity of linearity at low-dose modeling of cancer risks due to their enormous cost implications for regulations (379), as well the astute observations of independent investigators and their capacity to generalize their findings across biological systems (267, 423).

What has emerged from these research initiatives from highly diverse biomedical areas is the recognition that hormetic dose responses were common and highly generalizable, being independent of biological model, endpoints measured, and chemical class and/or physical agent studied (50–54, 68, 306, 448). This was an unexpected finding as hormetic responses were often considered by many in the so-called mainstream branches of toxicology and pharmacology to be paradoxical, not commonly expected and being of questionable reliability with a lack of capacity for replication. The casual dismissal of the hormesis concept during the mid decades of the last century is reflected in the general absence of the hormesis concept from the leading toxicological and biomedical textbooks. This situation has radically changed such that hormesis is now incorporated into all leading textbooks of toxicology (e.g., ref. 167) encyclopedias (89, 94) and other leading monographs. In fact, while the terms hormetic and hormesis were cited only about 160 times during the entire decade of the 1980s within the Web of Science database, in 2008 alone these terms were cited nearly 2300 times.

Of further significance were observations that these broad-ranging dose–response relationships also shared the same general quantitative features. More specifically, the low-dose stimulation that becomes manifested immediately below the pharmacological and toxicological thresholds is modest in magnitude, being at most only about 30%–60% greater than the control group response. The width of the hormetic stimulation is usually about 10–20-fold starting immediately from the zero equivalent dose (i.e., estimated threshold) (Fig. 1). The hormetic dose response may result from either a direct stimulation or *via* an overcompensation stimulatory response after disruption in homeostasis (49, 50). Regardless of the mode of action by which the stimulation occurs, the quantitative features of hormetic dose responses are similar. These observations are based on copious data derived from the published literature ranging from plants to humans (68, 93), involving numerous receptor systems (61–64). These findings have recently led to nearly 60 biomedical scientists recommending that biological stress responses, including those of pre- and postconditioning, be integrated within an hormetic context, along with the adoption of a terminology that would be based within an interdisciplinary framework (72).

The hormetic dose response confers a new set of interpretations for the dose response. At high doses within a toxicological setting, the typical endpoints measured indicate cellular damage. However, as the dose decreases below the threshold, the low-dose stimulation more likely represents a manifestation of an adaptive response that conforms to a measure of biological performance as may be seen in the cases of modest increases in cognition, growth, longevity, bone density, and other biomedical endpoints of interest (424).

The consistency of the vast array of hormetic findings suggests strongly that this dose response may be a manifestation of the plasticity of biological systems. That essentially all biological models respond to imposed stress with the same quantitative features of the dose response is a central finding within the biological sciences that has not been previously recognized. These findings suggest that the hormetic dose response would have been broadly selected for and highly conserved. This adaptive response not only enhances survival by conferring resistance to environmental stress, but also represents a way to regulate the allocation of biological

resources in a manner that ensures cellular and organismal stability. The consistency of the hormetic dose response across the vast array of biological models, at different levels of biological organization, regardless of the type of stress and health status of the individual, indicates that hormesis provides a quantitative index of biological plasticity across multiple levels of biological organization, making it a central biological element for enhancing survival.

These quantitative features of the hormetic dose response have important medical implications. Most significantly, the hormetic dose response imposes constraints upon the magnitude of a drug to induce a desired effect. For example, if a drug increased cognitive performance in an elderly patient by approximately 25%–30%, the hormetic model suggests that this level of performance could not be further increased using a new drug combination. This concept has been supported in a variety of studies on hormesis and drug interaction. Flood (173–176) has demonstrated that the hormetic response for memory was bounded by the 30%–60% increase even when several drugs were used in combination that were designed to maximize memory outcome. This response magnitude constraint has been reported for immune stimulation, bacterial growth, increases in hair growth, plant growth, decrease in anxiety, decreases in tumor incidence, and numerous other endpoints (73).

This limitation in the magnitude of the stimulatory response is a critical implication of the hormesis dose–response concept. It is an observation that is based on extensive findings, and it is a controlling feature that defines what pharmaceutical companies can expect to achieve with drugs that are designed to enhance performance. However, the limitation in the magnitude of response is also potentially important with respect to the capacity to detect a desirable response. This may not be a particularly important issue when using highly inbred animal models or cell cultures where experimental conditions can be highly controlled. However, attempting to measure a low-dose hormetic stimulation within the context of a clinical trial can be problematic. Given the likelihood of considerable human variation in response to a drug, it is possible that the test population may have their responsiveness distributed over a range of responses that includes toxicity, optimal response, and a group in which the dose is ineffective. The data from all subjects in such studies would normally be averaged together leading to a marked dilution of an overall positive treatment effect in the optimal response zone subgroup. This suggests a possible reason why drugs that were very successfully tested in preclinical studies with highly inbred strains of animals could and often have failed during the clinical trial. Of particular note is that investigators may have to modify doses based upon the sensitivity or susceptibility of the subjects. Calabrese and Baldwin (59) have shown that the hormetic dose response is often expressed in the broad range of subjects independent of their susceptibility. As expected, those individuals who are very resistant to the drug or chemical treatment would have their hormetic response shifted to the right on the dose–response graph, whereas those individuals with greater-than-normal susceptibility would have their hormetic response shifted to the left. The hormetic dose response therefore imposes considerable challenges to the biomedical community that is interested in the development of drugs that are concerned with improvements in human performance.

The hormetic dose response can also have undesirable effects. This may be most readily seen in the case of drugs that are designed to suppress growth or kill cells or organisms at higher doses. For example, there is now substantial evidence that low doses of many antitumor drugs can stimulate the proliferation of such cells at lower concentrations (67). This also been shown to be the case with antibiotics, including penicillin (366) and streptomycin (366, 465). This phenomenon has also been reported with selected cardiac glycosides that have effects on nontarget tissues such as the prostate, where it is able to enhance the proliferation of smooth muscle cells by about 30% with clinically relevant doses (1, 127). Such a 30% increase in prostate smooth muscle was considered likely to impede urination in males. The failure to consider the possibility of the hormetic response not only can lead to a lack of recognition of a desirable drug-induced response but also can result in failure to prevent an adverse effect of drug treatment.

Since hormetic dose responses have now been widely reported in biological systems, there is the desire to develop a new subfield of hormetic mimetics. These mimetics are agents that can activate hormetic pathways with the intention of producing a desirable clinical effect. For example, it would be desirable to develop agents that can induce the desirable adaptive hormetic response without having risks associated with the exposures as in the case of certain chemical agents and radiation.

In the ensuing sections of this article we consider several of the major cellular and molecular systems that mediate adaptive stress responses/hormesis, with a focus on the nervous system in health and disease.

### III. Membrane Radical Dynamics

To elucidate the roles of hormesis in protecting cells and organs against disease, it is important to understand the nature of the potentially damaging stresses to which cells are subjected. While our focus in this article is on neurodegenerative conditions, many of the mechanisms we describe are also operative in disorders of other organ systems. The plasma membrane serves as the proximate sensor of extrinsic stressors. Membranes serve vital functions in all cells, not only by maintaining the ionic and molecular (proteins, nucleic acids, *etc.*) compositions of subcellular compartments, but also by serving as signal transduction platforms for a range of extracellular (hormones, growth factors, neurotransmitters, lipid messengers, and others) and intracellular (inositol phospholipids, kinases and their substrates, *etc.*) signaling molecules. Lipids that comprise membranes (phospholipids, cholesterol, sphingomyelins, and others) and the various proteins associated with membranes (receptors, ion channels, cell adhesion proteins, and others) encounter a range of ROS including hydrogen peroxide, hydroxyl radical, superoxide, nitric oxide (NO), and others. Excessive attack by free radicals can impair fundamental functions of membranes, resulting in cell damage and death. Such oxidative damage to membranes is believed to play major roles in a range of disorders, including myocardial infarction (172), stroke and traumatic brain injury (254), and Alzheimer's disease (AD) (286). However, as described below, lower amounts of membrane-associated oxidative stress may activate adaptive stress response pathways.

#### IV. Lipid Peroxidation and Sphingomyelin Metabolism

The unsaturated (double) bonds in the fatty acid chains of the membrane lipid bilayer are prone to attack by free radicals, particularly hydroxyl radical and peroxynitrite (282, 459). Hydroxyl radical is formed from hydrogen peroxide in the Fenton reaction that is catalyzed by  $\text{Fe}^{2+}$  or  $\text{Cu}^+$ , whereas peroxynitrite is generated when superoxide interacts with NO (150). Both hydroxyl and peroxynitrite radicals can abstract a hydrogen atom from a fatty acid, quenching the original radical but generating a lipid radical that interacts with oxygen to form a lipid peroxyl radical. The peroxyl radical can then interact with neighboring fatty acids, thereby setting in motion a self-propagating lipid peroxidation reaction. Lipid peroxidation can occur in any cellular membranes (mitochondria, endoplasmic reticulum [ER], nucleus, *etc.*), but for the purposes of the present article we will focus on the plasma membrane. Lipid peroxidation generates lipid cleavage products, including aldehydes of various chain lengths and isoprostanes. Among the products of lipid peroxidation, 4-hydroxynonenal (HNE) has received considerable attention for its possible contributions to the pathogenesis of several major disorders, including cardiovascular, renal, and neurodegenerative diseases (226, 252, 411). For example, evidence from studies of experimental models of Alzheimer's disease has shown that HNE can impair the function of ion-motive ATPases (sodium and calcium pumps) (277), glucose transporters (279), and GTP-binding proteins coupled to muscarinic acetylcholine receptors (37) in neurons.


In addition to lipid peroxidation, membrane-associated oxidative stress can activate sphingomyelinases (basic and acidic sphingomyelinases), which cleave sphingomyelin to generate ceramides (140) (Fig. 2). Sphingomyelinases are also activated by tumor necrosis factor (TNF) and some growth factors. Ceramides can activate signaling pathways involved in the regulation of cell growth and survival. However, excessively high amounts of ceramide can trigger a form of programmed cell death called apoptosis (415). Ceramides


generated in response to membrane-associated oxidative stress are implicated in the dysfunction and death of cells in a range of disorders, including diabetes (428), emphysema (352), ischemic stroke (476), Alzheimer's disease (141), and amyotrophic lateral sclerosis (142).

#### V. Plasma Membrane Redox System

An understudied redox system of enzymes is associated with the plasma membrane where it is involved in modulating levels of oxidative stress (210). The plasma membrane redox system (PMRS) includes the following enzymes reduced nicotinamide adenine dinucleotide (Fig. 3): (a) reduced nicotinamide adenine dinucleotide (NADH)-ascorbate free radical reductase; (b) NAD(P)H-quinone oxidoreductase 1 (NQO1), (c) NADH-ferrocyanide reductase; (d) NADH-coenzyme Q10 reductase; and (e) NADH-cytochrome *c* reductase. In addition, the lipophilic antioxidants  $\alpha$ -tocopherol and coenzyme Q10 are involved. The PMRS is therefore similar to the redox system of the inner mitochondrial membrane, which is involved in electron transport and energy metabolism. The PMRS plays an important role in the response of cells to membrane-associated oxidative stress by transferring electrons from reduced nicotinamide adenine dinucleotide phosphate [NAD(P)H] and ascorbate to extracellular free radicals/oxidants. Within the membrane, coenzyme Q10 (CoQ) can be reduced by either NQO1 or NADH-cytochrome b5 reductase. Dietary CoQ is important for the maintenance of sufficient levels of reduced CoQ and  $\alpha$ -tocopherol in the plasma membrane, thereby protecting against lipid peroxidation. Expression and activity of the PMRS enzymes can be altered in response to physiological challenges. For example, activity and protein levels of NADH-ascorbate free radical reductase; NQO1, NADH-ferrocyanide reductase; and NADH-coenzyme Q10 reductase are decreased in brain cells during normal aging and are increased in response to dietary energy restriction (211). The PMRS is therefore ideally poised to mediated hormetic responses of neurons and other cells to a range of stimuli that increase oxidative stress.

FIG. 2. Membrane sphingomyelin and ceramide metabolism pathways involved in adaptive stress responses and neurodegenerative conditions. Modified from Cutler *et al.* (142). FA, fatty acids; ROS, reactive oxygen species; SMase, sphingomyelinase; SPT, serine palmitoyl CoA transferase; TNF, tumor necrosis factor.





**FIG. 3.** The plasma membrane redox system is a conserved sensor of cellular redox status and energy metabolism. Modified from Hyun *et al.* (210). CoQ, coenzyme Q10; ETS, electron transport system;  $\text{NAD}^+$ , oxidized nicotinamide adenine dinucleotide;  $\text{NADH}$ , reduced nicotinamide adenine dinucleotide;  $\text{NAD(P)H}$ , reduced nicotinamide adenine dinucleotide phosphate; NQO1,  $\text{NAD(P)H}$  quinone oxidoreductase 1. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

## VI. Membrane-Related Hormesis Mechanisms

Evidence is emerging to support hormetic roles for low and transient increases in membrane oxidative stress. Levels of membrane lipid peroxidation are relatively low under most normal conditions. However, in some types of cells, lipid peroxidation increases considerably during periods of increased energy demand. For example, during vigorous physical exercise there is a marked increase in production of superoxide and hydrogen peroxide, hydroxyl radical, peroxynitrite, and lipid peroxidation (377). Evidence suggests that free radicals and products of lipid peroxidation generated during moderate exercise play important roles in hormetic effects of exercise on muscles, including changes in energy metabolism pathways, mitochondrial biogenesis, and upregulation of protein chaperones and antioxidant systems (377). Benefits of exercise on the cardiovascular system may also involve membrane oxidative stress-related mechanisms. Thus, it was reported that HNE activates nuclear factor erythroid 2-related factor 2 (Nrf2) and antioxidant gene expression in vascular cells (412). HNE may also activate other adaptive stress response pathways that promote the survival and plasticity of cells (349).

Ceramide is also believed to mediate hormetic effects of moderate/transient increases in membrane-associated oxidative stress. For example, pretreatment of neurons with subtoxic concentrations of ceramide results in increased resistance of the neurons to subsequent high levels of oxidative stress (191). Other studies have provided evidence for a pivotal role for ceramide in the cardioprotective effect of preconditioning ischemia in animal models of myocardial infarction (16, 149). Preconditioning ischemia is a classic example of hormesis, wherein exposure of cells to a moderate transient stress protects them against more severe stresses. Changes in the PMRS in response to stress may also allow cells to adapt to potentially damaging conditions. A dramatic example comes from a study in which the mitochondria of cells were rendered dysfunctional, and the cells were able to survive because of a compensatory upregulation of PMRS enzyme activities (212).

## VII. Mitochondria: A Hub of Cellular Redox Processes

Mitochondria are the major source of energy (ATP and oxidized nicotinamide adenine dinucleotide [ $\text{NAD}^+$ ]) production in eukaryotic cells, and produce correspondingly large amounts of superoxide anion radical through abstraction of an electron from oxygen in the so-called electron transport chain at the inner mitochondrial membrane (291). Mitochondria may produce superoxide in relatively constant amounts, or may elicit spontaneous or environmentally induced superoxide flashes (462). Much of the superoxide produced is efficiently converted to hydrogen peroxide *via* the activity of superoxide dismutases, including cytoplasmic (SOD1) and mitochondrial (SOD2) forms of the enzyme. Being a highly reactive free radical, superoxide can damage molecules (DNA, proteins, and lipids), and so its conversion to hydrogen peroxide protects cells. However, in the presence of even very low concentrations of  $\text{Fe}^{2+}$  or  $\text{Cu}^+$ , hydrogen peroxide can generate hydroxyl radical, which is a potent inducer of membrane lipid peroxidation (Fig. 3). In addition, NO (which is generated in response to activation of the enzyme NO synthase by  $\text{Ca}^{2+}$ /calmodulin) can interact with mitochondrial superoxide to generate the highly reactive free radical peroxynitrite. Methods have been developed to detect and quantify oxidative damage to proteins, lipids, and DNA, with antibodies that selectively recognize proteins modified by the lipid peroxidation product 4-hydroxynonenal (37, 242, 279) and by nitration (124, 220) being particularly useful. In addition, fluorescent probes for imaging relative levels of overall mitochondrial redox status and superoxide have been used to elucidate roles for mitochondrial ROS in a range of physiological and pathological processes (178, 243, 261, 462). The damaging effects of excessive production of ROS are believed to contribute to a wide range of diseases, including cancers, cardiovascular disease, and inflammatory conditions such as arthritis (2, 250, 296). Neurons may be particularly vulnerable to mitochondrial ROS because of their high energy demands and their excitability, and because they are post-mitotic and are therefore in most cases irreplaceable (284, 291). However, lower subtoxic levels of mitochondrial ROS can

activate signaling pathways that protect cells against injury and disease.

### VIII. Hormesis, Mitochondria, and Neuroprotection

Recent findings have overturned the long-held belief that mitochondrial ROS have only a negative impact on cell function and survival. It is now clear that mitochondrial superoxide and hydrogen peroxide play important roles in a range of cellular functions, and can also activate signaling pathways that promote cell survival and disease resistance. Exposure of hippocampal neurons to subtoxic levels of hydrogen peroxide triggers the release of  $\text{Ca}^{2+}$  from the ER by causing the opening of both  $\text{IP}_3$  and ryanodine receptor channels (184). Interestingly, superoxide enhances long-term potentiation of synaptic transmission in hippocampal CA1 neurons by a mechanism requiring activation of ryanodine receptors and extracellular regulated kinases (207). Mitochondrial ROS may also play roles in recovery from injury. For example, superoxide can stimulate neurite outgrowth by directly activating protein kinase C (192). Moreover, peroxynitrite can promote the phosphorylation and nitration of regulatory sites within receptor tyrosine kinases, thereby activating cell survival signaling pathways, including those involving phosphatidylinositol 3-kinase (PI3K)–protein kinase B (Akt) and mitogen-activated protein (MAP) kinases (38). Nitration of proteins involved in synaptic vesicle trafficking can enhance glutamate release, suggesting a potential role for superoxide and peroxynitrite in regulating neurotransmission (151).

Mitochondrial superoxide production is believed to contribute to damage of neurons in conditions ranging from chronic intermittent cerebral hypoxia (402) to Alzheimer's disease (225). However, it has been widely reported that transient exposure of neurons to low levels of superoxide that are converted into hydrogen peroxide can protect the neurons against a subsequent exposure to what would have otherwise been a lethal level of stress. This neuroprotective effect of a subtoxic increase in cellular oxidative stress has been termed "preconditioning" by neuroscientists who study stroke (162), but clearly falls under the broad umbrella of hormesis (72). Although the involvement of oxidants in many signaling pathways is well documented, the cellular strategies for conferring pathway specificity to such reactive molecules have remained more recondite. Recent studies now suggest that cells may spatially restrict oxidant production to allow microdomain-specific signaling (446). The specific molecular mechanisms by which mitochondrial ROS elicit hormetic responses in neurons are poorly understood, but emerging evidence suggests important roles for certain transcriptional regulators. For example, we showed that the transcription factor  $\text{NF}\kappa\text{B}$  is activated in neurons in response to oxidative stress and plays a pivotal role in the adaptive response that protects the neurons against more severe oxidative stress [see ref. (288) for review].  $\text{NF}\kappa\text{B}$  induces expression of genes encoding several proteins that protect mitochondria against oxidative stress, including SOD2 and Bcl-2 (46, 115, 281). We also found that, contrary to the view that TNF exerts only detrimental effects on neurons, TNF upregulates expression of Mn-SOD *via* an  $\text{NF}\kappa\text{B}$ -mediated mechanism and can thereby protect neurons against excitotoxic, ischemic, and oxidative injury (45, 47).

While mitochondrial  $\text{H}_2\text{O}_2$  may activate adaptive stress response pathways in neurons, they may also play neuroprotective roles by acting on other cell types in the nervous system. For example, microglial activation, which occurs in response to increased oxidative stress, can have either beneficial or detrimental effects on neurons and neural progenitor cells depending upon the type and amounts of cytokines and growth factors secreted by the microglia (168). A final example of *trans*-cellular hormesis mediated by ROS comes from studies showing that oxidative stress can stimulate angiogenesis in the brain (217, 295), a process that could be very important in restoring blood flow to neurons during the days and weeks after a stroke.

### IX. Proteotoxicity, Cellular Stress Response, and the Vitagene Network

Protein thiols play a key role in redox sensing, and regulation of cellular redox state is a crucial mediator of multiple metabolic signaling and transcriptional processes (97, 108). More in general, protein quality control, which is a critical feature of intracellular homeostasis (100), is maintained by a highly complex network of molecular interactions that balances protein biosynthesis, folding, translocation, assembly/disassembly, and clearance (98, 312). The ability to ensure proper protein folding is critical for cellular function and organismal viability. In cells undergoing division, damaged and oxidized proteins can be sequestered and retained in mother cells, enabling daughter cells to have a pristine, undamaged proteome. However, in postmitotic cells, such as most neurons, protein quality control must be maintained by other, possibly more complex, mechanisms. Further, particular neuronal populations are more vulnerable to proteotoxicity, whereas others are more able to tolerate the misfolding and aggregation of disease proteins. Thus, the cellular environment must play a significant role in determining whether disease proteins are converted into toxic or benign forms. The endomembrane neuronal network divides brain cells into different subcellular compartments that possess distinct sets of molecular chaperones and protein interaction networks (164). Cells buffer proteotoxic events related to intracellular protein misfolding *via* chaperone-mediated partitioning of nonnative conformers between pathways for proper folding, inclusion body formation, and degradation. Chaperones, in fact, act as agonists and antagonists of disease protein aggregation to prevent the accumulation of toxic intermediates in the aggregation pathway. Interacting partners can also modulate the conformation and localization of disease proteins and thereby influence proteotoxicity. Thus, interplay between these protein homeostasis network components can modulate the self-association of disease proteins and determine whether they elicit a toxic or benign outcome (164, 203). Polypeptides that fail to fold properly, along with damaged and oxidized mature proteins, are targeted for degradation by specialized cellular degradation machineries. A failure to prevent the misfolding and aggregation of one protein can destabilize the proteome, resulting in uncontrolled aggregation of other polypeptides. When conformationally challenged aggregation-prone proteins are expressed, the resulting unfolded or misfolded proteins are rapidly degraded *via* the ubiquitin–proteasome pathway. However, in some cases, protein aggregation leads to the development of




the so-called conformational diseases. Among the conformational diseases are the human neurodegenerative diseases, such as Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD). In AD, dual digestion of amyloid precursor protein (APP) releases the aggregation-prone peptides that are collectively termed amyloid- $\beta$  ( $A\beta$ ). The accumulation and aggregation of  $A\beta$  (particularly the highly aggregative  $A\beta$ 1-42) is associated with AD. Similarly, aberrant aggregation of  $\alpha$ -synuclein is associated with the emergence of PD, whereas Huntington and other CAG triplet diseases are typified by the accumulation of polyglutamine-containing aggregates. This also includes prion diseases such as Creutzfeldt-Jakob disease with accumulation of misfolded prion protein, type II diabetes with accumulation of islet amyloid polypeptide, and amyotrophic lateral sclerosis with aggregated superoxide dismutase-1 (186). One of the most characteristic features present in most brain oxidant disorders is the occurrence of extra- or intracellular fibrillar aggregates containing misfolded proteins with beta-sheet conformation. These aggregates are composed of distinct proteins in each neurodegenerative disease. As already mentioned, toxicity deriving from misfolded proteins or peptides are collectively termed proteotoxicity, and it has become evident that protein aggregation is tightly linked to the emergence and development of neurodegenerative diseases. Moreover, the mechanisms that have been found to counter toxic protein aggregation in different cell types and different organisms are highly conserved. Thus, it is likely that proteotoxicity that is associated with the expression of neurodegeneration-linked aggregation-prone proteins in any tissue can provide insights into the neuronal defence mechanisms. Many of the insights that have been obtained from invertebrate-based or nonneuronal studies await confirmation in mammalian neuronal systems and clinical observations (132). Recent data suggest that small oligomeric aggregating structures, termed also protofibrils, are the underlying cause, rather than high-molecular-mass aggregates as previously assumed. *In vitro* studies on fragments of amyloidogenic proteins and synthetic peptides have established that the tendency for a protein to form amyloid is often limited to a short sequence of the full protein, known as an SRE (selfrecognition element). SREs form the core of amyloid fibrils. These amyloidogenic sequences constitute hotspots for aggregation of the native protein into amyloid fibrils and are often the sites of mutations leading to early-onset amyloidosis. In the case of tau-paired helical filaments, which accumulate in the neurofibrillary tangles characteristic of AD and other neurodegenerative diseases, it has been shown that only three residues (Val-Tyr-Lys) are sufficient for fibril formation. Similarly, short sequences forming the core domain of various amyloid fibrils have been identified for  $A\beta$  (amyloid  $\beta$ -peptide), calcitonin, IAPP (islet amyloid polypeptide), insulin, and  $\alpha$ -synuclein. It may be possible to delete residues freely on either side of an SRE while retaining the ability to form amyloid (11). Genetic and age-related factors, as it is known, act as vicious cycle increasing the amounts of pathogenic proteins in AD, where the increase in  $A\beta$ 42 levels is caused by (a) mutations in amyloid precursor protein or presenilins (*e.g.*,  $\gamma$ -secretase), (b) by reactive oxygen species, and (c) by reductions in  $A\beta$ -degrading enzymes ( $A\beta$ DE), such as neprilysin and insulin-degrading enzyme, as well as increases in tau concentrations are influenced by oxidant damage, phosphorylation, and calcium (278); in PD, where

increased levels of  $\alpha$ -synuclein caused by triplication of its gene or mutations in parkin, DJ1, ubiquitin carboxy-terminal hydrolase 1 (UCHL1), phosphatase and tensin homolog induced kinase 1 (PINK1), or leucine-rich repeat kinase 2 (LRKK2) are associated with proteasome impairment and oxidative stress; and in HD, with polyglutamine expansions in huntingtin (HTT). The protein aggregation process itself is enhanced by increasing protein concentration; the action of transglutaminases; protein chaperone insufficiency; mutations in  $\alpha$ -synuclein (PD) and polyglutamine expansions in huntingtin (HD); and/or posttranslational modifications, such as oxidations induced by, for example, hydrogen peroxide ( $H_2O_2$ ),  $Fe^{2+}$ , and  $Cu^+$ , and phosphorylation. Although the proteins involved can differ, there is considerable overlap in the mechanisms by which they damage and kill neurons. Oligomers of  $A\beta$ ,  $\alpha$ -synuclein, and HTT might damage and kill neurons by inducing membrane-associated oxidative stress (MAOS), thereby impairing mitochondrial function and thus causing degenerative cell death (287).

Cellular stress response is the ability of a cell to counteract stressful conditions (Fig. 4). This phenomenon, which includes heat shock response (HSR), represents an ancient and highly conserved cytoprotective mechanism (270, 312, 416). Production of Hsps, including protein chaperones, is essential for the folding and repair of damaged proteins, serving thus to promote cell survival conditions that would otherwise result in apoptosis (20). The term "molecular chaperone" denotes a large family of ubiquitous proteins that function as part of an ancient defense system in our cells. Chaperones promote cell survival by sequestering damaged proteins and preventing their aggregation. During stressful conditions, such as elevated temperature, they prevent protein aggregation by facilitating the refolding or elimination of misfolded proteins. The stress-induced response to damaged proteins is helped by a sophisticated regulatory system, which shuts down most cellular functions and, in parallel, induces the synthesis of several chaperones and other survival-promoting proteins. Therefore, many of the chaperones are also called stress or heat shock proteins in reference to the archetype of cellular stress, heat shock. Besides their role during stress, chaperones have multiple roles under normal conditions. They promote the transport of macromolecules (*e.g.*, proteins and RNA) and participate in remodeling events involving larger protein complexes, including signaling, transcription, cell division, migration, and differentiation. Molecular chaperones both in the cytosol (heat-shock proteins, crystallins, prefoldin, and Hsc70) and in the ER (Bip, Grp94, calnexin, and calreticulin) form large complexes and have a large number of cochaperones to regulate their activity, binding properties, and function (380). These chaperone complexes regulate local protein networks, such as the mitochondrial protein transport apparatus and the assembly and substrate specificity of the major cytoplasmic proteolytic system, the proteasome (380). For instance, mood and anxiety disorders are considered stress-related diseases characterized by an impaired function of mineralocorticoid and glucocorticoid receptors (MR and GR, respectively), the major regulatory elements of the hypothalamus-pituitary-adrenocortical (HPA) axis. Hence, a number of chaperone proteins moderate the function of these receptors. Genetic variations in one of these chaperones, FKBP5, have been associated with antidepressant treatment response and with a major risk factor for the development of





**FIG. 4. Cell stress responses.** Expression of HS genes including chaperones and components of the clearance machinery is induced in response to physiological and environmental stress conditions, including longevity stimuli, such as fasting, caloric restriction, or polyphenol antioxidants, and protein conformational diseases. HSF1 can also be directly stimulated by longevity stimuli such as the histone deacetylase SIRT1 that directly activates HSF1 by deacetylation, thus fostering longevity. The increased flux of damaged or misfolded proteins in response to proteotoxic environmental conditions (stress) is the trigger for the induction of the cellular stress response. Aging, however, is associated with a gradual decline in potency of the heat shock response and this may prevent repair of protein damage, leading to degeneration and cell death. HSF, heat shock transcription factor; SIRT, silent information regulator two. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

posttraumatic stress disorder (395). Chaperones are well known to protect the cell nucleus after stress. Consistent with this, Hsp70 was shown to drive damaged nuclear proteins to the nucleolus, clearing other nuclear components of misfolded proteins and decreasing the danger of their widespread aggregation (139). In agreement with these findings, chaperones promote the transport of ribosomal subunits and the mobility of steroid receptors inside the nucleus (139). Molecular chaperones regulate both the activation and the disassembly of numerous transcriptional complexes (380). Thus, chaperones emerge as regulators of the transcriptional network (139, 272). Stress-induced nuclear translocation of chaperones may preserve nuclear remodeling capacity during environmental damage, and thus protect the integrity of DNA. Consistently, there is significant interest in the discovery and development of small molecules that modulate HSRs and parallel stress response pathways for therapeutic purposes (99, 106, 108, 309, 452).


Cellular stress response (Fig. 4) requires the activation of pro-survival pathways that, under control of protective genes called vitagenes (99, 100, 106–108), result in the production of molecules (Hsps, glutathione, and bilirubin) endowed with antioxidant and antiapoptotic activities. Generally, molecular chaperones help hundreds of signaling molecules to keep their activation-competent state, and regulate various signaling processes ranging from signaling at the plasma membrane to transcription. In addition to these specific regulatory

roles, recent studies have revealed that chaperones act as genetic buffers stabilizing the phenotypes of various cells and organisms (43). Protein function is regulated by the proteostasis network (20), an integrated biological system that generates and protects the protein fold. Proteostasis refers to controlling the concentration, conformation, binding interactions (quaternary structure), and location of individual proteins making up the proteome by readapting the innate biology of the cell, often through transcriptional and translational changes. Proteostasis thus influences specific cellular functions and enables differentiated cells to change their physiology for successful organismal development and aging in the face of constant intrinsic and environmental challenges to prevent disease onset. Proteostasis is influenced by the chemistry of protein folding/misfolding and by numerous regulated networks of interacting and competing biological pathways that influence protein synthesis, folding, trafficking, disaggregation, and degradation. The composition of the proteostasis network is regulated by signaling pathways, including the unfolded protein response (UPR), the HSR, the ubiquitin proteasome system (UPS), together with epigenetic programs (185). The same networks are preferentially remodeled in various diseases and aging, which may help us to design novel therapeutic and antiaging strategies (312). Among the cellular pathways involved in the so-called programmed cell life conferring protection against oxidative stress, a key role is played by the products of vitagenes

(97–100, 105–108, 281). These include members of the Hsp family, such as heme oxygenase-1 and Hsp72, sirtuins, and the thioredoxin/thioredoxin reductase system (103, 106, 107). Recent studies have shown that the HSR contributes to establishing a cytoprotective state in a wide variety of human diseases, including inflammation, cancer, aging, and neurodegenerative disorders. Given the broad cytoprotective properties of the HSR, there is now strong interest in discovering and developing pharmacological agents capable of inducing the HSR (99). Molecular chaperones are known to disrupt aggregates actually promoted active aggregation when the concentration of the aggregating protein is high. Consistent with this notion, it has been proposed that, although protein aggregation is hazardous under certain circumstances, the creation of apparently less-toxic large aggregates is protective (335). This hypothesis is the basis of the therapeutic potential of Hsps, which prevent protein misfolding and aggregation. Transgenic animal models of the diseases have demonstrated that induction or overexpression of Hsps can suppress neuronal dysfunction and degeneration. Hsp70 can reduce the amount of misfolded and aggregated  $\alpha$ -Syn species *in vivo* and *in vitro*, and protect neuronal cells from  $\alpha$ -Syn-dependent neurotoxicity (120). Hsp104 reduced the phosphorylation of  $\alpha$ -Syn inclusions and prevented the nigrostriatal dopaminergic neurodegeneration induced by mutant  $\alpha$ -Syn (A30P) (235). Recent findings regarding the pathogenic species generated during fibril formation have highlighted some of the beneficial and problematic aspects of Hsp-based therapy.

## X. Sirtuins and the Integration of Adaptive Stress Responses in Neurons

Sirtuins are a family of histone deacetylases that, in humans, includes at least seven members (silent information regulator two [SIRT]1–7) that exhibit different cellular and subcellular localizations and substrate specificities [see ref. (144) for review]. The best studied sirtuin is SIRT1, an NAD<sup>+</sup>-dependent enzyme that deacetylates several different protein substrates involved in the regulation of cellular energy metabolism and redox state, thereby influencing cell survival and plasticity (Fig. 5). In yeast, worms, and flies, the SIRT1 homolog (Sir2) has been shown to play a major role in lifespan determination and stress resistance [see ref. (34) for review]. Similarly, emerging evidence suggests important roles for SIRT1 in hormetic responses of cells to a range of metabolic and oxidative stressors. In addition to roles in chromatin remodeling effected by deacetylating histones, SIRT1 has been shown to deacetylate and thereby activate a transcriptional regulator called peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$  (PGC-1 $\alpha$ ). PGC-1 $\alpha$  is believed to play a pivotal role in adaptive responses of cells to dietary energy restriction and exercise (30, 183), effectively increasing cellular stress resistance by upregulating expression of a set of genes that encode proteins (peroxisome proliferators activated receptor- $\gamma$ , pyruvate dehydrogenase kinase isoform 4, and estrogen-related receptor- $\gamma$ ) that control the production of antioxidant and detoxifying enzymes (Fig. 5). PGC-1 $\alpha$  has also been shown to increase the proliferation of mitochondria in



**FIG. 5. SIRT1-based and related hormetic signaling pathways in neurons are coupled to transcriptional regulators that control expression of genes involved in neuronal plasticity and cell death.** AMPK, adenosine monophosphate-activated protein kinase; AOE, antioxidant enzyme; BDNF, brain-derived neurotrophic factor; CREB, cyclic AMP response element binding protein; ERK, extracellular signal regulated kinase; ERR, estrogen-related receptor; FH, forkhead transcription factor; HIF, hypoxia inducible factor; JNK, jun *N*-terminal kinase; PDK, pyruvate dehydrogenase kinase; PGC-1 $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$ ; PPAR, peroxisome proliferator activated receptor; SOD, superoxide dismutase. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

neurons (362). In comparison with SIRT1, very little is known concerning the functions of SIRT2–7, but their differential subcellular localization is providing interesting clues; for example, SIRT3 is associated with mitochondria, where it may deacetylate protein substrates involved in energy metabolism (3).

Together with DNA methylation, acetylation of histones and transcription factors plays roles in regulating gene expression in neurons [see ref. (285) for review]. Through these activities, sirtuins are shown to regulate important biological processes, such as apoptosis, cell differentiation, energy transduction, and glucose homeostasis (262, 289, 361). In cultured mammalian cells, Sirt1 is activated in response to growth factor deprivation and increased oxidative stress. Changes in the cellular redox state as reflected by pyridine nucleotide homeostasis, specifically concentrations of  $\text{NAD}^+$  or the ratio of the concentration of  $\text{NAD}^+$  and its reduced form NADH, control the deacetylase activity of Sir2 and its homologs. During hypoxic stress, redox changes in cellular metabolism occur that activate Sirt1 and integrate also with hypoxia-inducible factors (HIFs) which are transcriptional regulators that control genes induced during hypoxia and other stresses (Fig. 5). Activation of the founding HIF member, HIF-1 $\alpha$ , is increased when oxygen concentrations are reduced. The second HIF  $\alpha$  member, endothelial known as HIF-2 $\alpha$ , is closely related to HIF-1 $\alpha$  in structure and is likewise activated during hypoxia. HIF-2 $\alpha$  target genes identified from mouse knockout studies include Sod2 encoding the mitochondrial-localized manganese superoxide dismutase, VegfA encoding the proangiogenic regulator vascular endothelial growth factor A, and Epo encoding the cytokine erythropoietin. Sirt1 augmentation of HIF-2 signaling is conferred through formation of a Sirt1/HIF-2 $\alpha$  complex as well as through Sirt1-mediated deacetylation of acetylated HIF-2 $\alpha$  (161). Some studies have provided evidence that activation of SIRT1 can protect neurons against degeneration, whereas others suggest that SIRT1 promotes neuronal death. In a mouse model of peripheral nerve degeneration, nicotinamide prevents axonal degeneration and SIRT1 is a pivotal downstream mediator of axonal protection (15). Overexpression of nicotinamidase in flies increases their lifespan in a Sir2-dependent manner, and nicotinamidase overexpression in cultured human neurons increases their resistance to oxidative stress, also in a sirtuin-dependent manner (19). The function of Sir2 deacetylases is negatively regulated by nicotinamide, a by-product feedback inhibitor in deacetylation reactions involving  $\text{NAD}^+$ -dependent deacetylases and also a metabolite in the nucleotide salvage pathway. Reactions performed by these enzymes can rapidly deplete cellular NAD and generate nicotinamide, which acts as a potent feedback inhibitor of the  $\text{NAD}^+$ -dependent deacetylases (199). Thus, in the absence of nicotinamide, sirtuin protein activity is enhanced. Salvage enzymes, such as nicotinamidase that deaminates nicotinamide into metabolites that can be recycled back to NAD, increase activity of Sir2 deacetylases, thus exerting, in yeast, effects on life span. All this is corroborated in mammals, by the finding that increased nicotinamide clearance in cells provides positive effects on organism life span and cellular response to oxidative stress. This supports the hypothesis that manipulation of nicotinamide metabolism through genetic approaches or pharmacological agents in vertebrates could yield similar beneficial results (125). D'Mello and his colleagues showed

that SIRT1 can protect cultured cerebellar neurons against apoptosis induced by potassium deprivation, apparently by a mechanism independent of its deacetylase activity (352). In contrast, SIRT2, 3, and 6 induced apoptosis, suggesting opposing actions of different sirtuins, at least in this particular cell culture model.

Interestingly, emerging evidence suggests that sirtuins may be involved in the regulation of synaptic plasticity (22, 303), and adaptive responses of brain cells to a range of stressors (Figs. 4 and 5). For example, decreased activities of histone deacetylases (HDAC1 and HDAC2), whose activity is not dependent on  $\text{NAD}^+$ , during early synaptic development enhance excitatory synapse maturation associated with increased synapse numbers, whereas in mature neurons a decrease in HDAC2 levels attenuates basal excitatory neurotransmission without a change in the numbers of synapses (4). SIRT1 may also play important roles in the regulation of neural progenitor cell fate decisions because SIRT1 is upregulated in neural progenitor cells in response to mild oxidation, and suppression of SIRT1 expression in neural progenitors prevents oxidative stress-induced suppression of neurogenesis (360). Because of their roles in cellular stress responses, sirtuins would be expected to play particularly important roles in adaptive responses of neural cells to stress and, presumably, the enhancement of synaptic plasticity and neurogenesis in response to exercise, dietary energy restriction, and other hormetic environmental factors (291). In support of this notion, SIRT1 has been shown to interact either directly or indirectly with several pathways known to be involved in adaptive neural plasticity, including the  $\text{Ca}^{2+}$ -calmodulin-cyclic adenosine monophosphate (AMP) response element binding protein (409) and  $\text{NF-}\kappa\text{B}$  (382) systems (Fig. 5).

It has also been reported that the SIRT1 activator resveratrol can protect neurons against degeneration in experimental models of Alzheimer's disease and amyotrophic lateral sclerosis (229). Similarly, resveratrol treatment protected neurons against the toxic effects of polyglutamine proteins in animal models of Huntington's disease (348). Dietary energy restriction can protect neurons against dysfunction in mouse models of Alzheimer's disease (197), and recent evidence suggests a role for SIRT1 in this neuroprotective action of caloric restriction (363).

Resveratrol was recently shown to affect the activity of SIRT1 *in vitro* although its effects seem to depend on the nature of the substrate for deacetylation (6). However, *in vivo*, resveratrol has been shown to exert effects dependent on sirtuin orthologs—extension of lifespan in yeast, *C. elegans*, and *Drosophila*, and metabolic effects on mammalian cells (378). In addition, resveratrol protects *C. elegans* neurons expressing a fragment of the Huntington-disease-associated protein huntingtin and mammalian neurons from mutant polyglutamine cytotoxicity in an HdhQ111 knock-in mouse model of Huntington disease (144). Two recent studies have also shown that deleterious effects of high-fat, high-caloric diets in mice were mitigated by resveratrol feeding. In one study, the shortening of lifespan by the high-fat diet was reversed (305). In a second study, resveratrol increased SIRT1 activation, PGC-1 $\alpha$  deacetylation, and mitochondrial biogenesis in muscle (247). Although resveratrol has been claimed to be a *bona fide* SIRT1 activator, whereby offering a promising approach for treating metabolic disorders, with a potential to change the practice of medicine, recent reports indicate that

this finding might be an experimental artifact and need to be clarified (26). It has been suggested that metabolism of the redox couple NAD/NADH provides a link between sirtuin activity and the control of cell senescence and organism lifespan: NAD-dependent protein deacetylation helps maintain the juvenile phenotype, whereas inhibition of deacetylation activity by NADH or nicotinamide, or by NAD unavailability, promotes the onset of cellular aging and decrease organism lifespan (6, 100). Raising NAD levels, or lowering NADH levels by increasing its oxidation also promote sirtuin activation, with concomitant beneficial effects on cell survival (201). There exists an interrelationship and overlap between sirtuin regulation, generation of altered proteins, and mitochondrial activity, exerted by metabolic effects on NAD and NADH levels (Fig. 5). It has been proposed that when protein synthesis is strongly upregulated (*e.g.*, during growth and sirtuin-enhanced mitogenesis) there is a concomitant stimulation in chaperone protein synthesis and proteolytic potential, to ensure rapid removal of erroneously synthesized/misfolded polypeptide chains. This hypothesis is sustained by recent finding that heat-shock protein expression (466) and autophagy (383) are enhanced by NAD<sup>+</sup>-activated SIRT1 activity, thereby facilitating recognition and elimination of altered proteins. Further, sirtuin-mediated stimulation of aerobic mitochondrial activity, for example, in response to caloric restriction (14), will also facilitate NADH oxidation back to NAD<sup>+</sup>, thereby improving NAD<sup>+</sup> availability and decreasing the potential for generation and accumulation of altered proteins (202). In the Wallerian degeneration slow (Wlds) mouse model, SIRT1 activation protects axons against neuronal injury (144). This Wlds mouse bears in fact a dominant mutation producing an overexpressed chimeric Wlds protein composed of the ubiquitin assembly protein Ufd2a and the NAD<sup>+</sup> salvage pathway enzyme NMNAT1. Decreasing SIRT1 activity reduces the axonal protection originally observed, whereas SIRT1 activation by resveratrol decreases the axonal degeneration after neuronal injury (430). This suggests that the neuroprotection in the Wlds mouse model is achieved by increasing the neuronal NAD<sup>+</sup> reserve and/or SIRT1 activity (144). In addition, SIRT1 activation significantly decreases neuronal cell death induced by amyloid-beta (A $\beta$ ) peptides through inhibition of NF $\kappa$ B signaling (144). Specific brain hSIRT1 overexpression in transgenic animals induces a significant increase in the  $\alpha$ -secretase activity, an enzyme that cleaves the amyloid precursor peptide (APP) within the A $\beta$  peptide, thereby mediating the nonamyloidogenic pathway of the APP processing (144). These studied animal models have indicated that SIRT1 could contribute to the pathogenesis of some complex diseases. In line with this hypothesis, genetic variants (single nucleotide polymorphisms) in the human SIRT1 gene have been shown to be tightly associated with energy expenditure (247).


While SIRT1 may promote neuronal survival and plasticity in some settings, it can contribute to the death of neurons in experimental models of some neurodegenerative disorders (353). For example, sirtuin inhibitors protect neurons against  $\alpha$ -synuclein-mediated toxicity in models of Parkinson's disease (309). Others have reported that nicotinamide treatment restores cognitive performance in Alzheimer's disease transgenic mice *via* a mechanism involving sirtuin inhibition and reduction of levels of hyperphosphorylated tau (194). Another study provided evidence that SIRT1 may promote neuronal

death by activating a insulin-like growth factor-1 signaling pathway (258), although other findings suggest that insulin-like growth factor-1 signaling is itself neuroprotective (123). Our own findings suggest that SIRT1 can promote neuronal survival under conditions where cellular energy levels are sufficient, but may endanger neurons by depleting NAD<sup>+</sup> under conditions of marginal cellular energy levels (262, 263). This biphasic action of SIRT1 depending upon cellular NAD<sup>+</sup> levels is similar to that previously described for PARP [poly-ADP(ribose) polymerase], which can protect neurons against apoptosis when energy levels are sufficient, but contributes to energy failure in conditions such as ischemia and hypoxia (169). While the roles of SIRT1 in neurodegenerative conditions therefore appear complex, the development of agents that selectively activate or inhibit SIRT1 is being actively pursued with the expectation of novel therapeutic treatments for a range of neurological disorders (248). Moreover, it has been recently shown that SIRT2 inhibition, through nicotinamide (NAM), O-acetyl-ADP-ribose (O-AA-ribose), and AGK, prevented  $\alpha$ -synuclein cytotoxicity and modulated its aggregation in cultured cells; ameliorated mutant  $\alpha$ -synuclein neurotoxicity in rat primary dopamine-positive neurons; and rescued degeneration of dopaminergic neurons from  $\alpha$ -synuclein toxicity in a *Drosophila* animal PD model (341). These results suggested that modulation of  $\alpha$ -synuclein aggregation pathway could be one of the sirtuin neuroprotective mechanisms (340). The exact mechanism whereby SIRT2 inhibition affects  $\alpha$ -Synuclein aggregation remains uncertain. Increased  $\alpha$ -tubulin acetylation is associated with microtubule stabilization, and has been reported to interact with  $\alpha$ -tubulin as well as the microtubule-binding proteins MABP1 and tau. One possibility is that the increase in acetylated  $\alpha$ -tubulin resulting from SIRT2 inhibition may stimulate aggregation of  $\alpha$ -Synuclein through its affinity to microtubules. Moreover, microtubule stabilization itself could be an important factor contributing to neuroprotection (341). Sirtuins hold a great potential as therapeutic targets in neurodegeneration; however, the development of therapeutic activators and inhibitors against the various sirtuin isoforms is necessary to assess the therapeutic potential of these targets in rodent models of neurodegenerative diseases, so that the development of lead-candidate compounds for human clinical trials can be expedited.

## XI. The Kelch-Like ECH-Associated Protein 1 / Nrf2/Antioxidant Response Element Pathway


As mentioned above, a central regulator in gene expression of Hsps is heat shock transcription factor 1 (HSF1) (310). In addition, some of the vitagenes are also upregulated as part of the phase 2 response, also known as the electrophile counterattack response, a cytoprotective response that protects against various electrophiles and oxidants (97, 104–106, 146) (Figs. 6 and 7). Examples include heme oxygenase 1, thioredoxin, and thioredoxin reductase, all of which can be upregulated by the transcription factor Nrf2 (Nuclear factor-erythroid 2 p45-related factor 2) coordinately with a battery of cytoprotective proteins, such as glutathione S-transferases (GSTs), UDP-glucuronosyltransferase, NAD(P)H quinone oxidoreductase 1 (NQO1), epoxide hydrolase, ferritin,  $\gamma$ -glutamylcysteine synthetase, glutathione reductase, aldo-keto reductases, and glutathione conjugate efflux pumps (106).





**FIG. 6. Endogenous biosynthetic pathways of (a) NO, involving NOSs, (b) CO, involving HO isoforms (HO-1, HO-2), and (c) H<sub>2</sub>S, involving CBS, CSE, and MPST.** Methionine, which is derived from alimentary sources, is converted to S-adenosylmethionine by methionine adenosyltransferase. S-adenosylmethionine is subsequently hydrolyzed to homocysteine by glycine N-methyltransferase. Cystathionine β-synthase catalyzes the production of cystathionine by transferring serine to homocysteine. Cystathionine γ-lyase, a pyridoxal 5'-phosphate-dependent enzyme, subsequently converts cystathionine to cysteine. In the mitochondria, cysteine can get converted to 3-mercaptopyruvate by aspartate aminotransferase, which can then be converted to H<sub>2</sub>S by MPST. CBS, cystathionine β-synthase; CO, carbon monoxide; CSE, cystathionine γ-lyase; HO, Heme oxygenase; H<sub>2</sub>S, hydrogen sulfide; MPST, 3-mercaptopyruvate sulfur transferase; NO, nitric oxide; NOS, NO synthase. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

This elaborate network of protective mechanisms allows eukaryotic organisms to counteract the damaging effects of oxidants and electrophiles, major agents involved in the pathogenesis of cancer, atherosclerosis, neurodegeneration, and aging (227). Gene expression of this group of functionally diverse proteins is regulated by the Kelch-like ECH-associated protein 1 (Keap1)/Nrf2/antioxidant response element (ARE) pathway (Fig. 7). Long before this pathway was discovered, it had been reported that exposure to low doses of carcinogens protects against the toxicity of a subsequent encounter with high doses of carcinogens [reviewed in ref. (205)], illustrating the phenomenon of hormesis, or preconditioning. Thus, as far back as the late 1920s Berenblum showed that topical application of dichlorodiethyl sulfide reduced skin tumor incidence in mice painted with tar (31). Similar were the findings of Lacasagne and colleagues and Riegel and colleagues, who reported that weakly carcinogenic hydrocarbons (*e.g.*, 1,2,5,6-dibenzofluorene and 1,2,5,6-dibenzoacridine) protected against the carcinogenicity of highly active carcinogenic hydrocarbons 1,2,5,6-dibenzo(*a*)anthracene and 3-methylcholanthrene (246, 371). Importantly, the protection was much more effective with pretreatment and simultaneous treatment compared to simultaneous treatment alone. The studies of Richardson and Cunningham, who showed that intravaginal administration of 3-methylcholanthrene could inhibit liver carcinogenesis caused by orally administered 3'-methyl-4-dimethyl-aminoazobenzene, demonstrated that protection could be achieved even when the protector and the carcinogen were administered by two different routes (370) and thus excluded the possibility of a direct interaction between the protector and the carcinogen. The first



**FIG. 7. The Keap1/Nrf2/ARE pathway.** Under basal conditions transcription factor Nrf2 is bound to a cytoplasmic repressor Keap1, which targets Nrf2 for ubiquitination and proteasomal degradation *via* association with the Cullin 3-based E3 ubiquitin ligase complex. Small molecule inducers modify highly reactive (sensor) cysteine residues of Keap1, which loses its ability to target Nrf2 for degradation. This results in stabilization of Nrf2, binding to the ARE (in heterodimeric combinations with a small Maf transcription factor), and activation of the transcription of cytoprotective (phase 2) genes. ARE, antioxidant response element; Keap1, Kelch-like ECH-associated protein 1; Nrf2, nuclear factor-erythroid 2 p45-related factor 2. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

insights into the protective mechanism(s) were provided by James and Elizabeth Miller and their colleagues, who demonstrated that 3-methylcholanthrene was an inducer of enzymes that catalyze the conversion of carcinogens to inactive (detoxification) products (134, 304).

In the 1960s Charles Huggins and his colleagues reported that small doses of various aromatic hydrocarbons protected against the toxicity and carcinogenicity of subsequent exposure to large doses of 7,12-dimethylbenz(*a*)anthracene (208, 209). The phenomenon was called induced protection. Importantly, protection only occurred when the protector was given before the carcinogen and protection was long-lasting (in some cases up to 6 days), indicating that some synthetic process was of critical importance. This hypothesis was further strengthened by the finding that protein synthesis was required for protection; protection was abolished by the protein synthesis inhibitor ethionine and could be specifically restored only by methionine, but not by any other amino acid (208). This study led to the discovery that NQO1 was induced by the protective agents in several tissues, that is, in liver, lung, adrenal, and mammary gland (208). It is now widely recognized that NQO1 is a cytoprotective enzyme (152, 439, 440). A highly quantitative and robust bioassay based on the ability to induce NQO1 in murine hepatoma (Hepa1c1c7) cells is used to screen for potent small molecule inducers. Importantly, inducers identified using this screen have subsequently been confirmed to protect against tumor development, and to confer cardiovascular and neuroprotective effects in various animal models (155, 170, 222, 357).

In the 1960s Frankfurt (180) and Wattenberg (463) found independently that the phenolic antioxidants BHA and BHT that are widely used as food preservatives and therefore consumed by humans protected experimental

animals against the toxicity and carcinogenicity of 7,12-dimethylbenz(a)anthracene and other carcinogens. The findings of Talalay, Bueding, and their colleagues that supplementation of the diet of rodents with BHA resulted in dramatic reduction of the mutagenic metabolites of benzo(a)pyrene, which was accompanied by selective induction (by enhanced transcription) of several cytoprotective proteins (*i.e.*, GSTs, uridine diphosphate [UDP]-glucuronosyltransferases, and NQO1) without significant effects on enzymes that catalyze the activation of this pro-carcinogen (*e.g.*, cytochrome P450 enzymes), provided a mechanistic explanation for the observed protection [reviewed in refs. (435, 436)]. Subsequent studies involving many inducers some of which are related to BHA, but many of which belong to a wide variety of structurally unrelated chemical classes, led to two crucial discoveries: (a) all inducers share a common chemical property, namely, the ability to react with sulfhydryl groups (437); (b) inducers activate the transcription of cytoprotective genes that occurs in the liver and many peripheral tissues [reviewed in ref. (356)] ensuring fitness for meeting subsequent challenges, and ultimately survival. Again, these discoveries represented an illustration of the hormesis phenomenon and the designation of the Electrophile Counterattack response was proposed (356). It is now recognized that due to their functional versatility (Table 1) the transcriptional induction of cytoprotective genes is a highly effective strategy for achieving protection against a variety of chronic conditions, such as neoplasia, atherosclerosis, hypertension, and neurodegeneration (205, 219, 228, 329, 438).

Gene expression of these cytoprotective proteins is coordinately regulated by a common molecular mechanism that involves the Keap1/Nrf2/ARE pathway (Fig. 7). The upstream regulatory regions of these genes contain single or multiple copies of the antioxidant/electrophile response ele-

ments (ARE and EpRE) with the consensus sequence 5'-A/CTGAC/GNNNGCA/G-3' (182, 324, 375, 376). The major transcription factor that binds to the ARE is Nrf2, a basic leucine zipper transcription factor. Activation of gene expression requires that Nrf2 binds to the ARE in heterodimeric combinations with members of the small Maf family of transcription factors (314). Under basal conditions the pathway operates at low levels due to the repressor function of the cytosolic protein Keap1, which binds to the E3 ubiquitin ligase Cullin3-RING box1 and presents Nrf2 for ubiquitination and subsequent proteosomal degradation (200, 236, 324).


Inducers of the Keap1/Nrf2/ARE pathway belong to at least 10 distinct chemical classes: (a) oxidizable diphenols, phenylenediamines, and quinones; (b) Michael acceptors (olefins or acetylenes conjugated to electron-withdrawing groups); (c) isothiocyanates; (d) thiocarbamates; (e) trivalent arsenicals; (f) dithiolethiones; (g) hydroperoxides; (h) vicinal dimercaptans; (i) heavy metals; and (j) polyenes. The only common property among them is their chemical reactivity with sulfhydryl groups by oxido-reduction, alkylation, or disulfide interchange. (153, 155, 356, 358, 421, 438). This common property led Talalay and his colleagues to propose that the sensor for inducers must be a molecule (perhaps a protein) endowed with exquisitely reactive cysteine residues (160, 438). Indeed, there is now compelling experimental evidence that exogenous and endogenous inducers chemically modify specific and highly reactive cysteine residues of Keap1, which, in addition to being a repressor for Nrf2, also functions as the intracellular sensor for inducers (157, 216). This reaction leads to conformational changes in Keap1 that abrogate its ability to repress Nrf2, ultimately resulting in Nrf2 stabilization, binding to the ARE and recruitment, the basal transcriptional machinery to activate transcription of cytoprotective genes (200, 237, 315). Whereas many aspects of the model are still controversial and the intricate details of the regulation of the pathway are not fully understood (200, 324, 345), there is voluminous experimental evidence for a mechanism of regulation of Keap1 activity through its reactive cysteine residues. Of note, even though Nrf2 is regulated primarily at the level of protein stability, the consequences of its stabilization are due to its downstream target genes that have relatively long half-lives (on the order of days). Thus, the evaluation of the effects of inducers on the levels of the Nrf2-target gene expression or activity rather than on Nrf2 levels themselves represents a much more biologically meaningful measure of cellular protection against damage.

Murine Nrf2 is composed of 597 amino acids and has a molecular weight of ~60 kD (Fig. 8). Nrf2 is a Cap 'n' Collar (CNC) transcription factor that belongs to the class of basic leucine zipper (b-Zip) proteins. These proteins form heterodimers with members of the Maf family of transcription factors. Keap1 is a multidomain homodimeric protein that comprises 624 amino acids and has a molecular weight of ~69 kD. Murine Keap1 contains 25 cysteine residues (its human homologue has 27), 9 of which (*i.e.*, C23, C38, C151, C241, C273, C288, C297, C319, and C613) are flanked by basic amino acids, which in turn are known to lower the pKa values of the cysteines, favoring the formation of the thiolate anions at neutral pH, thus making them potentially highly reactive. We and others have reported that C151, C273, and C288 are of particular importance in the function of Keap1 as a sensor for inducers and as a repressor of Nrf2 (154, 253, 461, 477).

TABLE 1. EXAMPLES OF THE VERSATILITY OF FUNCTIONS OF CYTOPROTECTIVE PROTEINS

Conjugation and export
Glutathione transferases
UDP-glucuronosyltransferases
Multidrug resistance proteins
Glutathione homeostasis
$\gamma$ -Glutamylcysteine ligase
Glutathione reductase
Thioredoxin
Thioredoxin reductase
Antioxidant
Heme oxygenase 1
Ferritin
Catalase
Antiinflammatory
Leukotriene B <sub>4</sub> dehydrogenase
Synthesis of reducing equivalents:
Glucose-6-phosphate dehydrogenase
Maleate dehydrogenase
Repair and removal of damaged macromolecules
Heat shock protein 40
Heat shock protein 70
26S proteosome subunits
O <sup>6</sup> -methylguanine-DNA methyltransferase

UDP, uridine diphosphate.



**FIG. 8. Overall structures of Nrf2 and Keap1 showing the different domains.** In Nrf2, the DLG motif (amino acids 27–32) and the ETGE motif (amino acids 77–82) of the Neh2 domain comprising the two Keap1-binding sites are indicated and the black bars represent the lysine residues that are ubiquitinated by Cul3-Rbx. The Neh1 and Neh3 domains form the DNA-binding site of the transcription factor. In Keap1, the BTB domain is the dimerization domain and the site of interaction with Cul3. The Kelch domain is the Nrf2-binding domain. The black bars indicate the distribution of the cysteine residues of Keap1. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

The BTB domain of Keap1 represents a protein–protein interaction motif (Fig. 8). Indeed, Keap1 exists as a homodimer through the BTB domains of its subunits. Two groups have reported the crystal structure of the Kelch domain showing the formation of a 6-bladed  $\beta$ -propeller structure, with residues at the C-terminus forming the first strand in the first blade (257, 344, 449). It is through the Kelch domain that Keap1 binds to the Neh2 domain of Nrf2. For binding between Keap1 and Nrf2 to occur, two motifs within Nrf2 are critically important: the ETGE and the DLG. On the basis of a series of elegant studies, McMahon *et al.* (299, 450, 451) proposed that, first, the ETGE motif of Nrf2 binds to an arginine triad on one of the Keap1 subunits. This binding then positions the DLG motif of Nrf2 in the vicinity of the triad on the second subunit of Keap1. This so-called fixed-ends or hinge-and-latch model explains the observation that the binding affinity of Keap1 for the ETGE motif is much higher than its affinity for the DLG motif and predicts that the lysine residues in Nrf2 targeted for ubiquitination must be positioned between the two Keap1-binding sites. Indeed, all seven lysine residues of Nrf2 (out of a total of 27) that have been implicated in ubiquitination are located between the ETGE and DLG motifs, a portion of the protein that is largely helical (451).

Whereas Keap1 is the major repressor of Nrf2 and the sensor for inducers of Nrf2-dependent genes, DJ-1 has been recently implicated as a necessary factor required for Nrf2 stability and activity (130), even though up to date no evidence for a physical interaction between DJ-1 and either Nrf2, Keap1, or Cullin 3 has been reported. Nonetheless, the ability of DJ-1 to stabilize Nrf2 may be an essential contributor to the importance of DJ-1 for cellular protection against oxidative and ER stress. Conversely, the loss of DJ-1 may represent an important factor in the decreased inducibility of Nrf2-dependent genes that has been observed under certain disease conditions (275) and with aging (133). Thus, loss-of-function mutations in *PARK7*, the gene encoding DJ-1, are associated with autosomal recessive early onset Parkinsonism (39).

Another protein that interacts with Keap1 resulting in Nrf2 activation is p62 (238). Both genetic and pharmacological activation of Nrf2 leads to accumulation of p62, which can then further activate Nrf2. Conversely, impaired p62 expression could lead to decreased Nrf2 activity and may further explain the association between low p62 levels, a common occurrence in many neurodegenerative disorders (165), and decreased Nrf2-dependent inducibility. Importantly, mice that lack p62 have increased oxidative DNA damage in brain as well as biochemical and cognitive defects that resemble Alzheimer's disease (342, 365).

The generation of the *nrf2*-knockout mouse (117, 215) provided an unequivocal demonstration of the cytoprotective role of Nrf2-dependent gene battery [see ref. (227) for a scholarly review]. Under standard laboratory conditions, *nrf2*-knockout mice do not display any obvious phenotypic abnormalities. In contrast to wild-type mice, however, they fail to adapt to environmental challenges and are much more sensitive to the toxicity and carcinogenicity of electrophiles and oxidants. Unlike their wild-type littermates, *nrf2*-knockout mice have low basal levels of cytoprotective proteins and cannot be protected by inducers. Conversely, liver-specific *keap1*-knockout mice and *keap1*-knockdown mice have constitutively high basal levels of cytoprotective proteins and are much more resistant to acute drug toxicity (332, 333, 336, 369, 370, 471).

The neuroprotective effects of upregulation of the Keap1/Nrf2/ARE pathway have been demonstrated in several *in vitro* and *in vivo* models. Thus, adenovirus-mediated overexpression of Nrf2 was shown to upregulate ARE-dependent genes in primary cultures of neurons and astrocytes that were derived from the cortex of the rat (407) or the mouse (249) brain. Importantly, this upregulation of the Keap1/Nrf2/ARE pathway protected against the toxicity of glutamate and  $H_2O_2$ . Similar protection was also observed when the small molecule inducers *tert*-butyl hydroquinone (tBHQ) or sulforaphane were used instead of Nrf2 overexpression (240, 407). Strikingly, the protective effects of induction of the Keap1/Nrf2/ARE pathway in astrocytes extend beyond this cell type and also provide protection to neurons. Even though the intricate mechanisms are not fully understood, one very important player is undoubtedly reduced glutathione, the secretion of which from the astrocytes increases after Nrf2 activation. It has been hypothesized that this effect is the primary factor leading to neuroprotection of both cortical and motor neurons in culture (219). In addition, the upregulation of proteins that are concerned with the synthesis, use, and transport of reduced glutathione (GSH), including xCT cystine/glutamate antiporter,  $\gamma$ -glutamylcystine ligase, glutathione *S*-transferases, glutathione reductase, and the multidrug resistance protein 1, in the astrocyte were shown to be critical for neuronal protection. However, contrary to the expectations based on the *in vitro* experiments, *nrf2*-knockout mice did not differ from their wild-type littermates in terms of basal activity of the xCT cystine/glutamate antiporter in the ventral striatum, cocaine-induced behaviors either after acute or repeated exposure, or dopamine depletion after methamphetamine-induced oxidative stress (343).

Compared to their wild-type counterparts, neurons isolated from *nrf2*-knockout mice were much more sensitive to the cytotoxic effects of the mitochondrial toxins 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and rotenone (249). Oligonucleotide microarray analysis on primary neuronal cultures



isolated from wild-type and *nrf2*-knockout mice revealed differences in several functional categories of genes: (a) detoxification/antioxidant/reducing potential; (b) calcium homeostasis; (c) receptor/channel/carrier proteins; (d) growth factors; (e) cell signaling; (f) defense/immune/inflammation; and (g) neuron-specific proteins (249). Of special interest are the genes playing roles in calcium homeostasis. Indeed, neuronal cultures isolated from *nrf2*-knockout mice were more sensitive to increases in intracellular  $\text{Ca}^{2+}$  levels caused by ionomycin- and 2,5-di-(*t*-butyl)-1,4-hydroquinone (249). Importantly, adenoviral-vector-mediated overexpression of Nrf2 recovered ARE-dependent gene expression in *nrf2*-knockout neuronal cultures and protected *nrf2*-knockout neurons from rotenone- or ionomycin-induced cell death.

The exciting findings using mixed primary cultures of neurons and astrocytes showing that activation of the Keap1/Nrf2/ARE pathway in astrocytes provides protection to neurons prompted subsequent *in vivo* studies. A large number of *in vivo* experiments have demonstrated the neuroprotective role of the Keap1/Nrf2/ARE pathway and suggested the potential use of Nrf2 inducers for achieving protection against neurodegenerative diseases. Thus, in comparison to wild-type mice, *nrf2*-knockout mice are hypersensitive to the mitochondrial complex II inhibitors 3-nitropropionic acid and malonate, which induce lesions in the striatum (111, 406). Hypersensitivity was both time and dose dependent such that motor deficits and striatal lesions developed more rapidly in homozygous null mice than in animals that are either homozygous or heterozygous for *nrf2* (406). Importantly, striatal succinate dehydrogenase activity, the target of 3-nitropropionic acid, was inhibited to the same extent in all genotypes, indicating that the absence of Nrf2 did not lead to alterations in metabolism and brain concentration of the drug. The toxicity of 3-nitropropionic acid was lower when the diet of wild-type but not *nrf2*-knockout mice was supplemented with the Nrf2 inducer tBHQ, suggesting that protection was dependent on Nrf2. Indeed, similar protective effects were achieved *via* intrastriatal adenovirus-mediated Nrf2 overexpression, which significantly reduced lesion size compared with green fluorescent protein-overexpressing controls. tBHQ, administered intracerebroventricularly or intraperitoneally, was also protective against the occurrence of cortical damage and sensory and motor deficits at 24 h and even at 30 days after ischemia-reperfusion in rats (408). In mice, tBHQ attenuated neuronal death caused by intracortical endothelin-1 microinjection (a penumbral model of stroke), but was ineffective in *nrf2*-knockout animals (408). *Nrf2*-knockout mice are also more susceptible to seizures, neuronal damage, and microglial infiltration in hippocampus induced by kainic acid exposure (241). Nrf2-dependent protection against excess release of dopamine was also recently reported (405).

Transplanted Nrf2-overexpressing astrocytes into the mouse striatum before challenge with malonate provided dramatic protection against malonate-induced neurotoxicity; remarkably, brain hemispheres receiving Nrf2-producing astrocyte transplants were essentially resistant to malonate toxicity, whereas hemispheres receiving control astrocytes were no different from untransplanted controls (111). Recently, transgenic mice overexpressing Nrf2 selectively in astrocytes have been generated using the glial fibrillary acidic protein (GFAP) promoter (456). These mice were crossed with two ALS-mouse models. It was found that overexpression of

Nrf2 in astrocytes significantly delayed disease onset and extended survival. In a model of Parkinson's disease, *nrf2*-knockout mice were found to be more sensitive than wild-type mice to the toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (48, 122). Further, whereas MPTP challenge led to upregulation of the Keap1/Nrf2/ARE pathway in substantia nigra of wild-type mice (indicative of a counterattack in response to the toxic challenge), such upregulation was absent in *nrf2*-knockout mice, demonstrating that the absence of Nrf2 results in failure of an adaptive stress response (122). Importantly, activation of the Keap1/Nrf2/ARE pathway by oral administration of the Nrf2 inducer 3H-1,2-dithiole-3-thione to wild-type mice resulted in partial protection against MPTP-induced neurotoxicity, but had no effect when administered to *nrf2*-knockout mice (48). Strikingly, the toxicity of MPTP was abolished in GFAP-Nrf2 transgenic mice (overexpressing Nrf2) on both *nrf2*-wild-type and *nrf2*-knockout backgrounds. Because the GFAP-Nrf2 transgenic mice on an *nrf2*-knockout background express Nrf2 only in astrocytes, this finding confirmed the previous observations that Nrf2 expression restricted to astrocytes is sufficient to protect the brain against MPTP toxicity. In a model of permanent cerebral ischemia it was shown that whereas absence of Nrf2 appears to have no significant effect on cortical infarction at 24 h, it exacerbates tissue injury at 7 days after permanent ischemia, as demonstrated by the large increase (twofold) in infarct volume at the 7-day time point (408). In contrast, there was no increase in infarct size between 24 h and 7 days in wild-type animals. On the basis of this observation, the authors proposed a model in which Nrf2-dependent gene expression in surviving glial cells restricts infarct expansion in wild-type, but is unable to do so in *nrf2*-knockout mice (408). It was recently reported that *nrf2*-knockout mice develop spongiform leukoencephalopathy characterized by degeneration of myelin in the white tracts of the brain accompanied by widespread reactive gliosis (206). In this study, the mean age of the mice with vacuolar leukoencephalopathy was  $8.3 \pm 2.6$  months (mean  $\pm$  SE), and the prevalence at the age of 1 year or older was 100% (11 of 11 animals). In the age- and gender-matched wild-type controls, only one animal had a locally extensive area of mild vacuolar degenerative changes in the cerebellar white tracts. These findings show the importance of Nrf2 in supporting myelin integrity and suggest that antioxidant responses mediated through the Keap1/Nrf2/ARE pathway are essential to prevent oxidative injury within the myelin sheath. Taken together, these studies convincingly demonstrate the neuroprotective effect of the Keap1/Nrf2/ARE pathway and it was recently proposed that it represents a novel neuroprotective pathway that confers resistance to a large variety of oxidative-stress-related and neurodegenerative insults (112, 219, 327).

It is noteworthy that the levels of markers of the Keap1/Nrf2/ARE pathway such as NQO1, GST, and GSH in brain do not differ as dramatically as they do in liver of wild-type and *nrf2*-knockout mice (406). Thus, *nrf2*-knockout mice have only  $\sim 25\%$  of the liver NQO1 activity of wild-type controls. In sharp contrast, the brain NQO1 activity in *nrf2*-knockout mice is  $\sim 85\%$  of the wild type. Liver glutathione levels in *nrf2*-knockout mice are  $\sim 30\%$  lower than in wild-type mice, whereas there is no significant difference between the two genotypes in terms of total glutathione content in the

brain. The implications of these findings are at least twofold. First, there must be other Nrf2-independent pathways of regulation of cytoprotective genes in brain. Curiously, the roles of the other members of the Nrf family of transcription factors (Nrf1 and Nrf3) have not been investigated in the brain even though the expression levels of brain Nrf1 are much higher than those of Nrf2 (298). Second, because *nrf2*-knockout mice are clearly much more sensitive than their wild-type littermates to all of the above mentioned challenges, differences in expression of cytoprotective genes as small as 10%–20% seem to have a very significant impact on the sensitivity of the brain to damage, and especially on its ability to cope with the long-term consequences of such damage. Because the battery of cytoprotective genes is so large (>100) and their functions so diverse, it is perhaps not surprising that very small differences in a large number of proteins could have a big overall impact.

## XII. Hormetic Phytochemicals and the Neuroprotective Effects of Pharmacological Activators of the Keap1/Nrf2/ARE Pathway

Phytochemicals include compounds with various biological properties (*i.e.*, antimicrobial, antifungal, antioxidant, and antiproliferative) that have presumably evolved, in part, to allow plants to cope with environmental challenges, including exposure to radiation and toxins, and defense against pests and infectious agents. These chemicals, or their metabolic precursors, are particularly concentrated in the seeds, the growing buds, and the skin of fruits and function as natural pesticides. From an evolutionary perspective, the noxious properties of such phytochemicals play an important role in dissuading insects and other pests from eating the plants. However, at the relatively small doses ingested by humans who consume the plants, the phytochemicals are not toxic and instead induce mild cellular stress responses (319). The now compelling evidence for biphasic dose–response effects of environmental toxins in biological systems suggests the possibility that chemicals in foodstuffs, particularly from plants, might also exert biphasic dose responses with health benefits resulting from ingestion of the chemicals in doses within the hormetic range. Whereas at high concentrations phytochemicals can be toxic to mammalian cells, subtoxic doses may induce adaptive stress responses. Thus, there is voluminous evidence on the protective effects of isothiocyanates, curcumin, and resveratrol, all present in edible plants. In spite of this, however, high doses of these phytochemicals can also be toxic to some types of cells (289, 291, 293). Although in the past it was assumed that the direct free radical scavenging activity of phytochemicals might be responsible for their direct health benefits, to date it is unclear, if not unlikely, whether humans consume fruits and vegetables to an extent sufficient to achieve the high (micromolar) concentrations of the phytochemicals required to scavenge free radicals directly. Indeed, epidemiological studies and clinical trials have failed to demonstrate benefits of dietary supplementation with antioxidants such as vitamin E and vitamin C. Within this context, emerging evidence suggests that hormetic mechanisms may account for the health benefit of phytochemicals (330). One general mechanism of action of phytochemicals is that they activate adaptive cellular stress response pathways, including kinases and transcription fac-

tors that induce the expression of genes that encode antioxidant enzymes, protein chaperones, phase 2 enzymes, neurotrophic factors, and other cytoprotective proteins (294). Sulforaphane, curcumin, and resveratrol are inducers of the Keap1/Nrf2/ARE pathway. Resveratrol activates the sirtuin–FOXO pathway, resulting in increased expression of antioxidant enzymes and cell survival-promoting proteins (294). Ingestion of other phytochemicals may activate the hormetic transcription factors cyclic AMP response element binding protein, resulting in the induction of genes encoding growth factors and antiapoptotic proteins (289, 293).

### A. *Tert-butylhydroquinone*

Several pharmacological activators (inducers) of the Keap1/Nrf2/ARE pathway have been shown to be neuroprotective (Fig. 9). Most of them are either natural products or synthetic compounds that are present in the human diet. As already discussed, tBHQ is one of the most widely used inducers of the Keap1/Nrf2/ARE pathway in both *in vitro* and *in vivo* studies. tBHQ is also one of the very early inducers that was shown to elevate cytoprotective enzymes (NQO1 and GST) in several tissues of CD-1 mice and Hepa1c1c7 murine hepatoma cells (145, 359, 360) and to reduce the number of gastric tumors in female ICR/Ha mice treated with benzo[a]pyrene (464) in a series of elegant studies carried out more than a decade before the discovery of the Keap1/Nrf2/ARE pathway. Among several phenolic antioxidants, tBHQ is more potent as an inducer compared to compounds in which the phenolic groups are alkylated. Further, its oxidation-reduction lability was identified as an essential feature for its inducer ability (359). It was recently suggested that compounds with hydroquinone and catechol moieties could constitute novel neuroprotective agents based on their ability to activate the Keap1/Nrf2/ARE pathway (388). It was pointed out that such molecules have an advantage over classical antioxidants (such as ascorbic acid) because their action is sustained and amplified by transcription-mediated signaling pathways (385). Further, because hydroquinones and catechols are not electrophilic themselves, they could be viewed as pro-drugs that are converted to the ultimate inducers by oxidation reactions (29). Critically, because redox imbalance is a recognized component of many neurodegenerative states, a novel strategy against neurodegenerative disorders has been proposed, namely, activation of such pro-drugs *via* the pathological activity that they are intended to combat (260). Thus, the catechol-containing carnosic acid is a compound abundant in rosemary (*Rosmarinus officinalis*) that accounts for 5% of the dry weight of the leaves (239). Carnosic acid induces Nrf2-dependent genes by binding to specific cysteine residues of Keap1 located in its BTB and/or IVR domains (386). Further, carnosic acid crosses the blood–brain barrier, increases the level of reduced glutathione in the brain, and protects against ischemia/reperfusion (386). Electrophilic neurite outgrowth-promoting prostaglandin derivatives have been shown to be taken up preferentially into neurons, where they bind to Keap1 leading to Nrf2 activation, binding to the ARE and upregulation of ARE-dependent genes (387). These electrophilic neurite outgrowth-promoting prostaglandin are neuroprotective *in vitro* against glutamate-related excitotoxicity as well as *in vivo* in a model of cerebral ischemia/reperfusion injury. Because of their neuroprotective effects,




FIG. 9. Chemical structures of inducers of the Keap1/Nrf2/ARE pathway for which neuroprotective activities have been demonstrated.

there are currently efforts toward the targeted development of neuroprotective electrophilic drugs, including prostaglandin derivatives and hydroquinones that exert their activity through activating the Keap1/Nrf2/ARE pathway (385).

### B. Sulforaphane

One of the most potent naturally occurring inducers of the Keap1/Nrf2/ARE pathway is the isothiocyanate sulforaphane, and it is therefore not surprising that the interest in its development as a protective agent in many chronic conditions, including neurodegeneration, is growing rapidly. The protective activities of sulforaphane in various animal models of carcinogenesis have been recently reviewed (159). The focus here is on its neuroprotective activities. Sulforaphane (Fig. 9) was isolated from extracts of the common cruciferous vegetable broccoli (*Brassica oleracea*) via an activity-guided fractionation using the Prochaska test (see above), a bioassay based on induction of the prototypical ARE-dependent gene NQO1 (480, 481). In the brain of male Long-Evans rats, the levels of heme oxygenase-1 (HO-1) mRNA were elevated after intraperitoneal administration of sulforaphane (5 mg/kg) (482). The protein expression of HO-1 was increased by ~1.5-fold in both neurons and astrocytes. In a model of brain ischemia/reperfusion, administration of sulforaphane 15 min after the onset of ischemia reduced the infarct volume (which was evaluated 3 days later) by ~50%. The same dose of sul-

foraphane administered to Sprague-Dawley rats 6 h after traumatic brain injury attenuated the loss of the water channel aquaporin-4 in the injury core, and additionally, it also increased the levels of aquaporin-4 in the penumbra region (483). The protective effects were long-lasting, and even 3 days postinjury there was a significant, although modest, reduction in brain edema. The mRNA levels of several cytoprotective genes (*i.e.*, HO-1, NQO1, and GST) in the parietal cortex and brain microvessels were increased 24 h after dosing (484). Postinjury (6 h later) administration of sulforaphane reduced the loss of endothelial cell markers and tight junction proteins and preserved the blood brain barrier function. The protective effects were evident only in wild-type but not in *nrf2*-knockout mice. Moreover, compared to their wild-type counterparts, *nrf2*-knockout mice were hypersensitive to injury-induced blood-brain barrier permeability.

In a model of intracerebral hemorrhage in Sprague-Dawley rats, sulforaphane administration caused induction of several Nrf2-dependent genes (catalase, superoxide dismutase, GST, and NQO1) in brain 3 h later, concomitantly with reduction in markers of oxidative damage (3'-nitrotyrosine and 4-hydroxynonenal) in the perihematoma area (485). Three days after intracerebral hemorrhage, the perihematoma neutrophil count was reduced by ~60%, and the total intracerebral hemorrhage-affected striatum neutrophil count was reduced by 33%. Again, the protective effects were long-lasting; 10 days after intracerebral hemorrhage, the neurologic deficits (a composite score from several behavioral tests,

including foot fault, forelimb placing, postural reflex, cylinder, and circling) were substantially reduced. Conversely, Nrf2 deficiency resulted in exacerbated neurologic deficits and loss of the protection. In addition, treatment of organotypic nigrostriatal cocultures with tBHQ or sulforaphane protected dopaminergic neurons against 6-hydroxydopamine-induced toxicity (410).

Interestingly, sulforaphane as well as many other inducers of the Keap1/Nrf2/ARE pathway also have antiinflammatory properties. Further, there is a linear correlation spanning more than 6 orders of magnitude between Nrf2 inducer potency and potency in inhibiting pro-inflammatory responses among small molecules that belong to structurally diverse chemical classes (158, 264). In cultured murine macrophages sulforaphane induces NQO1 and inhibits the upregulation of inducible NO synthase (iNOS) and Cox-2 caused by lipopolysaccharide (LPS) or interferon (IFN)- $\gamma$  and TNF $\alpha$  (158, 264). Similarly, in primary cocultures of rat microglial and astroglial cells, sulforaphane induces Nrf2-dependent genes and attenuates LPS-stimulated production of TNF $\alpha$ , interleukin (IL)-1 $\beta$ , IL-6, and NO (466). The protective effects of sulforaphane against brain inflammation were recently reported in C57BL/6 mice that received endotoxin injection (213). Sulforaphane treatment decreased microglial activation and the upregulation of inflammatory markers (inducible NO synthase, IL-6, and TNF $\alpha$ ) in response to LPS. The same study also showed that compared to wild-type mice, *nrf2*-knockout mice were hypersensitive to LPS-induced neuroinflammation. Although the mechanistic relationship between Nrf2 inducer and antiinflammatory activities of sulforaphane (and other Nrf2 inducers) are not clear at present, there is no doubt that both of these activities contribute to the cytoprotective effects of these small molecules (441).

### C. Dimethyl fumarate

Fumaric acid is the active principal of shepherd's purse (*Capsella bursa-pastoris*), a cruciferous weed that has been widely used as a traditional herbal medicine. In the 1940s Crabtree (137, 138) demonstrated that fumaric acid and several related compounds delay or prevent the development of skin tumors caused by benzo(a)pyrene in mice. Fumaric acid is also protective against the carcinogenic effects of a nitro-furan on the forestomach and lung in mice and against the toxicity of mitomycin C (244, 245). It was shown nearly 20 years ago that addition of dimethyl fumarate to the diet of female CD-1 mice and female Sprague-Dawley rats at 0.2%–0.5% concentrations elevated cytosolic GST and NQO1 activities in many organs (420). In primary cocultures of rat microglial and astroglial cells, dimethyl fumarate attenuated LPS-induced production of TNF $\alpha$ , IL-1 $\beta$ , IL-6, and NO, in addition to inducing Nrf2-dependent genes (468). In a model of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice, treatment with dimethyl fumarate strongly reduced macrophage inflammation in the spinal cord and increased blood levels of IL-10 (391). In humans, fumaric acid salts and esters are already used as therapeutic agents, for example, ferrous fumarate for iron deficiency (487) and alkyl esters for psoriasis (10, 324). In human keratinocytes and peripheral blood mononuclear cells stimulated with IFN- $\gamma$  or LPS, dimethyl fumarate (Fig. 9) inhibits the production of chemokines that may be critically involved in the development and persistence of psoriatic lesions (426). In patients

with relapsing-remitting multiple sclerosis, dimethyl fumarate reduced the formation of new inflammatory lesions in both a pilot study (392) and a multicenter, randomized, double-blind, placebo-controlled, dose-escalation, Phase IIb study (224).

### D. Diallyl trisulfide

The volatile organosulfur compounds from *Allium* (garlic) plants are also inducers of the Keap1/Nrf2/ARE pathway (155). The unsaturated allyl or propenyl functionalities in their structures (Fig. 9) are critical determinants of inducer potency (318, 438). In the 1980s such compounds were found to elevate glutathione S-transferase activity in the forestomach and to protect against benzo(a)pyrene-induced carcinogenesis (419). Very recently using rat spinal cord explants, it was shown that pretreatment for 48 h with diallyl trisulfide elevates NQO1 and protects motor neurons against glutamate-induced excitotoxicity (429).

### E. Celastrol

The quinone methide triterpene celastrol (Fig. 9) is derived from the traditional Chinese medicinal plant known as Thunder of God Vine (*Tripterygium wilfordii*). Celastrol is an inducer of NQO1 (Albena T. Dinkova-Kostova and Paul Talalay, unpublished observations) and a potent inhibitor of NF $\kappa$ B (136, 400). Celastrol decreases induced expression of class II MHC molecules by microglia (9). Moreover, administration of celastrol to rats significantly improved their performance in memory, learning, and psychomotor activity tests. In addition, celastrol activates heat shock gene transcription synergistically with other stresses and exhibits cytoprotection against subsequent exposures to lethal heat stress (465). Celastrol administration significantly attenuated the loss of dopaminergic neurons and the depletion in dopamine concentration after MPTP treatment (131). In a model of Huntington's disease, celastrol decreased the striatal lesion volume induced by 3-nitropropionic acid (131). Hsp70 within dopaminergic neurons was induced by celastrol, whereas TNF- $\alpha$  and NF $\kappa$ B and astrogliosis were suppressed. Structure-activity studies revealed a remarkable specificity in activating HSF1 with kinetics resembling those of heat shock, as determined by induction of HSF1 binding to DNA and increased transcription of heat shock genes (466, 467). Moreover, celastrol induced HSR synergistically with other stressors and this induction was protective against subsequent exposure to otherwise lethal forms of stress.

### F. Curcumin

The neuroprotective role of curcumin (Fig. 9), another naturally occurring inducer of the Keap1/Nrf2/ARE pathway (151, 153), is also a subject of intense investigations (101, 102, 106). Curcumin (diferuloylmethane) is a component of turmeric, a yellow spice extracted from the rhizome of the East Indian herb *Curcuma longa* L., that is widely used as a food flavoring and coloring agent (*e.g.*, in curry). Thus, treatment of astrocytes with curcumin induced the cytoprotective proteins HO-1, NQO1, and GST and provided protection against the damaging effects of glucose oxidase-mediated toxicity (390). Further, curcumin was reported to bind to amyloid plaques, and to reduce amyloid levels and plaque burden in aged

Tg2576 mice (a model of familial Alzheimer's disease) with advanced amyloid accumulation (469). Extensive research within the past two decades has shown that curcumin mediates its antiinflammatory effects through the downregulation of inflammatory transcription factors (such as nuclear factor- $\kappa$ B [NF $\kappa$ B]), enzymes (such as cyclooxygenase 2 and 5 lipoxygenase), and cytokines (such as TNF, IL-1 $\beta$  and IL-6) (12, 444), as well as upregulation of cytoprotective vitagenes (102, 106, 107). Curcumin has antiinflammatory, antioxidant, and anticancer activities. One of the most challenging tasks concerning cancer is to induce apoptosis in malignant cells; thus, more focus has been given on natural products to modulate apoptotic signaling pathways. Curcumin has chemopreventive properties, which are mainly due to its ability to arrest cell cycle and to induce apoptosis. The anticarcinogenic properties of curcumin in animals have been demonstrated by its inhibition of tumor initiation and tumor promotion (12). The number of signaling pathways and molecular targets involved is continuously growing and consequently the picture is becoming more and more complex, not least because the results often appear to be cell type specific and dose dependent (12).

Curcumin is quite stable at acidic pH, and upon ingestion almost 40%–80% of this compound remains in the gastrointestinal tract. However, curcumin undergoes a marked first-pass metabolism that limits its systemic bioavailability (~60%) as demonstrated in humans and rodents (102, 109). Interestingly, to increase its bioavailability, the coadministration of curcumin with piperine or its complexation with phospholipids to form a curcumin-phospholipids complex has been proposed (12). Preclinical studies have shown that administration of 1 g/kg of curcumin to the rat allows the polyphenol to reach plasma concentrations around 1.3  $\mu$ M. Early studies have shown that curcumin has strong antioxidant activity. In fact, the beta-diketone moiety, especially the phenolic hydroxyl group, is critical for the antioxidant activity of curcumin and its analogs (109, 151, 206). Very recently, many articles have appeared in the literature demonstrating that curcumin and its metabolites interact with several intracellular systems such as transcription factor NF $\kappa$ B, iNOS, and HIF-1 and members of the vitagene family (see below). This complex array of interactions is in agreement with the well-known ability of curcumin to serve not only as an antioxidant but also as antiinflammatory and anticarcinogenic molecule (264). In lung epithelial cells, curcumin exerted anticarcinogenic activity and prevented the cigarette-smoke-induced NF $\kappa$ B activation through inhibition of I $\kappa$ B $\alpha$  kinase activation, I $\kappa$ B $\alpha$  phosphorylation, and degradation (264). The inhibition of the NF $\kappa$ B activation was paralleled by the suppression of many NF $\kappa$ B-related genes, including cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9 (264). Particularly interesting is the interaction of curcumin with the vitagene system. Notably, curcumin increased expression of HO-1 in human cardiac myoblasts, hepatocytes, monocytes, and endothelial cells (316), as well as rat neurons and astrocytes (390). In several rodents and human cells, the curcumin-induced HO-1 overexpression was correlated with production of mitochondrial ROS, activation of transcription factors Nrf2 and NF $\kappa$ B, induction of mitogen-activated protein kinase (MAPK) p38, and inhibition of phosphatase activity (300). Moreover, curcumin upregulated Hsp70 in human colorectal carcinoma cells, proximal tubule cells, and leukemia cells (443). Quite different is the effect of curcumin on thioredoxin

reductase, as it has been shown that curcumin irreversibly inhibits thioredoxin reductase activity. As a consequence, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity is stimulated with overproduction of ROS (171). This latter paradoxical effect may explain, at least in part, the cancer chemopreventive activity of curcumin (171).

### G. Ferulic acid

Ferulic acid is another phenolic compound (Fig. 9) and a major constituent of fruit and vegetables with strong antioxidant and antiinflammatory properties. Recently, it has been demonstrated that ferulic acid ethyl ester, a more hydrophobic form of ferulic acid, protects synaptosomal membrane system and neuronal cell culture systems against hydroxyl and peroxy radical oxidation, as well as mice against A $\beta$ -induced microglial activation (97, 351). In addition to this direct antioxidant property, ferulic acid ethyl ester has been shown to increase HO activity in rat astrocytes and neurons (106, 389). Recent finding indicates that ferulic acid promotes nuclear translocation of Nrf2, whereby increasing the transcription of HO-1 together with other antioxidant related genes, such as GCLC (glutamate-cysteine ligase catalytic subunit), GCLM (glutamate-cysteine ligase regulatory subunit), and NQO1. These changes involve increase of the intracellular GSH and activation of PI3K and extracellular signal regulated kinase signaling pathways (268). All this corroborates the hypothesis that HO activation is a common pathway through which phenolic compounds can exert neuroprotective effects (106).

## XIII. Heme Oxygenases

The heme oxygenases have been recognized as dynamic sensors of cellular oxidative stress and modulators of redox homeostasis throughout the phylogenetic spectrum. Heme oxygenases are located within the ER where they act in association with NADPH cytochrome P450 reductase to oxidize heme to biliverdin, free ferrous iron, and carbon monoxide (CO) (Fig. 6). Biliverdin reductase further catabolizes biliverdin to the bile pigment, bilirubin (104, 105, 108, 274), a linear tetrapyrrole that has been shown to effectively counteract nitrosative stress due to its ability to interact with NO and reactive nitrogen species (RNS) (99, 106–108). Bilirubin is then conjugated with glucuronic acid and excreted (393). In the last 20 years, many research articles have demonstrated that bilirubin is an endogenous cytoprotective molecule. The first evidence about the antioxidant activity of bilirubin was provided by Stocker and colleagues in 1987, who suggested that bilirubin may act as chain-breaker because of its ability to scavenge peroxy radicals transforming itself in a stable carbon centered radical (425). Later, Snyder and colleagues based on the evidence that bilirubin, in the nanomolar range, may protect cortical neurons from the toxicity elicited by ~10,000 times higher levels of hydrogen peroxide (163), proposed a novel mechanism based on an amplification cycle whereby bilirubin is oxidized to biliverdin by reactive oxygen species and then recycled by biliverdin reductase back to bilirubin. However, only a small fraction of the bile pigments undergo this redox cycle; therefore, the relevance of this mechanism of action is still debated. Finally, bilirubin has been shown to serve as an endogenous scavenger for both NO and reactive nitrogen species, which may alter the redox status of the cell and originate nitrosative

stress (276). Despite this important antioxidant properties, if produced in excess, as in the case of haemolytic anaemia or sepsis, unconjugated bilirubin becomes neurotoxic through multiple mechanisms involving the disruption of cell membrane structure, the reduction of mitochondrial transmembrane potential, and the activation of the apoptotic cascade.

Mammalian cells express at least two isoforms of HO, HO-1 and HO-2. A third protein, HO-3, determined to be a retrotransposition of the HO-2 gene (pseudogene), has been found unique to rats (390). Heme oxygenase-1, also referred as Hsp32, is induced by various stimuli, including oxidative and nitrosative stress, ischemia, heat shock, LPS, hemin, phenolic compounds, and the neuroprotective agent Neotrofin. Further, in cultured human and rodent cells, HO-1 expression can be repressed by hypoxia, cigarette smoke, or by treatment with IFN- $\gamma$  or desferrioxamine. On the other hand, HO-2, the constitutive form, is responsive to developmental factors and adrenal glucocorticoids. Although HO-1 and HO-2 catalyze the same reaction, they play different roles in protecting tissues against injury. A convincing hypothesis suggests that HO-1 induction is one of the earlier cellular response to tissue damage and is responsible for the rapid clearance of the intracellular pro-oxidant heme and its transformation into CO and biliverdin, the latter being the precursor of the antioxidant bilirubin. On the contrary, constitutively expressed HO-2 is primarily involved in maintaining cell heme homeostasis and in the sensing of intracellular levels of gaseous compounds including NO and CO.

Although HO-1 and HO-2 exhibit identical substrate and cofactor specificities, the isoforms are encoded by distinct genes, which share only 43% amino acid sequence homology in humans, and exhibit significant differences with regard to molecular weight, electrophoretic mobility, tissue distribution, regulation, and antigenicity (393). HO-1 contains a destabilizing proline-glutamic acid-serine-threonine sequence at the carboxy terminus that renders the peptide sensitive to rapid proteolysis, a characteristic not exhibited by HO-2. The half-lives of HO-1 mRNA and protein have been estimated to be 3 and 15–21 h, respectively (148). The HO-1 gene is now well defined in its redox regulation as it contains the ARE in its promoter region, similar to other antioxidant enzymes (223, 273). HO-1, in fact, can be induced by several stimuli associated with oxidative and/or nitrosative stress, such as heme, A $\beta$ , dopamine analogues, H<sub>2</sub>O<sub>2</sub>, hyperoxia, UV light, heavy metals, prostaglandins, NO, peroxynitrite, Th1 cytokines, oxidized lipid products, and LPS, as well as certain growth factors (148, 273, 393). HO-1 gene expression is regulated by a variety of factors such as pro-oxidant states or inflammation (273). The molecular mechanism that confers inducible expression of *ho-1* in response to numerous and diverse conditions has remained elusive. One important clue has recently emerged from a detailed analysis of the transcriptional regulatory mechanisms controlling the mouse and human *ho-1* genes, which in humans is located on chromosome 22q12. The induction of *ho-1* is regulated principally by two upstream enhancers, E1 and E2 (5, 106, 273). Both enhancer regions contain multiple stress (or antioxidant) responsive elements (StRE, also called ARE) that also conform to the sequence of the Maf recognition element (5, 325, 393) with a consensus sequence (GCnnnGTA) similar to that of other antioxidant enzymes (107) (Fig. 6). Polymorphisms in the lengths of GT repeats [11–40] within the *ho-1* gene

(HMOX1) promoter appear to be an important determinant of HO-1 expression and function in humans. Long GT sequences code for relatively unstable (Z-conformational) DNA with attenuated transcriptional activity and diminished baseline and stimulated HO-1 protein expression profiles. Significantly higher HO-1 activity is associated with the short-GT polymorphisms, which may protect against atherosclerosis-linked conditions (e.g., coronary artery disease), whereas the malignant behavior of various neoplasms was fairly consistently enhanced by the short-GT form (393). Due to its strong antioxidant properties and wide distribution within the CNS, HO-1 has been proposed as a key enzyme in the prevention of brain damage (106, 107). The neuroprotective effects of overexpressed HO-1 can be attributed to (a) increase in cGMP and bcl-2 levels in neurons; (b) inactivation of p53, a protein involved in promoting cell death; (c) increase in antioxidant sources, and (d) increase in the iron sequestering protein, ferritin (346). Specifically, the interaction between HO-1, p53, and Bcl2 could involve the heme-regulating motifs of HO-2 (297), which could modulate gene expression by promoting oxygen radical formation and acting as a sink for NO. When HO-1 levels are increased, as in Tg mice, a decreased level of heme for binding to HO-2 heme-regulating motifs may alter heme/oxygen gene-regulating events. bcl-2 and p53 may well be among those genes whose expression would be affected as the consequence of the change in the oxidoreductase state of the cell brought about by altered heme-regulating motif interactions with oxygen and/or NO.

Particularly interesting is the role played by HO-1 in AD, a neurodegenerative disorder that involves a chronic inflammatory response associated with both oxidative brain injury and A $\beta$ -associated pathology. Significant increases in the levels of HO-1 have been observed in AD brains in association with neurofibrillary tangles and also HO-1 mRNA was found increased in AD neocortex and cerebral vessels; the HO-1 increase also colocalized with senile plaques and glial fibrillary acidic protein-positive astrocytes in AD brains (393).

It is plausible that the dramatic increase in HO-1 in AD may be a direct response to an increase in free heme concentrations, associated with neurodegeneration, and can be considered as an attempt of brain cells to convert the highly toxic heme into the antioxidants CO and bilirubin (100). The protective role played by HO-1 and its products in AD raised new possibilities regarding the possible use of natural substances, which are able to increase HO-1 levels, as potential drugs for the prevention and treatment of AD. In this light very promising are the polyphenolic compounds contained in some herbs and spices, for example, curcumin (102, 106, 109). Curcumin is the active antioxidant principle in *Curcuma longa*, a coloring agent and food additive commonly used in Indian culinary preparations. This polyphenolic substance has the potential to inhibit lipid peroxidation and to effectively intercept and neutralize ROS and RNS (102, 105, 109, 390). In addition, curcumin has been shown to significantly increase HO-1 in astrocytes and vascular endothelial cells (316, 317). This latter effect on HO-1 can explain, at least in part, the antioxidant properties of curcumin, in particular keeping in mind that HO-1-derived bilirubin has the ability to scavenge both ROS and RNS (316). Epidemiological studies suggested that curcumin, as one of the most prevalent nutritional and medicinal compounds used by the Indian population, is responsible for the significantly reduced (4.4-fold) prevalence of AD in India

compared to United States (102, 259, 469). On the basis of these findings, Lim and colleagues have provided convincing evidence that dietary curcumin given to an AD transgenic APP<sup>Sw</sup> mouse model (Tg2576) for 6 months resulted in a suppression of indices of inflammation and oxidative damage in the brain of these mice (258). Further, increasing evidence indicates that curcumin inhibits NF $\kappa$ B activation, efficiently preventing cell death (12, 384).

In the absence of elevated intracellular heme or oxidative stress, the basic region leucine zipper transcriptional regulator BACH1 binds HMOX1 AREs and represses transcription. Conversely, increased intracellular heme or sulfhydryl oxidation inactivates BACH1, permitting transcriptional induction of HMOX1. Although it is generally agreed that increased HO-1 expression is a common feature during oxidative stress, recent articles demonstrated that HO-1 can be repressed during oxidative stress conditions. In particular, human cells exposed to hypoxia, thermal stress, and IFN- $\gamma$  showed a marked HO-1 repression, and this effect seems to be peculiar for human, because rodent cells increased HO-1 expression when exposed to the same stimuli (232). The importance of HO-1 repression has been corroborated by the discovery of Bach1/Bach2 as heme-regulated transcription factors for HO-1 gene (232). In fact, Bach1 is broadly expressed in mice and human tissues; in human cells, it is induced by the same stimuli that are able to repress HO-1 gene (5, 325). Current hypothesis suggests that HO-1 repression is useful for the cell because it (a) decreases the energy costs necessary for heme degradation, (b) reduces the accumulation of CO and bilirubin, which can become toxic if produced in excess, and (c) increases the intracellular content of heme necessary for the preservation of vital functions such as respiration (5, 126, 232). Delineation of the diverse roles of HO-1 in brain senescence, aging-related human neurodegenerative disorders, and other CNS conditions has progressed substantially in these last years. Whereas the acute induction of this enzyme in neural and other tissues is predominantly cytoprotective in nature, protracted or repeated upregulation of the *Hmox1* gene in astrocytes, oligodendroglia, and possibly neurons may perpetuate cellular dysfunction and demise in many chronic degenerative and neuroinflammatory conditions long after provocative stimuli have dissipated. In the case of normal brain aging, AD, PD, and other late-life neurodegenerations, there is converging evidence that the associated tissue iron sequestration, intracellular oxidative stress, and mitochondrial dysfunction may constitute a single pathogenic *momentum* acting downstream from the sustained action of HO-1 within the astrocytic compartment. In AD and mild cognitive impairment, immunoreactive HO-1 protein is overexpressed in neurons and astrocytes of the cerebral cortex and hippocampus relative to age-matched, cognitively intact controls and colocalizes to senile plaques, neurofibrillary tangles, and corpora amylacea. In PD, HO-1 is markedly overexpressed in astrocytes of the substantia nigra and Lewy bodies in affected dopaminergic neurons. HMOX1 is also upregulated in glial cells located around human cerebral infarcts, hemorrhages, and contusions, within multiple sclerosis plaques, and in other oxidant degenerative and inflammatory human CNS disorders. Within this context, heme-derived free ferrous iron, CO, and biliverdin/bilirubin are all biologically active substances that can either ameliorate or exacerbate neural injury contingently to the specific disease conditions, such as inten-

sity and duration of HO-1 expression and/or the nature of the resulting redox milieu. In stressed astroglia, HO-1 hyperactivity promotes mitochondrial sequestration of nontransferrin iron and macroautophagy and may thereby contribute to the pathological iron deposition and bioenergetic failure found in most age-related oxidant neurodegenerative disorders. Glial HO-1 expression may impact also cell survival and neuroplasticity by modulating brain sterol metabolism and proteosomal degradation of neurotoxic protein aggregates (394).

#### XIV. Adaptive ER Stress Responses: Calcium and Protein Chaperones

Two major functions of the ER are the biosynthesis and quality control of proteins, and the regulation of cellular calcium homeostasis (302, 478). Several key proteins that control these two ER functions are responsive to cellular stress, including metabolic and oxidative stress. One of the first ER stress-responsive proteins discovered is glucose-regulated protein 78 (GRP78 or Bip), which is a protein chaperone that protects nascent proteins from misfolding and damage (326). The expression of GRP78 is highly sensitive to metabolic stress, and its upregulation under such adverse conditions has been shown to protect cells against death (326). Several other such chaperones, with complementary functions, have been identified, including GRP94, GRP170, and calreticulin. Interestingly, even relatively mild physiological stressors can upregulate ER chaperones, including dietary energy restriction (17) and exercise (454). ER Ca<sup>2+</sup>-regulating proteins, including IP<sub>3</sub> receptors, ryanodine receptor, and the sarco-/endo-plasmic reticulum Ca<sup>2+</sup>-ATPase, are also influenced by and, in turn, modify cellular stress. For example, activation of IP<sub>3</sub> receptor channels in the ER of nerve cells leads to activation of the transcription factor NF $\kappa$ B, which, in turn, induces expression of proteins that protect the neurons against stress, including Mn-superoxide dismutase and Bcl-2 (188).

A very important stereotyped sequence of events is now known as the UPR (320). Eukaryotic cells respond to unfolded proteins in their ER stress, amino acid starvation, or oxidants by phosphorylating the alpha subunit of translation initiation factor 2 (eIF2 $\alpha$ ). This adaptation inhibits general protein synthesis while promoting translation and expression of the transcription factor ATF4. Atf4(-/-) cells are impaired in expressing genes involved in amino acid import, glutathione biosynthesis, and resistance to oxidative stress (198). Under low stress conditions, GRP78 is associated with several different ER proteins, including protein kinase-like ER kinase (PERK), inositol requiring element-1 (IRE-1), and activating transcription factor 6 (ATF6). When cells are under oxidative and metabolic stress, GRP78 is recruited to oxidatively damaged and misfolded proteins, and PERK, IRE-1 and ATF-6 are mobilized to serve the complementary roles in the UPR. PERK suppresses protein translation by phosphorylating eIF2 $\alpha$ , and also phosphorylates and thereby activates the transcription factor Nrf2, resulting in the production of antioxidant and phase 2 enzymes. IRE-1 activation results in the production and nuclear translocation of the transcriptional regulator XBP-1, which, in turn, induces expression of GRP78 and GRP94. During the UPR, ATF-6 is cleaved to generate an active transcription factor that translocates into the nucleus and induces expression of several cytoprotective proteins. Examples of stimuli that activate the UPR include nutrient




deprivation, altered protein glycosylation, oxidative stress, and increased intraluminal  $\text{Ca}^{2+}$  levels.

Until recently, the ER was viewed as a protein synthesis factory that was not involved in signal transduction processes or cellular stress responses. We now know that the ER plays pivotal roles in regulating cellular  $\text{Ca}^{2+}$  homeostasis and transduces  $\text{Ca}^{2+}$ -mediated signals from extracellular signals (excitatory neurotransmitters and growth factors) and signals emanating from internal organelles, including mitochondria and the nucleus (456). Indeed, the ER is believed to be involved in the integration of signaling events within axon terminals and dendrites of neurons (283, 347, 413). When stimulated by  $\text{IP}_3$  or  $\text{Ca}^{2+}$  itself,  $\text{Ca}^{2+}$  is released from the ER through opened  $\text{IP}_3$  receptor and ryanodine receptor channels, respectively (Fig. 10). An ER membrane  $\text{Ca}^{2+}$  ATPase is responsible for transporting  $\text{Ca}^{2+}$  into the ER. Excessive ER stress and dysregulation of ER  $\text{Ca}^{2+}$  homeostasis is believed to contribute to the dysfunction and death of neurons in ischemic stroke (412), AD (32, 283, 290), and Parkinson's disease (233). The ER is also an important sensor of cellular stress. In response to energetic, oxidative, and ionic (particularly  $\text{Ca}^{2+}$ ) stress, protein synthesis may be decreased, and signals are sent from the ER to the nucleus that result in the upregulation of expression of genes encoding ER protein chaperones such

as GRP78 and GRP94, and antioxidant enzymes (320). Recently, an ER membrane-associated protein called Herp was shown to stabilize cellular  $\text{Ca}^{2+}$  homeostasis in neurons during ER stress (118).

The ER plays important roles in hormetic responses to stress in neurons. Thapsigargin is an agent that inhibits the ER  $\text{Ca}^{2+}$ -ATPase resulting in depletion of ER  $\text{Ca}^{2+}$  stores and activation of the UPR. Treatment of cultured cerebellar neurons with thapsigargin increased their survival under culture conditions (low extracellular  $\text{K}^+$  concentration) in which they would otherwise undergo apoptosis (470). The mechanism by which ER  $\text{Ca}^{2+}$  mobilization can promote neuron survival is poorly understood, but emerging data suggest the involvement of both the released  $\text{Ca}^{2+}$  itself and a protein(s) released from the ER. In either case, it appears that transcription factors are activated, resulting in the upregulation of cell-survival-promoting proteins. Glazner *et al.* (188) showed that a cell survival signal is released from the ER in response to emptying of  $\text{IP}_3$ -sensitive  $\text{Ca}^{2+}$  stores; the signal, which may be a protein, activates  $\text{NF}\kappa\text{B}$ . Another study showed that the immediate early gene *pip92* and mitogen-activated protein kinase are activated in response to ER  $\text{Ca}^{2+}$  mobilization (129). Interestingly, Bcl-2 can decrease ER  $\text{Ca}^{2+}$  uptake, resulting in enhanced  $\text{Ca}^{2+}$  signaling and activation of cyclic



**FIG. 10. Regulatory systems in mitochondria and the endoplasmic reticulum involved in hormetic responses of neurons to a range of environmental factors.** Modified from Mattson *et al.* (292). CytC, cytochrome c; ER, endoplasmic reticulum; GRP, glucose regulated protein; PTP, permeability transition pore; RyR, ryanodine receptor; SERCA, sarco endoplasmic reticulum calcium ATPase; TCA, tricarboxylic acid cycle; UCP, uncoupling protein; VDAC, voltage-dependent anion channel. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

AMP response element binding protein, thereby promoting the regeneration of injured axons (218). Moreover, Mendes *et al.* (301) showed that an ER-mediated signal associated with the UPR enhances antioxidant defenses and inhibits caspase-dependent cell death. Thus, mild ER stress can elicit multiple hormetic responses in neurons.

A better understanding of adaptive responses to ER stress may lead to novel therapeutic approaches for both acute and chronic neurodegenerative conditions. As evidence, it has been reported that, by activating ryanodine receptors in the ER, paraxanthine (the major metabolite of caffeine) can prevent the degeneration of dopaminergic neurons in a model of Parkinson's disease (196). Induction of ER protein chaperones is another therapeutic approach that is supported by experimental data showing that GRP78 (474), GRP94 (21), and ORP150 (234) can protect neurons against excitotoxic and ischemic death. Mild ER stress responses may be elicited by factors that are known to be neuroprotective including mild energetic stress (dietary energy restriction and 2-deoxyglucose treatment) (166, 475) and exercise (454).


### XV. Hsps and Neuroprotection

The HSR is one possible cellular stress response where a set of Hsps are induced, playing important roles in cellular repair and protective mechanisms (311, 312). HSR is regulated at the transcriptional, translational, and posttranslational levels by a family of heat HSFs that are expressed and maintained in an inactive state under nonstress conditions. Among three functionally different HSFs in humans, HSF1 represents the major regulator of the HSR genes, mediating signaling of stress-induced stimuli, such as elevated temperatures, as well as those involved in development and in many pathophysiological conditions, including cancer, ischemia-reperfusion injury, diabetes, and aging (Figs. 4 and 11) (452, 466). HSF1

is generally found in the cytoplasm as an inert monomer lacking transcriptional activity; both DNA-binding and transcriptional transactivation domains are repressed through intramolecular interactions and constitutive serine phosphorylation (308). Upon exposure to heat shock and other types of stresses, which cause protein damage, HSF1 is de-repressed in a stepwise process that involves oligomerization of HSF1 monomers to a trimeric state, localization to the nucleus, inducible phosphorylation and sumoylation, binding of nuclear-localized trimers to DNA, and transcription of HS genes [reviewed in ref. (13)]. The main targets for HSF1 are specific promoter elements composed of repeats of the pentameric sequence nGAAn (heat shock elements [HSE]) located upstream of HS genes. High rates of transcription are maintained only when HSF1 trimers remain bound to the HSE; when either the stress signal is removed or damaged proteins are no longer generated, the HSR attenuates rapidly, with subsequent conversion of HSF1 back to the monomeric state (310). Inducible acetylation has also been recently shown to negatively regulate DNA binding activity (42, 311).

Mammalian genomes encode three homologs of HSF (HSF1, HSF2, and HSF4) regulating Hsp expression. Among these HSF1 is considered to be the paralog responsible for regulating the heat-induced transcriptional response (42, 311, 312). HSF2 has also been reported to contribute to inducible expression of heat shock genes through interplay with HSF1 (373). Whereas it is well established that HSF1 regulates inducible Hsp expression, recently it has become evident that the regulation of the mammalian HSR is a more complex phenomenon than previously thought. Microarray and chromatin immunoprecipitation analysis, while confirming that many known heat-inducible genes have HSF1-binding sites in their promoters, have defined another class of genes that recruit HSF1 to their HSE promoter elements but that nevertheless are not induced by heat shock (373). On the other

#### CELLULAR STRESS RESPONSE : REGULATION OF Hsp70



**FIG. 11. Damaged or misfolded proteins titrate away heat shock proteins that are bound to HSF1 and maintain it in a repressed state before stress, resulting in its activation.** Multistep activation of HSF1 involves posttranslational modifications, such as hyperphosphorylation and deacetylation, which allow HSF1 to trimerize and translocate into the nucleus, where inducible acetylation, phosphorylation, and sumoylation occur before binding of nuclear-localized trimers to DNA, and HS genes are transcribed. In particular, upon activation, HSF1 is transiently sumoylated on lysine 298, which requires the phosphorylation of serine 303 adjacent to the consensus site (13). Hence, small ubiquitin-related modifier modification is

elaborately regulated, and the small ubiquitin-related modifier substrate specificity can be determined by regulatory elements outside the consensus site. Hsp, heat shock protein. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).

hand, these studies have provided evidence that, in some cases, HSF1 may also control expression of genes with non-chaperone function (373), such as superoxide dismutase, the multiple-drug resistance genes, lactate dehydrogenase, and the T-cell death-associated gene 51 (373). Neurons appear to be deficient in the HSR while retaining the ability to express such HSF proteins (312). Further, HSF1 fails to be activated in motor neurons even when microinjected with plasmids encoding an HSF1 expression vector, suggesting a block to the HSF1 signal transduction pathways in these cells (24). HSF1 is repressed under nonstress conditions by a complex containing Hsp90 and other proteins (Fig. 11). In this inactive state, HSF1 is a monomer that lacks the ability to bind *cis*-acting HSE in the promoters of Hsp genes (110). During protein stress and the consequent generation of misfolded proteins that displace HSF1 from the inhibitory chaperone complex, HSF1 trimerizes, become phosphorylated, and is translocated to the nucleus, where it is acetylated and sumoylated before being able to bind to the heat shock element of Hsp genes (310, 466). Activation of HSF1 by heat shock is a multistep process, involving multiple inducible phosphorylation, dephosphorylation, acetylation, deacetylation, and sumoylation steps, the sum of which results in the transcription of Hsp genes (Fig. 11). Extracellular signal input during heat shock involves tyrosine phosphorylation upstream of HSF1, involving the receptor tyrosine kinase HER2 and launching downstream signaling cascades through intracellular kinase Akt (110). (Fig. 11) Akt regulates HSF1 at least in part through modulating its association with the phosphoserine binding scaffold protein (110).

In addition to thermal stress, the inducible expression of Hsps is also triggered by environmental redox changes or exposure to electrophiles, which cause trimerization and DNA binding of HSF1 (310, 452), pointing to the importance of the cysteine redox state for the activation of this transcription factor. Thus, an intermolecular disulfide bond formation between C36 and C103 within HSF1 causes trimerization and DNA binding, whereas an intramolecular disulfide bond formation (in which C153, C373, and C378 participate) is inhibitory for the activity of the transcription factor (266).

Manipulation of HSR may offer strategies to protect brain cells from damage that is encountered after cerebral ischemia or during the progression of neurodegenerative diseases (309). Hsps are evolutionarily conserved and present in all cellular compartments (417, 418). Some of the major chaperones (Hsc70, Hsp90, and small Hsps) are present at high concentrations in nonstressed cells reaching 1%–5% of total cellular protein, consistent with an important role for chaperones in cellular homeostasis. Hsps are classified according to their molecular weight (270). Hsp70, the 70 kDa family of stress proteins, is one of the most extensively studied. Included in this family are Hsc70 (heat shock cognate, the constitutive form), Hsp72 (the inducible form, also referred to as Hsp72), and GRP75 (a constitutively expressed glucose-regulated protein found in the ER) (269). Hsp70s function in co- and posttranslational folding and the quality control of misfolded proteins (139). More specifically, Hsp70s participate in folding and assembly of newly synthesized proteins into macromolecular complexes, aggregation prevention, dissolution and refolding of aggregated proteins, as well as protein degradation (43). Hsp70s have an N-terminal ATP-binding domain (NBD) and a C-terminal substrate-binding

domain (SBD), which are both critical for chaperone function. Nonnative substrates with exposed hydrophobic stretches within an accessible polypeptide backbone associate transiently with Hsp70 *via* its SBD. ATP binding to the NBD triggers opening of the SBD binding pocket, decreasing affinity for polypeptide substrates, thereby accelerating both on and off rates. Reciprocally, substrate binding induces ATP hydrolysis, closing the SBD and thus stabilizing the substrate-Hsp70 complex (43). It is this cycle of rapid but controlled binding and release of the substrate that fosters folding and assembly with partner proteins while preventing aggregation of substrates; however, detailed mechanistic understanding of how Hsp70 accomplishes these feats is not yet available (43). Numerous hypotheses have been put forth to explain the molecular mechanism of Hsp70-induced structural conversion of substrate proteins. For example, an entropic pulling mechanism has been proposed, whereby Hsp70 binding stabilizes peptide segments in an unfolded state, causing local unfolding, thereby facilitating disaggregation and allowing refolding upon Hsp70 release (189). Cofactors, such as the nucleotide exchange factors and cochaperones, are crucial regulatory components of the Hsp70 cycle that confer versatility and specificity to the Hsp70 chaperone machine (43). The Hsp40 cochaperone targets substrates to Hsp70 while stimulating ATP hydrolysis; nucleotide exchange factors like Bag-1 (BCL2-associated athanogene 1) and Hsp110 reinitiate the Hsp70 cycle by facilitating ADP release and rebinding of ATP (380). Moreover, Bag-1 has the additional ability to bind to the 26S proteasome, and another BAG isoform, the Bag-3 cochaperone, links Hsp70 to the macroautophagic degradation pathway during aging (110). Carboxy terminus of Hsc70-interacting protein, a cochaperone of Hsp70 that also has E3 ubiquitin ligase activity, cooperates with Bag-1, and possibly Bag-3, to facilitate degradation of terminally misfolded substrate proteins. Notably, mutations in Hsp70 cofactors are lethal (271) or may be associated with neurodegenerative disease (269, 271).

Recent studies indicate that the HSR declines in aging cells and becomes weaker as organisms live beyond the mature adult stage (104). Cells lose the capacity to activate the transcriptional pathways leading to Hsp synthesis (Fig. 4). In neuronal tissues, decline in protein quality control has been widely predicted, as the etiology of a number of diseases involves aggregation-prone proteins that form inclusion bodies whose occurrence is linked to pathology. Hsp70 has been extensively implicated in the pathogenesis of misfolding disease (110). Numerous studies indicate that Hsp70 and components of the ubiquitin-proteasome system associate with inclusion bodies/plaques characteristic of misfolding diseases, indicating a general activation of the cellular quality control machinery in an attempt to circumvent the accumulation of misfolded species (201). In these conditions the Hsp70 system is unable to refold disease-related proteins, causing perturbation of protein homeostasis associated with disease onset. Several hypotheses account for this apparent disruption of the balance between the production of misfolded proteins and Hsp70 activity. As misfolded disease proteins accumulate, these can overwhelm the capacity of the Hsp70 system to control the cellular folding milieu (312). Progressive reduction in protein levels and/or activity of Hsp70 and other components of the quality control network may exacerbate this imbalance, permitting further

accumulation of toxic misfolded proteins. Such reduction could be due to the aging process, as transcription of Hsp70 decreases during aging of the human brain (43). Alternatively, disease processes themselves might cause, or worsen, chaperone deficiency. Inclusions have been proposed to sequester Hsp70 and other proteins in a nonfunctional state, inhibiting their essential function in cellular processes (43).

The availability of transgenic animals and gene transfer allowing overexpression of the gene encoding for Hsp70 has revealed that overproduction of this protein leads to protection in several different models of nervous system pathology (97). Overexpression of Hsp70 and/or its cochaperones suppresses huntingtin aggregation and toxicity in yeast and mammalian cell models of misfolding disease (380). Increased Hsp70 levels caused reduced aggregation and toxicity of tau and A $\beta$ , respectively, two components associated with Alzheimer's disease (269). Similarly, overexpression of Hsp70 reduces toxicity and accumulation of  $\alpha$ -synuclein in high-molecular-weight and detergent-insoluble deposits (269). Increased expression of Hsp70 has been reported to be associated with a decrease in apoptotic cell death, an increase in expression of the antiapoptotic protein Bcl-2, a suppression of microglial/monocyte activation, and a reduction in matrix metalloproteinases. Upregulation of Hsp70 likewise reduced apoptosis and the formation of coaggregates of the prion disease protein, PrP (104). Numerous studies have also shown that Hsp70 overexpression reduces polyQ toxicity. Results obtained *in vitro* have elucidated the mechanism of action of Hsp70 against misfolding and thus toxicity of disease proteins. Purified Hsp70 acts preferentially on monomers or oligomers, rather than fibrillar aggregates of A $\beta$ , huntingtin, and  $\alpha$ -synuclein species modulating the aggregation process (104). Hsp70 inhibits the aggregation of A $\beta$  and  $\alpha$ -synuclein species even at substoichiometric levels, suggesting that Hsp70 can recognize multimeric protein assemblies (43). As mentioned before, the effect of Hsp70 on aggregation, which requires its ATPase activity, is enhanced by the cochaperone Hsp40. Thus, Hsp70, together with Hsp40, stabilizes huntingtin in a monomeric conformation and prevents accumulation of spherical oligomers, which are the toxic species for fibril formation (403). As a result, mutant huntingtin is deviated from the potentially toxic, fibrillar aggregation pathway and instead accumulates in amorphous aggregates, or other benign conformers. Sequestered in these conformers, mutant huntingtin may no longer participate in heterotypic interactions known to inactivate essential cellular machinery, such as polyQ-containing transcription factors (311, 403).

After focal cerebral ischemia, Hsp70 mRNA is synthesized in most ischemic cells except in areas of very low blood flow, due to scarce ATP levels. Hsp70 proteins are produced mainly in endothelial cells, in the core of infarcts in the cells that are most resistant to ischemia, in glial cells at the edges of infarcts, and in neurons outside the areas of infarction (479). It has been suggested that this neuronal expression of Hsp70 outside an infarct can be used to define the ischemic penumbras, which means the zone of protein denaturation in the ischemic areas; consistently in *in vivo* transgenic mice overexpressing Hsp70, compared to wild-type mice in a middle cerebral artery occlusion model of permanent cerebral ischaemia, it has been demonstrated that overexpression of Hsp70 reduces the overall lesion size and also limits the tissue damage within the lesion (479). Hsp72 overexpression has been documented in

postmortem cortical tissue of AD patients (95, 270). Consistently, the use of agents that limit microglial activation and inflammation in AD has recently emerged as an attractive therapeutic strategy for this disease. For instance, the vasoactive intestinal peptide has been shown to prevent A $\beta$ -induced neurodegeneration, through inhibition of major pathways involved in the production of inflammatory mediators, such as the p38 MAPK, p42/p44 MAPK, and NF $\kappa$ B cascades, in activated microglial cells (147, 221).

A large body of evidence now suggests a correlation between mechanisms of nitrosative stress and Hsp induction. We have demonstrated *in vitro* and *in vivo* that cytokine-induced nitrosative stress is associated with an increased brain synthesis of Hsp70 stress proteins. The molecular mechanisms regulating the NO-induced activation of heat-shock signal seem to involve cellular oxidant/antioxidant balance, mainly represented by the glutathione status and the antioxidant enzymes (27, 98, 99).

#### A. Neuroprotective effects of extracellular Hsps

Hsps are transferred between cell types in the nervous system. Thus, stress tolerance in neurons is not solely dependent on their own Hsps, but can be supplemented by additional Hsps transferred from adjacent glial cells. Therefore, supplying exogenous Hsps at neural injury sites could be an effective strategy to maintain neuronal viability. This idea has been tested in a number of model systems. Injection of Hsc/Hsp70 into the vitreous chamber of the eye protected retinal photoreceptors from photodamage. Application of exogenous Hsc/Hsp70 to the cut end of the sciatic nerve reduced cell death in sensory and motor neurons. Extracellular Hsp70 protected spinal cord motor neurons deprived of trophic support *in vitro* or undergoing cell death *in vivo*. Thus, exogenous application of Hsps has potential as a therapeutic strategy for acute injury in the nervous system. Hsps are released into the blood stream after stressful stimuli and this may represent an important feature of the stress response. Exercise stress has been reported to induce the release of Hsp70 from the human brain into the blood stream *in vivo*. The biological significance of this neural release is yet to be determined (44).

### XVI. Neuro Gas Biology and the Roles of CO, NO, and Hydrogen Sulfide in Brain Physiopathology

#### A. Carbon monoxide


The first detection of a combustible gas in the blood occurred in 1894 by Grehant (195). This gas was supposed by de Saint Martin and Nicloux to be CO. However, it was not until 1949 that Sjorstrand discovered that endogenously produced CO arose from the degradation of hemoglobin released from senescing erythrocytes (414). Greater than 75% of CO produced in humans arises from erythrocyte turnover generated as a by-product of haem metabolism. In 1969, the source of endogenous CO was discovered, as Tenhunen and collaborators described and characterized heme oxygenase as the enzyme responsible for breaking down heme in the body, demonstrating that heme catalysis resulted in the subsequent release of CO and free iron as by-products (445) (Fig. 6). Since then, a large body of experimental evidence has demonstrated that CO is an extraordinary signaling molecule playing an

important role in the regulation of cellular homeostasis, especially in the brain, where CO can influence physiological and pathological processes both in the central and peripheral nervous systems (Fig. 12). Due to its capacity to freely diffuse from cell to cell, together with the fact that it is not stored in synaptic vesicles from which is released through membrane depolarization processes, it is a nonconventional neurotransmitter capable of influencing signal transduction mechanisms. CO binds to heme in guanylyl cyclase to activate cGMP, a process responsible for maintaining endogenous levels of cGMP (354). This effect is blocked by potent HO inhibitors but not NO inhibitors (274). Consistent with endogenous distribution of HO in the brain, it has been suggested that CO can influence neurotransmission like NO (457). CO is involved as a retrograde messenger in LTP as well as in mediating glutamate effectson metabotropic receptors (193). This is corroborated by the finding that HO inhibitors block the conductance of specific ions channels associated with metabotropic receptor activation in the brain regulates *via* a cGMP-dependent mechanism (187, 255). Experimental evidence indicates that CO plays a role similar to that of NO in signal transduction processes. HO resembles NOS in that the electrons for CO synthesis are donated by cytochrome P450 reductase, which is 60% homologous at the amino acid level to the carboxy-terminal half of NOS (96, 458). Like NO, CO binds to iron in the heme moiety of guanylyl cyclase. However,

while NO mediates glutamate's effects primarily at *N*-methyl-D-aspartate (NMDA) receptors, CO is involved in the effects of glutamate at a level of metabotropic receptors. As CO and NO play important roles in the regulation of CNS function, impairment of CO and NO metabolism results in abnormal brain function (Fig. 12) (97, 99, 337).

CO, is a primordial gas, produced and metabolized in almost all organisms from prokaryotes to mammals, and serves as an important signaling molecule owing to its capability to bind to reduced transition metal centers in heme proteins (354). Both exogenous CO and endogenous CO produced by heme oxygenase generate a pro-oxidant milieu in aerobic mammalian cells that initiates signaling *via* ROS formation. Signaling promoted by CO and mediated by ROS presumably is dependent on the CO concentration and the time of exposure, on the localization of heme proteins (*e.g.*, mitochondrial or nonmitochondrial sites), or on the specificity of redox reactions. Activation of redox-sensitive transcription factors or stress-activated kinases, which induce expression of cytoprotective enzymes, thus conferring adaptations and tolerance to oxidative stress, represent a fundamental response to CO. However, elevated or protracted CO exposures elicit responses that generally are nonspecific, favoring biological oxidations to an extent that disrupt cellular homeostasis (354). It is generally recognized that CO exposures that avoid macromolecular damage should stand in a range of tissue CO

**FIG. 12. Schematic signal transduction pathways underlying the interfunctional role of CO, NO, and H<sub>2</sub>S in the modulation of cell survival.** NO exerts neuroprotection through stimulation of the sGC/cGMP/PKG system as well as through S-nitrosylation. As a consequence of S-nitrosylating reactions, inhibition of NFκB and caspase-3 activity and a decrease in cell death occur. NO-mediated transcriptional activation of the Keap1/Nrf2/ARE pathway, associated with activation of K<sub>Ca++</sub> channel and inhibition of mitochondrial energy transductions at level of complex IV (Cox), activates mitochondrial-dependent H<sub>2</sub>O<sub>2</sub>-mediated redox signaling, leading to upregulation of pro-survival mechanisms, such as vitagenes HO-1 and heat shock protein 70, Bcl2, and mitochondrial biogenesis. The latter results from activation of coactivator PGC-1α and mtTFA. CO-mediated activation of mitochondrial redox signaling results in antiinflammatory, antiproliferative, and antiapoptotic effects, which confer neuroprotection. This occurs through activation of multiple pathways, including PPARγ, PGC-1α, and mtTFA, which induce mitochondrial biogenesis; P38 MAPK, HIF1α, K<sub>Ca++</sub> channel, PI3K-Akt, and Nrf2, as well as inhibition of ERK-1/2. H<sub>2</sub>S is a highly reactive, strong reducing molecule that easily reacts with ROS and RNS, thus providing antioxidant activity and, in addition, activates ATP-sensitive potassium channels. Known cellular targets of H<sub>2</sub>S include cytochrome c oxidase (complex IV, Cox) and carbonic anhydrase (CA). This gas H<sub>2</sub>S has also been demonstrated to regulate cellular signal transduction pathways, including thioredoxin reductase, HO-1, and glutamyl-cysteine synthetase, resulting in cytoprotection. K<sub>ATP</sub>, ATP-dependent K<sup>+</sup>; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase.



and antiapoptotic effects, which confer neuroprotection. This occurs through activation of multiple pathways, including PPARγ, PGC-1α, and mtTFA, which induce mitochondrial biogenesis; P38 MAPK, HIF1α, K<sub>Ca++</sub> channel, PI3K-Akt, and Nrf2, as well as inhibition of ERK-1/2. H<sub>2</sub>S is a highly reactive, strong reducing molecule that easily reacts with ROS and RNS, thus providing antioxidant activity and, in addition, activates ATP-sensitive potassium channels. Known cellular targets of H<sub>2</sub>S include cytochrome c oxidase (complex IV, Cox) and carbonic anhydrase (CA). This gas H<sub>2</sub>S has also been demonstrated to regulate cellular signal transduction pathways, including thioredoxin reductase, HO-1, and glutamyl-cysteine synthetase, resulting in cytoprotection. K<sub>ATP</sub>, ATP-dependent K<sup>+</sup>; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase.




concentrations that are below those produced at 20%–25% carboxyhemoglobin, the conventional threshold in mammals for serious poisoning. Beneficial for health are slow CO-releasing agents that do not exceed a concentration of 50 micromolar within a cell, as well as inhaled CO concentrations that acutely do not exceed 500 ppm for 1 h or 50 ppm continuously, in rodents. In humans, exposure limits of 50 ppm for 8 h and exposure concentration maximum of 200 ppm appear safe and may induce physiological effects (354).

The normal rate of endogenous CO production results in cellular CO concentrations, ranging from picomolar to nanomolar levels. This physiological concentration, however, can increase several fold depending on the heme turnover, whereas cellular CO content can increase 20–50-fold after exogenous CO administration. At high CO levels, the physiology is dominated by a range of adaptive stress redox-related responses, overlapping those observed during hypoxia. In the past, mitochondrial CO effects in living tissues were considered minor because the  $a_3$  heme is primarily in the oxidized state. However, even at physiological  $PO_2$ , CO does bind cytochrome oxidase, as some  $a_3$  does remain in the reduced state, especially in metabolically active tissues like the brain and the heart. In this milieu, bound CO reduces the cytochrome  $bc_1$  region of the chain respiratory complexes, thereby promoting significant mitochondrial ROS production (Fig. 13), which disrupts mitochondrial glutathione redox status. CO-dependent mitochondrial ROS generation has also been demonstrated for endogenous CO (427). Recently, signalization through mitochondrial ROS production by CO has become an emerging area and mitochondrial ROS are now implicated in various cellular regulatory processes, including cell proliferation, expression of angiogenesis factor, metalloproteinase mitochondrial biogenesis (328), and stabilization of hypoxia-inducible factor-1 (HIF-1). Low physiological levels of CO such as those generated by HO-1 induction have

been demonstrated to elicit strong proliferative and anti-apoptotic effects mediated by various signaling pathways, including PI3K-Akt, signal transducer and activator of transcription, and MAPK-Erk (33) (Figs. 10 and 13). Consistent to the metal-binding properties of CO, all heme-containing proteins are possible candidates with biological significance as CO sensors. These include proteins with heme as prosthetic group, such as hemoglobin, myoglobin, sGC, cyclooxygenase, cytochrome p450, cytochrome c oxidase, NOS, NADPH oxidase (Nox), transcription factors, neuronal PAS domain protein 2, and Bach-1 and Bach-2 (33).

Although CO at high concentrations is toxic, generation of lower amounts of ROS in response to exogenous low-dose CO might affect cellular respiration eventually resulting in adaptation (33). This is consistent with the general notion that the mitochondrial respiratory chain complexes I and III are the main sites of superoxide production (177). In this context, any impairment in the electron transfer process determines that upstream carriers become more reduced, thus filling Q cycle electron pool. The cytochrome (cyt)  $bc_1$  complex (EC 1.10.2.2) (cyt  $bc_1$  complex), localized in the inner membrane of mitochondria, couples the oxidation of a substrate quinol (QH<sub>2</sub>) with the generating proton motive force across the energy transducing membrane system, where the energy is ultimately stored in the form of ATP (Fig. 13). Cytochrome  $bc_1$  complexes contain four redox-active metal centers, arranged in two separate chains. The high potential chain consists of the Rieske iron-sulfur [2Fe2S] cluster (Fig. 13) and cyt  $c_1$ . The low potential chain, which binds to the cyt  $b$  subunit of ubiquinol oxidizing complexes, consists of two b-type hemes, cyt  $b_L$  and  $b_H$ , labeled for their relatively lower and higher electrochemical potentials (177). Three enzymatic binding sites participate in catalysis on the cyt  $bc_1$  complex: the quinol oxidase (Qo) site, quinol reductase (Qi) site, and a docking site for soluble cyt  $c$  on cyt  $c_1$ . The Qo site is located toward the



**FIG. 13.** The ubiquinone (Q) cycle is initiated when one electron from ubiquinol (QH<sub>2</sub>) is donated to the Rieske-iron sulfur protein and the second electron is donated to cytochrome  $b$ . The intermediate moiety is the free radical ubisemiquinone (Qo), which can donate electrons to molecular oxygen to generate superoxide. Mitochondrial electron transport chain generates superoxide at complexes I, II, and III. Complexes I and II generate superoxide within the mitochondrial matrix. Complex III can generate superoxide in both the intermembrane space and the matrix. Release of superoxide from complex III into the cytosol is followed by conversion to H<sub>2</sub>O<sub>2</sub> and subsequent activation of oxidant-dependent (redox) signaling pathways, which results in preconditioning. R-FeS, Rieske-iron sulfur.

positively charged side of the membrane, where protons are released during turnover of the enzyme (Fig. 13). The  $Q_i$  site is located toward the negatively charged surface of the membrane, where protons are taken up during catalysis. The water-soluble cyt *c* docking site is located on the *c*-type cyt representing the terminal electron carrier within the cyt *bc*1 complex on the positive side of the membrane. Cyt *bc*1 complex catalysis is thought to occur by a Q-cycle mechanism (Fig. 13). Conceivably, a key reaction in the Q-cycle is the bifurcated electron transfer at the  $Q_o$  site, although the exact mechanism is still controversial (177). In the bifurcated reaction,  $QH_2$  is oxidized at the  $Q_o$  site, with one electron being transferred through the high potential chain to reduce cyt *c*, and the other electron is transferred through the low potential chain, to reduce a quinoid species (Q or SQ, depending on the state of the two-electron gate) at the  $Q_i$  site. Two turnovers of the  $Q_o$  site are required to reduce a  $Q_i$  site Q to a  $QH_2$  (Fig. 13). Under some conditions, the Q-cycle can be short-circuited by various bypass reactions, some of which yield the physiologically deleterious superoxide (177). The bypass reactions are typically observed *in vitro* under partially inhibited conditions, for example, in the presence of antimycin A, or under high proton motive force, where it is possible that the [2Fe2S] cluster can oxidize  $QH_2$  to a semiquinone (SQ), but processing of electrons by the low potential chain is hindered, resulting in the accumulation of an SQ intermediate, which in turn can reduce  $O_2$  to superoxide (427).

Physiologically, electron transport chain consumes up to 90% of the oxygen taken up by a cell, of which ~1% is transformed in superoxide under normal physiological conditions (33). The rate of mitochondrial electron transfer from semireduced Q to molecular  $O_2$  to form superoxide is proportional to the product of the concentrations of semireduced Q and  $O_2$ . It is estimated that under pathophysiological conditions, superoxide production can occur at 2%–10% of the uninhibited rates. Superoxide dismutases, in turn, generate the more stable hydrogen peroxide before it is transformed by catalase in water or, depending on the presence of metals, into highly reactive hydroxyl radicals. Thus, SOD2, which directs  $H_2O_2$  out of the mitochondrion, accomplishes two functions: the classical scavenging of superoxide, as well as its signalization as ROS-dependent signaling pathways. The binding of CO to cytochromes localized within complex IV (*i.e.*, cytochrome  $a_3$ ) promotes reduction in the respiratory carriers in the cytochrome *bc*1 region of complex III, associated with increased leakage of superoxide and  $H_2O_2$  production (Fig. 13).

ROS-dependent signaling mediated by CO may involve other pathways, such as xanthine oxidase and Nox. The latter is assembled at the membrane only after stimulation. This confers biological significance to the cytosolic compartment, where the NADPH membrane-dependent system generating radicals represent the primary site of action for the CO molecule, rather than oxidases, which are located in the more distal mitochondrial milieu. Increasing evidence indicates that CO modulates mitochondrial ROS production. Mitochondrial  $H_2O_2$  production as consequence of CO binding to Cox leads to activation of PI3K-Akt pathway with subsequent activation of mitochondrial biogenesis (33). Further, CO increases RNA expression of Nrf1, Nrf2, and peroxisome proliferator-activated receptor- $\gamma$  coactivator-1 $\alpha$ , the transcription factors involved in the regulation and activation of mitochondrial biogenesis (33). In addition, CO upregulates

mitochondrial transcription factor A, SOD2, Bad, as well as activates KCa channels and modulates vascular relaxation through inhibition of endothelin-1 (422). Of note, in *Rhodospirillum rubrum*, a photosynthetic bacterium, CO binds to CooA, which, upon exposure to CO, acquiring DNA-binding transcriptional activity for the CO dehydrogenase gene, promotes the oxidative conversion of CO to  $CO_2$ . Consistently, heart cytochrome c oxidase is able to metabolize CO to  $CO_2$ , *via* its oxygenase activity (473). However, whether this occurs also in brain mitochondria remains to be determined.

CO was also found to be protective through an anti-inflammatory action, as demonstrated initially in a model of endotoxic shock, as well as mouse cardiac xenotransplantation (336). Accordingly, mouse hearts transplanted into rats treated with cyclosporine A and cobra venom factor as immunosuppressants survive indefinitely. However, in these experimental conditions, inhibition of HO activity or ablation of gene expression for HO-1 causes acute rejection, unless the donor and recipient received CO at a concentration of 250 ppm, similar to that found in heavy smokers, in which case grafts survive indefinitely (338). In this experimental paradigm, CO appears to be able to substitute for HO-1 in suppressing the pro-inflammatory response that causes graft rejection (339). These seminal experiments launched CO as a powerful anti-inflammatory agent acting at a level of macrophages, to control the balance of pro-inflammatory and anti-inflammatory molecular events. Inflammation is a complex dynamic process initiated by the body in response to tissue injury or infective agents. In this context macrophages are central for initiation, maintenance, and resolution of inflammatory process, through a series of steps involving antigen presentation, phagocytosis, and immunomodulation *via* cytokines and growth factors production (338). Activation signals include cytokines, such as IFNs, granulocyte-macrophage colony-stimulating factor, and TNF $\alpha$  as well as bacterial LPS, extracellular matrix proteins, and other chemical mediators. Macrophages recognize distinct pathogen-associated molecular patterns by Toll-like receptors (TLRs) that activate signaling pathways inducing expression of pro-inflammatory genes (33, 334). Consequently, inhibition of inflammatory events is a necessary process when the noxious stimulus promoted by invading cells and pathogens has been removed, so that survival of host cells is ensured. During the inflammatory process, secretion of anti-inflammatory cytokines such as IL-10 and transforming growth factor  $\beta$  promoted by CO leads to neutralization of activated macrophages, as demonstrated *in vivo* and *in vitro* after LPS administration (121). Notably, IL-10 itself induces HO-1 expression, thus generating a feedback mechanism whereby a persistent anti-inflammatory effect promoted by CO is maintained (33). In conclusion, CO modulates inflammatory processes through the (a) prevention of platelet aggregation, thus exerting antithrombotic affects, (b) downregulation of plasminogen activator inhibitor type 1 expression, and (c) anti-apoptotic action in several cell types, including endothelial cells, fibroblasts, hepatocytes, and  $\beta$ -cells of the pancreas (25). In addition, CO inhibits smooth muscle cell proliferation associated with neointimal thickening in inflammatory lesions *in vivo* (339). Many of the observed effects of CO have been obtained by exposing cells or animals to gaseous CO by inhalation; interestingly, the recently discovered CO-releasing molecules appear to afford similar protective action, thereby



providing an alternative therapeutic approach for those pathophysiological conditions where CO treatment is warranted (7, 121).

### B. NO and NO synthases

NO plays multiple roles in the nervous system (18, 108, 323). In addition to regulating proliferation, survival, and differentiation of neurons, NO is also involved in synaptic activity, neural plasticity, and memory function. NO exerts long-lasting effects through regulation of transcription factors and gene, thus modulating cell differentiation and survival processes in the brain. Signaling by NO is also mediated by reactive nitrogen species through targeted modifications of critical cysteine residues in proteins, including S-nitrosylation and S-oxidation, as well as by lipid nitration. NO is involved in neuroinflammation and neurodegeneration, such as in AD, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, Friedreich's ataxia, and Huntington's disease. Susceptibility to NO and its reactive nitrogen species is modulated by intracellular reducing potential, mainly reduced glutathione with its related antioxidant enzymes as well as redox-dependent cellular stress resistance signaling pathways. In view of this, neurons, in contrast to astrocytes, appear particularly vulnerable to the effects of nitrosative stress (323).

NO synthesis is catalyzed by the NOS family of enzymes, which convert arginine to citrulline and NO• (Fig. 6). NOS, localized in the CNS and in the periphery (323), is present in three well-characterized isoforms: (a) neuronal NOS (nNOS, type I), (b) endothelial NOS (eNOS; type III), and (c) inducible NOS (iNOS, type II). Activation of different isoforms of NOS requires various factors and cofactors. In addition to a supply of arginine and oxygen, an increase in intracellular calcium leads to activation of eNOS and nNOS, and formation of calcium/calmodulin complexes is a prerequisite before the functional active dimer exhibits NOS activity, which depends also on cofactors such as tetrahydrobiopterin, flavin adenine dinucleotide, flavin mononucleotide, and NADPH (99). nNOS has a predominant cytosolic localization, whereas the eNOS is bound to the plasma membrane by N-terminal myristylation (18). In contrast to nNOS and eNOS, iNOS can bind to calmodulin even at very low concentration of intracellular calcium; thus, iNOS can exert its activity in a calcium-independent manner. iNOS, usually present only in the cytosol, also requires NADPH, flavin adenine dinucleotide, flavin mononucleotide, and tetrahydrobiopterin for full activity. eNOS expressed in cerebral endothelial cells critically regulates cerebral blood flow. However, a small population of neurons in the pyramidal cells of CA1, CA2, and CA3 subfields of the hippocampus and granule cells of the dentate gyrus express eNOS. nNOS, which is expressed in neurons, is critically involved in synaptic plasticity, neuronal signaling, and neurotoxicity. Activation of nNOS forms part of the cascade pathway triggered by glutamate-receptor activation that leads to intracellular cyclic GMP elevation. The levels of iNOS expression in the CNS are generally very low. However, after noxious stimuli, such as viral infection or trauma, astrocytes and microglia express high levels of induced iNOS (350). Activation of iNOS requires gene transcription, and the induction can be promoted by endotoxin and cytokines (IL-1, IL-2, IFN- $\gamma$ , and TNF). iNOS induction can be blocked by antiin-

flammatory drugs (dexamethasone), inhibitory cytokines (IL-4 and IL-10), prostaglandins, tissue growth factors, or inhibitors of protein synthesis, for example, cycloheximide (350).

The discovery of the role of NO as a messenger molecule has revolutionized the concept of neuronal communication in the CNS. NO is a gas freely permeable to the plasma membrane. Thus, NO does not need a biological receptor to influence the intracellular communication or signaling transduction mechanisms (108). Once generated, the cell cannot regulate the local concentration of NO; therefore, the other way to influence NO activity is to control its synthesis. The activity of NO also terminates when it chemically reacts with a target substrate. NO when produced in small quantities can regulate cerebral blood flow and local brain metabolism (8, 99, 149), neurotransmitter release, and gene expression, and play a key role in morphogenesis and synaptic plasticity (181, 288). It is also generally accepted that NO is a major component in signaling transduction pathways controlling smooth muscle tone, platelet aggregation, host response to infection, and a wide array of other physiological and pathophysiological processes (317, 398, 453). Under conditions of excessive formation, NO is emerging as an important mediator of neurotoxicity in a variety of disorders of the nervous system (8, 486).

A large body of evidence shows cytoprotection by NO in various models of cellular toxicity and death: (a) direct scavenging of superoxide, as well as indirect action on the release of iron from ferritin stores through formation of iron-nitrosyl (399); (b) interaction of NO with cysteine residues on the NMDA receptor and inhibition of calcium influx (321); (c) inactivation of caspases (486); (d) activation of a cyclic GMP-dependent survival pathways (181); and (e) signal for the induction of cytoprotective proteins, such as Hsps (108). Current opinion holds that the intracellular redox state is the critical factor determining whether in brain cells NO is toxic or protective (323). The mechanistic involvement of NO as proinflammatory or antiinflammatory agent is dictated by the complexity of NO chemistry when applied to biological systems (190) (Fig. 12). As described in complete mechanistic details by Stamler, the reactivity of the NO depends on the oxidation state of the nitrogen atom, which makes this molecule prone to acquire different redox-active forms (190). In contrast to NO, which contains one unpaired electron in the outer orbital, nitrosonium cation and nitroxyl anion are charged molecules being, respectively, the one-electron oxidation and reduction products of NO. Whereas nitrosonium cation can be transferred reversibly between cysteine residues (transnitrosation), nitroxyl anion can be formed by hemoglobin, nNOS, and S-nitrosothiols (RSNO). Central to the biochemistry of NO is the reaction with sulphhydryl moieties to form S-nitrosyl derivatives or RSNO, a process termed S-nitrosation (28). Conceivably, RSNO, such as S-nitroso-glutathione or nitroso-cysteine, represents a chemical process for storage, stabilization, and preservation of bioavailable NO *in vivo* (179). In addition, due to its relatively abundant presence, GSH, as the main intracellular free thiol, represents a critical determinant of the reactivity and fate of NO. Thus, through S-nitrosation NO modulates activity and function of several enzymes and proteins (28). However, oxidative modification in protein structure and function may occur when reactive nitrogen species reach a critical threshold, and hence nitrosative stress may ensue (179). At the cellular level, nitrosative stress inhibits cell growth and causes apoptosis,

mediating a wide array of pathogenic effects elicited by NO (179). The intriguing aspect of the parallels between the effects mediated by increased RNS and ROS is the ability of cells to respond to these two types of stress, and depending on the severity of the nitrosative/oxidative insult, this response may result in adaptation and resistance to toxicity (108, 179, 281, 292, 317).

### C. Hydrogen sulfide

Hydrogen sulfide ( $H_2S$ ), a gas with the characteristic odor of rotten eggs, is known for its toxicity and as an environmental hazard, inhibition of mitochondrial respiration resulting from blockade of cytochrome c oxidase being the main toxic mechanism. Recently, however,  $H_2S$  has been recognized as a signaling molecule of the cardiovascular, inflammatory, and nervous systems; therefore, alongside NO and CO,  $H_2S$  is referred to as the third endogenous gaseous transmitter (404, 434, 460) (Fig. 12).

$H_2S$  is an endogenously produced gas in the central nervous system (442) as well as in various peripheral tissues and is present in the blood at an estimated concentration of approximately  $1 \mu M$ , which can rise up one order of magnitude in pathological states such as diabetes or hepatic encephalopathy (230, 434). There is some lack of clarity about the various biological forms of  $H_2S$ . Chemically, it can be distinguished as free  $H_2S$ , acid-labile sulfide (ALS), and dithiothreitol-labile sulfide (DLS) forms, each probably having quite different physiological significance. Free  $H_2S$  is the form also known as inorganic sulfide, which can be present as  $H_2S$ ,  $HS^-$  (hydrosulfide anion), or  $S^{2-}$  (sulfide anion) in the aqueous milieu and as  $H_2S$  in the gas phase (breath and flatus). The  $pK_a$  values for the first and second dissociation steps of  $H_2S$  are 7.04 and 11.96, respectively. Therefore, in the aqueous state, such as within a cell or in plasma at physiologic pH 7.4, approximately one-third exists in the undissociated volatile form ( $H_2S$ ) and the remainder largely as the hydrosulfide anion ( $HS^-$ ). Very small amounts of ( $S^{2-}$ ) are present. However, there is considerable ambiguity in literature regarding the terms describing free  $H_2S$ . Besides inorganic sulfide, terms such as  $H_2S$ , sulfide, and total sulfide are used. We here refer to the sum of  $H_2S$  and  $HS^-$  as total sulfide. Also convenient is to distinguish these forms of  $H_2S$  from acid-labile sulfide (ALS) and dithiothreitol-labile sulfide (DLS). ALS is the form from which  $H_2S$  is liberated when a biological matrix is treated under acidic conditions, and is contained in iron-sulfur clusters of nonheme iron-sulfur proteins (*e.g.*, ferredoxins). DLS is the form from which  $H_2S$  is liberated when a biological matrix is treated with dithiothreitol (DTT). This form belongs to the class of biological sulfane sulfur. Sulfane sulfur atoms are defined as divalent sulfur atoms bonded only to other sulfur, except that they may also bear ionizable hydrogen at some pH values. Labile sulfane compounds are compounds where elemental sulfur is associated with protein, either in the form of persulfides ( $R-SSH$ ) or polysulfides such as ( $R-S_n-R$ ) where  $n \geq 3$ , polythionates ( $^-O_3S-S_n-SO_3^-$ ), thiosulfate ( $SSO_3^{2-}$ ), and thiosulfonates ( $R-S(O_2)S^-$ ) (443).

$H_2S$  is produced by three enzymes in mammalian tissues, two pyridoxal phosphate-dependent enzymes (cystathionine  $\beta$ -synthase [CBS] and cystathionine  $\gamma$ -lyase [CSE]), and a newly described enzyme, 3-mercaptopyruvate sulfurtransferase (460) (Figs. 6 and 12). CBS utilizes pyridoxal

phosphate as a cofactor (Hishigami 2009) and it catalyzes the production of  $H_2S$  from cysteine by  $\beta$ -elimination ( $L-cys + L-Hcy \rightarrow L-cystathionine + H_2S$ ) or  $\beta$ -replacement reactions ( $L-cys + 2\text{-mercaptoethanol} \rightarrow S\text{-hydroxyl-L-cysteine} + H_2S$ ) (442). In addition, nonenzymatic  $H_2S$  production from organic polysulfides derived from garlic has been suggested as a potential source in the circulation (434).

There are three known pathways of  $H_2S$  degradation: mitochondrial oxidation to thiosulfate, which is further converted to sulfite and sulfate; cytosolic methylation to dimethylsulfide; and sulfhemoglobin formation after binding to hemoglobin (434). Similar to NO and CO,  $H_2S$  can also bind to hemoglobin—which represents the biochemical sink for these gaseous transmitters. Consequently, saturation with one of these gases might lead to enhanced plasma concentrations and, subsequently, to biological effects of the other gases.  $H_2S$  is oxidized into thiosulfate ( $S_2O_3^{2-}$ ), sulfite ( $SO_3^{2-}$ ), and sulfate ( $SO_4^{2-}$ ) (113) and excreted from the kidney (434).

In the central nervous system,  $H_2S$  functions not only as a neuromodulator, but also a neuroprotectant against oxidative stress (455). In the cardiovascular system,  $H_2S$  relaxes vascular smooth muscles by the activation of ATP-dependent  $K^+$  channels and inhibits smooth muscle cell proliferation *via* the mitogen-activated protein kinase signaling pathway. These effects are important for maintaining blood pressure and preventing vessel structural remodeling, and identifies  $H_2S$  as an important factor in the development of some vascular diseases, such as hypertension.  $H_2S$  also shows cardioprotective effects in ischemic myocardium and septic and endotoxin shock (119).

In the CNS, CBS is highly expressed in the hippocampus and the cerebellum (230). CBS is mainly localized to astrocytes (442). CSE is mainly expressed in cardiovascular system, but was also found in microglial cells, spinal cord, and cerebellar granule neurons. 3-Mercaptopyruvate sulfurtransferase is localized to neurons (442).  $H_2S$  production in astrocytes is approximately 10-fold higher than in cultured microglial cells, in NT-2 cells, or in SH-SY5Y cells (251). This finding suggests that astrocytes are the main brain cells producing  $H_2S$ .  $H_2S$  selectively enhances the NMDA receptor-mediated responses and facilitates the induction of hippocampal long-term potentiation (LTP), a synaptic model of memory and learning (433).  $H_2S$  may activate NMDA receptor by virtue of its reducing property. One plausible redox modulatory site is the cysteine (Cys) pair (Cys744 and Cys798) located on the extracellular domains of the NR1 subunit (442). Intracellularly,  $H_2S$  enhances NMDA receptor-mediated response *via* cAMP production. Exogenous  $H_2S$  increases the production of cAMP in primary cultures of rat cerebral and cerebellar neurons, and in some neuronal and glial cell lines (230). cAMP activates cAMP-dependent protein kinase during the initiation and late phase of LTP; consequently, activated cAMP-dependent protein kinase may, in turn, phosphorylate NMDA receptor subunits NR1, NR2A, and NR2B at specific sites and thus enhance NMDA currents, which is essential for LTP induction (442).  $H_2S$  also modulates the synaptic responses of serotonergic neurons and regulates the release of corticotropin-releasing hormone from the hypothalamus (364).  $H_2S$  upregulates  $\gamma$ -aminobutyric acid B receptor, a G protein-coupled receptor located at pre- and postsynaptic sites (364). In addition,  $H_2S$  has been shown to hyperpolarize neurons in the CA1 and dorsal raphe nucleus by increasing

K<sup>+</sup> efflux probably *via* ATP-dependent K<sup>+</sup> channels (442). H<sub>2</sub>S influences tyrosine and mitogen kinases; receptor tyrosine kinases as well as MAPKs regulate fundamental cellular activities such as apoptosis, differentiation, metabolism, motility, cell division, and survival (442).

In addition to its role in signal transduction, H<sub>2</sub>S can protect neuron cells from oxidative stress, not only by increasing the levels of antioxidant glutathione (113), but also by activating ATP-dependent K<sup>+</sup> channels and Cl<sup>-</sup> channels (442). H<sub>2</sub>S appears to increase GSH levels by activating  $\gamma$ -glutamyl-cysteine synthetase (114). In addition, increased intracellular levels of cysteine were found as consequence of glutamate-independent activation of cystine/glutamate antiporter. This leads to increased cystine uptake that promotes formation of cysteine and glutathione (231). Another important mechanism for the effect of H<sub>2</sub>S on GSH may be *via* enhancing glutamate uptake (265). In human cultured neuron cells, H<sub>2</sub>S inhibits peroxynitrite, acting as an endogenous peroxynitrite scavenger (119). Thus, H<sub>2</sub>S may act as a neuroprotectant against oxidative stress (Fig. 6). Changes in the level of H<sub>2</sub>S in the brain have been demonstrated in various CNS pathologies. A 55% decrease in the brains of AD patients has been documented for both H<sub>2</sub>S content and CBS activity, which was associated with a parallel loss of AdoMet content, a CBS activator. The CBS activity is decreased in homocysteinuria, febrile seizure frequently occurring in children. Conversely, CBS levels in Down's syndrome brains were approximately three times greater than those found in normal controls (119).

#### D. H<sub>2</sub>S and suspended animation

Suspended animation is a hibernation-like metabolic status characterized by a marked, still reversible, reduction of energy expenditure, which allows nonhibernating species to sustain environmental stress, such as extreme changes in temperature or oxygen deprivation (460). The first line of experiments show that in animals that do not normally hibernate, an hibernation-like state can be obtained, as shown by the Roth laboratory (36, 331, 374). In this work, nematode embryos exposed to anoxic conditions were shown to survive by entering into a suspended animation-like state, which was associated with specific changes in gene expression. This was observed below and above a 10-fold range of hypoxic oxygen concentrations from 0.01% to 0.1%. While embryos exposed outside this range survived completely and progressed to normal development, exposure within this range was associated with loss of protection and cellular damage and death after 24 hours. In these conditions exposure to CO resulted in survival, an effect mediated by a competition with cytochrome oxidase as a target for gas binding resulting in a scavenging of all available oxygen (434). Subsequently, the Roth group provided further evidence that inhaled H<sub>2</sub>S can induce a suspended animation-like state in mice. In this condition, animals breathing 80 ppm H<sub>2</sub>S exhibited a dose-dependent reduction of respiratory and heart rates, oxygen uptake, and CO<sub>2</sub> production, associated with a drop in body core temperature to levels  $\sim 2^{\circ}\text{C}$  above ambient temperature (460). All these effects were totally reversible after H<sub>2</sub>S washout, with animals showing a complete recovery and normal behavior (363). Relevant to the finding that a controlled reduction in cellular energetic expenditure is consistent with maintenance of ATP homeostasis is the notion of an

improved outcome during shock states. Notably, pretreatment with inhaled H<sub>2</sub>S (150 ppm) for only 20 minutes significantly prolonged survival without apparent damage for mice exposed to lethal hypoxia (5% oxygen), as well as in rats receiving a single intravenous bolus of Na<sub>2</sub>S (460). Thus, H<sub>2</sub>S can induce adaptive (hormetic) stress responses that protect cells against a range of adverse conditions.

It is generally recognized that hibernation confers cytoprotection, so that tissues from hibernating animals are particularly resistant to various hypoxic and ischaemic insults (460). This is relevant in organ transplantation where, similarly to what was shown for CO, H<sub>2</sub>S effects may provide better preservation of transplantable organs. It is noteworthy that, owing to a larger surface area-to-mass ratio than humans, rodents are much more capable of a rapid reduction in core temperature when challenged with a toxic insult than are humans (434). This makes the clinical relevance of some murine models questionable. Mice, in fact, present a body mass 3,000-times less than that of adult humans, and a heart rate 14-times greater and respiratory rates 10-times faster than in humans. In addition, at rest, O<sub>2</sub> consumption is 10 times less in humans than in rodents, so that much of the oxygen consumed in a mouse is used for heat generation. It is possible, therefore, that in mice H<sub>2</sub>S-induced reduction of O<sub>2</sub> consumption may largely account for specific ATP-requiring processes, such as mitochondrial uncoupling, whereas ion homeostasis is not drastically compromised. As a consequence, the human window of compromised oxidative phosphorylation is likely to be much smaller than in rodents (460).

#### E. Functional interrelation of NO, CO, and H<sub>2</sub>S gases and their relevance to hormesis

Both CO and NO activate the GC system by binding the active heme and enhancing cGMP production. Although NO is definitely more potent than CO in activating guanylyl cyclase, CO generally operates in the system under specific physiological conditions, as in the case of regulation of vascular smooth muscle cell proliferation during hypoxic conditions (355). Of the two gases, NO is the more reactive, having the same effective size and polarity as the O<sub>2</sub> molecule, and, unlike CO, binds to both Fe<sup>2+</sup> and Fe<sup>3+</sup> heme. Moreover, low CO concentrations stimulate NO release and are associated with peroxynitrite generation in vascular cells. The chemistry of CO-mediated NO release depends on the initial distributions of NO and CO in the cell and the differing equilibrium constants for transition-metal binding of the two gases. The association constants for NO binding to Fe<sup>2+</sup> heme proteins such as myoglobin and hemoglobin are greater than those for CO (355). For hemoglobin, the affinity of Fe<sup>2+</sup> for NO is at least a thousand times greater than that for CO; however, CO dissociation is much slower than for NO or O<sub>2</sub>. Therefore, CO gradually displaces NO from Fe<sup>2+</sup> heme proteins, requiring minutes or longer for equilibrium even with an excess of CO. NO displacement from Fe<sup>2+</sup> by CO may also be enhanced in proximity to reduced thiols that serve as a sink for SNO protein formation. (355). HO-1 and/or CO, and NOS2 and/or NO are two systems functionally interrelated. In some situations, CO can induce expression of NOS2 and, in others, inhibits expression of NOS2 and consequently NO. NO up-regulates HO-1 with production of CO (316). We have recently found evidence for a functional relationship between

CO and NO. In endotoxic shock, the salutary action of CO in rat brain appears to depend on the activation of NF $\kappa$ B, which triggers transcription of NOS2 with production of NO, and subsequently results in the upregulation of HO-1 (96). In the absence of any of these steps, the beneficial effect of CO is lost (33). To what extent CO and NO act interdependently in other physiological and pathological conditions that involve CO and/or NO is unknown. Endogenous CO has been suggested to control constitutive NOS activity. Moreover, CO may interfere with NO binding to guanylyl cyclase, and this in addition to the important role of HO in regulating NO generation, owing to its function in the control of heme intracellular levels, as part of the normal protein turnover (33). This hypothesis is sustained by recent findings showing that HO inhibition increases NO production in mouse macrophages exposed to endotoxin (128).

H<sub>2</sub>S belongs to a family of labile biological mediators termed gasotransmitters, which share many similarities. As a gasotransmitter, H<sub>2</sub>S rapidly travels through cell membranes without using specific transporters (434). H<sub>2</sub>S can induce an upregulation of heme oxygenase 1 and cytochrome c oxidase subunit V. By upregulating HO1, H<sub>2</sub>S can trigger the production of CO, thus providing cytoprotective and anti-inflammatory effects. These effects are also mediated by inhibition of the nuclear factor- $\kappa$ B (NF $\kappa$ B) pathway and downregulation of inducible NO synthase (iNOS) expression and NO production by inflammatory stimuli. Expression of HO1 is probably the result of the activation by sulfide of the extracellular signal regulated kinase pathway (434). H<sub>2</sub>S can also inhibit cellular respiration, at a level of cytochrome c oxidase *via* a reaction with its copper center. Cytochrome c oxidase is a key regulator of cellular respiration; all three gasotransmitters (NO, CO, and H<sub>2</sub>S) have competitive effects on this enzyme. Inhibition of cytochrome c oxidase is central to the regulation of cellular oxygen consumption by H<sub>2</sub>S, and has been implicated in the pharmacological effects of H<sub>2</sub>S, together with induction of suspended animation (see above).

Moreover, evidence is accumulating to demonstrate that H<sub>2</sub>S, as opposed to NO and CO, induces vasorelaxation that is not mediated by the cGMP signaling pathway. This indicates that H<sub>2</sub>S is a novel endogenous gaseous modulator of vascular contractility. At the same time, similar to NO and CO, H<sub>2</sub>S can inhibit VSMC proliferation and induce apoptosis *in vitro* (23). Using cultured VSMC, exogenous H<sub>2</sub>S could dose dependently suppress the proliferation of VSMC through the MAPK signaling pathway. Studies using molecular means to overexpress CSE in cultured VSMC found that endogenous H<sub>2</sub>S could also attenuate the rate of cell proliferation and increase the rate of cell apoptosis. The latter effect is *via* the activation of MAPK and caspase-3. This may be relevant to the pathogenesis of atherosclerosis, as well as vascular graft occlusion and restenosis after angioplasty (23). However, the precise role of smooth muscle cell proliferation and apoptosis in the development of diseases, particularly the molecular mechanisms underlying the relationship between the diseases and cell proliferation, remains to be characterized.

As a key early event in the cellular phenotypic changes, smooth muscle cells that are in a quiescent state (G0) in normal uninjured vessels transit through the G1 phase of the cell cycle and enter into the S phase to undergo replication (472). Cell cycle progression is under the control of cyclin-dependent kinases, which phosphorylate different specific

target proteins when the cells enter different phases of cell cycle. Synchronized (G0) smooth muscle cells treated with S-diclofenac, a recently discovered H<sub>2</sub>S donor, recover at the early cell cycle alteration, a finding associated with a decreased p53 and p21 activity. Interestingly, it has been suggested that both vascular diseases and cancer similarly develop from a clonal proliferation at the sites of local tissue injury and inflammation, with underlying genomic alterations (23).

NO activity in the CNS provides an example of hormesis, being extremely toxic at high concentrations yet neurotrophic at lower concentrations. NO may be released by a variety of cell types (*i.e.*, astrocytes, activated microglia, and macrophages) after injury or disease, becoming 10-fold greater than normal physiological concentrations (35, 322). At such elevated concentrations, NO can facilitate massive cell death *via* apoptotic mechanisms, contributing to the progression of a variety of neurodegenerative diseases, including Alzheimer's disease and ALS. Of significance is that when low doses of NO are administered before a high and neurotoxic dose of NO, the prior preconditioning dose induces a marked protective effect. The dose-response characteristics of preconditioning doses conform to those of an hormetic dose response, suggesting that preconditioning is a manifestation of hormesis (87). The mechanism inducing the protective response appears to be mediated by the induction of HO-1 and is supported by multiple lines of research, including the use of HO1 inhibitors and HO1 null mice. HO-1 activation generates CO, bilirubin, and free iron *via* its actions on heme, which is released from NO-damaged heme proteins (35). It is likely that the protective effects induced by NO may be mediated, in part, by low doses of CO, which can induce the synthesis of MnSOD, and facilitate the activation of mitogen-activation protein kinase (MAKP) pathways, including the p38 MAPK pathway, which then activates NF $\kappa$ B, thereby inhibiting apoptosis (401, 447). These and other related findings have linked CO-induced effects at low and high concentrations with those of NO in an integrated, yet complex series of responses that are hormetic.

As is the case with NO and CO, H<sub>2</sub>S also has been reported to induce hormetic dose responses for a broad range endpoints of potential biomedical importance. In fact, the hormetic concept has integratively resolved numerous apparent disputes in the literature in which different groups of researchers reported opposite types of responses when using either high or low concentrations of H<sub>2</sub>S. However, when subsequent experiments were conducted that included a far broader dose-response continuum, the hormetic-biphasic dose response was typically found. This has been now widely reported for infarct volume in stroke-related experimental studies, investigations concerning various types of inflammatory processes, vasorelaxation/tension in aortic tissue, cell proliferation/apoptosis, as well as in the case of tumor promotion and inhibition. Since the concentration of H<sub>2</sub>S can vary considerably both within and between tissues and under differing conditions, it is likely that H<sub>2</sub>S could affect a complex array of biological responses that may challenge the capacity to make definitive biomedical and/or clinical interpretations or predictions. Li and Moore (256) closed their recent insightful review of the role of H<sub>2</sub>S in health and disease with a statement probing their articulated biological conundrum of how does one molecule display such widely differing effects and could it be due to different effects at differing

concentrations. The answer to this seminal question is found within the framework of an hormetic dose–response interaction that is independent of biological model, tissue, and endpoint.

## XVII. Future Directions

The burden of chronic neurodegenerative diseases on our society is expected to continue to increase, largely due to the aging of the population. Although no satisfactory treatments are yet available, it is timely to think about implementing prevention measures that harness the intrinsic cytoprotective mechanisms described in this review. Exploiting the ability of small molecules, many of which are dietary agents and therefore of presumed low toxicity, to mimic various stimuli that lead to the upregulation of these intracellular defenses is an exciting area for future development. As described in this review, oxidizable diphenols, sulforaphane, dimethyl fumarate, celastrol, curcumin, and FA induce the Keap1/Nrf2/ARE pathway and the HSR, which collectively control expression of more than 100 genes that are concerned with cellular protection and survival under various conditions of oxidative and electrophilic stresses. Importantly, this induction correlates with protection against chronic diseases, including neurodegenerative conditions, in many animal models. Since redox regulation and transcription factor cysteine modifications are central to both the Keap1/Nrf2/ARE pathway and HSR, such multitarget agents, all of which are reactive with sulfhydryl groups, are ideal for simultaneously manipulating these pathways and achieving synergistic protective effects.

Although there are many specific technical questions that could be identified and prioritized for follow-up research activities in the area of neurodegenerative disorders, we believe that the most significant future direction in this area is conceptual. That is, we believe that it is essential that the biomedical community become more informed about the robustness of the data underlying the hormetic dose response and the generalizability of this concept across biological models, endpoints, and chemical classes and its many biomedical and therapeutic implications. We believe that major concepts such as pre- and postconditioning are specific manifestations of the general hormesis concept. The hormesis concept has the capacity to expand the range of biological questions and testable hypotheses, as well as affect how studies are designed, including how results will be analyzed and modeled. The hormesis concept also suggests that therapeutic interventions will be constrained by the limits of biological plasticity that conforms to the quantitative features of the hormetic dose response. This framework would affect the expectations of pharmaceutical companies in their development of new treatment modalities across the broad spectrum of therapeutic activities. Thus, we believe that the hormetic concept is a basic biological concept that needs to be better studied and understood to more successfully treat human diseases and to improve human performance for numerous endpoints. In the future we would strongly encourage the many professional societies that are concerned with issues related to dose response to routinely include technical sessions at annual meetings and specialty conferences on hormesis. We would also recommend that the concept of hormesis be incorporated into the formal biomedical courses in graduate and medical schools. These suggestions are just

the start, but these are necessary if the biomedical and clinical fields, including the neurosciences, are going to get the dose right, improving the health and well-being of those individuals we serve.

## Acknowledgments

Work from the authors' laboratories was supported by grants from MIUR, FIRB RBRN07BMCT, I.N.B.B., RCUK, the American Cancer Society (RSG-07-157-01-CNE), Cancer Research UK (C20953/A10270), Tenovus, the Royal Society, the Anonymous Trust, and by "Fondi Ateneo" 2007 and 2008, and the National Institute on Aging Intramural Research Program (M.P.M.). The authors acknowledge helpful discussions for the HSF posttranslational regulation with M.G. Santoro (Department of Biology, University of Rome Tor Vergata, Rome).

## References

1. Abramowitz J, Dai C, Hirschi KK, Dmitieva RI, Doris PA, Liu L, and Allen JC. Ouabain- and marinobufagenin-induced proliferation of human umbilical vein smooth muscle cells and a rat vascular smooth muscle cell lines, A7r5. *Circulation* 108: 3048–3053, 2003.
2. Afonso V, Champy R, Mitrovic D, Collin P, and Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. *Joint Bone Spine* 74: 324–329, 2007.
3. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, and Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. *Proc Natl Acad Sci USA* 105: 14447–14452, 2008.
4. Akhtar MW, Raingo J, Nelson ED, Montgomery RL, Olson EN, Kavalali ET, and Monteggia LM. Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. *J Neurosci* 29: 8288–8297, 2009.
5. Alam J and Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? *Am J Respir Cell Mol Biol* 36: 166–174, 2007.
6. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, Salmona M, Caccia S, Negro A, and Forloni G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1–42) peptide. *J Neurochem* 110, 1445–1456, 2009.
7. Alberto R and Motterlini R. Chemistry and biological activities of CO-releasing molecules (CORMs) and transition metal complexes. *Dalton Trans* 7: 1651–1660, 2007.
8. Aliev G, Palacios HH, Lipsitt AE, Fischbach K, Lamb BT, Obrenovich ME, Morales L, Gasimov E, and Bragin V. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. *Neurotox Res* 16: 293–305, 2009.
9. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, and Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 25: 1341–1357, 2001.
10. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, and Lutz G. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. *J Am Acad Dermatol* 30: 977–981, 1994.
11. Amijee H, Madine J, Middleton DA, and Doig AJ. Inhibitors of protein aggregation and toxicity. *Biochem Soc Trans* 37: 692–696, 2009.

12. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, and Aggarwal BB. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity *in vitro* and superior bioavailability *in vivo*. *Biochem Pharmacol* 79: 330–338, 2010.
13. Anckar J and Sistonen L. Heat shock factor 1 as a coordinator of stress and developmental pathways. *Adv Exp Med Biol* 594: 78–88, 2007.
14. Anderson RM, Barger JL, Edwards MG, Braun KH, O'Connor CE, Prolla TA, and Weindruch R. Dynamic regulation of PGC-1 $\alpha$  localization and turnover implicates mitochondrial adaptation in caloric restriction and the stress response. *Aging Cell* 7: 101–111, 2008.
15. Araki T, Sasaki Y, and Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. *Science* 305: 1010–1013, 2004.
16. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, and Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 286: H246–H251, 2004.
17. Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP, and Wan R. Age and energy intake interact to modify cell stress pathways and stroke outcome. *Ann Neurol* 67: 41–52, 2010.
18. Averna M, Stifanese R, De Tullio R, Beccaria F, Salamino F, Pontremoli S, and Melloni E. Calpain-mediated activation of NO synthase in human neuroblastoma SK-N-BE cells. *J Neurochem* 110: 412–421, 2009.
19. Balan V, Miller GS, Kaplun L, Balan K, Chong ZZ, Li F, Kaplun A, VanBerkum MF, Arking R, Freeman DC, Maiese K, and Tzivion G. Life span extension and neuronal cell protection by *Drosophila* nicotinamidase. *J Biol Chem* 283: 27810–27819, 2008.
20. Balch WE, Morimoto RI, Dillin, and Kelly JW. Adapting proteostasis for disease intervention. *Science* 319: 916–919, 2008.
21. Bando Y, Katayama T, Kasai K, Taniguchi M, Tamatani M, and Tohyama M. GRP94 (94 kDa glucose-regulated protein) suppresses ischemic neuronal cell death against ischemia/reperfusion injury. *Eur J Neurosci* 18: 829–840, 2003.
22. Barrett RM and Wood MA. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. *Learn Mem* 15: 460–467, 2008.
23. Baskar R, Sparatore A, Del Soldato P, and Moore PK. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. *Eur J Pharmacol* 594: 1–8, 2008.
24. Batulan Z, Shinder GA, Minotti S, He BP, Doroudchi MM, Nalbantoglu J, Strong MJ, and Durham HD. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. *J Neurosci* 23: 5789–5798, 2003.
25. Bauer I and Pannen BH. Bench-to-bedside review: carbon monoxide—from mitochondrial poisoning to therapeutic use. *Crit Care* 13: 220, 2009.
26. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, and Wang M. Resveratrol is not a direct activator of SIRT1 enzyme activity. *Chem Biol Drug Des* 74: 619–624, 2009.
27. Bellia F, Calabrese V, Guarino F, Cavallaro M, Cornelius C, De Pinto V, and Rizzarelli E. Carnosinase levels in aging brain: redox state induction and cellular stress response. *Antioxid Redox Signal* 11: 2759–2775, 2009.
28. Benhar M, Forrester MT, and Stamler JS. Protein denitrosylation: enzymatic mechanisms and cellular functions. *Nat Rev Mol Cell Biol* 10: 721–732, 2009.
29. Bensasson RV, Zoete V, Dinkova-Kostova AT, and Talalay P. Two-step mechanism of induction of the gene expression of a prototypic cancer-protective enzyme by diphenols. *Chem Res Toxicol* 21: 805–812, 2008.
30. Benton CR, Wright DC, and Bonen A. PGC-1 $\alpha$ -mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. *Appl Physiol Nutr Metab* 33: 843–862, 2008.
31. Berenblum I. The modifying influence of dichloroethyl sulphide on the induction of tumours in mice by tar. *J Pathol Bacteriol* 32: 425–434, 1929.
32. Bezprozvanny I and Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends Neurosci* 31: 454–463, 2008.
33. Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, and Otterbein LE. Heme oxygenase and carbon monoxide initiate homeostatic signaling. *J Mol Med* 86: 267–279, 2008.
34. Bishop NA and Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. *Nat Rev Genet* 8: 835–844, 2007.
35. Bishop A, Gooch R, Eguchi A, Jeffrey S, Smallwood L, Anderson J, and Estevez AG. Mitigation of peroxynitrite-mediated nitric oxide (NO) toxicity as a mechanism of induced adaptive NO resistance in the CNS. *J Neurochem* 109: 74–84, 2009.
36. Blackstone E, Morrison M, and Roth MB. H<sub>2</sub>S induces a suspended animation-like state in mice. *Science* 308: 518, 2005.
37. Blanc EM, Kelly JF, Mark RJ, Waeg G, and Mattson MP. 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G $\alpha$ (q/11). *J Neurochem* 69: 570–580, 1997.
38. Bolanos JP, Garcia-Nogales P, and Almeida A. Provoking neuroprotection by peroxynitrite. *Curr Pharm Des* 10: 867–877, 2004.
39. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez J, Jooze M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299: 256–259, 2003.
40. Borak J and Sirianni G. Hormesis: implications for cancer risk assessment. *Dose Response* 3: 443–451, 2005.
41. Boreham DR, Dolling J-A, Somers C, Quinn J, and Mitchell REJ. The adaptive response and protection against heritable mutations and fetal malformation. *Dose Response* 4: 317–326, 2006.
42. Brignull HR, Morley JF, and Morimoto RI. The stress of misfolded proteins: *C. elegans* models for neurodegenerative disease and aging. *Adv Exp Med Biol* 594: 167–189, 2007.
43. Broadley SA and Hartl FU. The role of molecular chaperones in human misfolding diseases. *FEBS Lett* 583: 2647–2653, 2009.
44. Brown IR. Heat shock proteins and protection of the nervous system. *Ann NY Acad Sci* 1113: 147–158, 2007.
45. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, and Mattson MP. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. *Nat Med* 2: 788–794, 1996.
46. Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, Bredesen DE, Hutchins JB, Hensley K, and Mattson MP. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide. *J Neurochem* 70: 31–39, 1998.

47. Bruce-Keller AJ, Geddes JW, Knapp PE, McFall RW, Keller JN, Holtsberg FW, Parthasarathy S, Steiner SM, and Mattson MP. Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. *J Neuroimmunol* 93: 53–71, 1999.
48. Burton NC, Kensler TW, and Guilarte TR. *In vivo* modulation of the Parkinsonian phenotype by Nrf2. *Neurotoxicology* 27: 1094–1100, 2006.
49. Calabrese EJ. Evidence that hormesis represents an “overcompensation” response to a disruption in homeostasis. *Ecotoxicol Environ Saf* 42: 135–137, 1999.
50. Calabrese EJ and Baldwin LA. Chemical hormesis: its historical foundations as a biological hypothesis. *Hum Exp Toxicol* 19: 2–31, 2000.
51. Calabrese EJ and Baldwin LA. The marginalization of hormesis. *Hum Exper Toxicol* 19: 32–40, 2000.
52. Calabrese EJ and Baldwin LA. Radiation hormesis: its historical foundations as a biological hypothesis. *Hum Exp Toxicol* 19: 41–75, 2000.
53. Calabrese EJ and Baldwin LA. Radiation hormesis: the demise of a legitimate hypothesis. *Hum Exp Toxicol* 19: 76–84, 2000.
54. Calabrese EJ and Baldwin LA. Tales of two similar hypotheses: the rise and fall of chemical and radiation hormesis. *Hum Exp Toxicol* 19: 85–97, 2000.
55. Calabrese EJ and Baldwin LA. The frequency of U-shaped dose-responses in the toxicological literature. *Toxicol Sci* 62: 330–338, 2001.
56. Calabrese EJ and Baldwin LA. Hormesis: U-shaped dose-response and their centrality in toxicology. *Trends Pharmacol Sci* 22: 285–291, 2001.
57. Calabrese EJ and Baldwin LA. U-shaped dose responses in biology, toxicology, and public health. *Ann Rev Public Health* 22: 15–33, 2001.
58. Calabrese EJ. Overcompensation stimulation: a mechanism for hormetic effects. *Crit Rev Toxicol* 31: 425–470, 2001.
59. Calabrese EJ and Baldwin LA. Hormesis and high risk groups. *Regul Toxicol Pharmacol* 35: 14–428, 2002.
60. Calabrese EJ and Baldwin LA. The hormetic dose response model is more common than the threshold model in toxicology. *Toxicol Sci* 71: 246–250, 2003.
61. Calabrese EJ and Baldwin LA. Inorganics and hormesis. *Crit Rev Toxicol* 33: 215–304, 2003.
62. Calabrese EJ and Baldwin LA. Chemotherapeutics and hormesis. *Crit Rev Toxicol* 33: 305–354, 2003.
63. Calabrese EJ and Baldwin LA. Peptides and hormesis. *Crit Rev Toxicol* 33: 355–406, 2003.
64. Calabrese EJ and Baldwin LA. Ethanol and hormesis. *Crit Rev Toxicol* 33: 407–424, 2003.
65. Calabrese EJ. Historical blunders: how toxicology got the dose-response relationship half right. *Cell Mol Biol* 51: 643–654, 2005.
66. Calabrese EJ. Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical foundations. *Crit Rev Toxicol* 35: 89–295, 2005.
67. Calabrese EJ. Cancer biology and hormesis: Human tumor cell lines commonly display hormetic (biphasic) dose responses. *Crit Rev Toxicol* 35: 463–582, 2005.
68. Calabrese EJ and Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. *Toxicol Appl Pharmacol* 202: 289–301, 2005.
69. Calabrese EJ, Staudenmayer JW, and Stanek EJ. Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. *Curr Opin Drug Discov Dev* 9: 117–123, 2006.
70. Calabrese EJ, Staudenmayer JW, Stanek EJ, and Hoffmann GR. Hormesis outperforms threshold model in NCI anti-tumor drug screening data. *Toxicol Sci* 94: 368–378, 2006.
71. Calabrese EJ, Staudenmayer JW, Stanek III EJ, and Hoffmann GR. Hormesis and high throughput studies: crump’s analysis lacks credibility. *Toxicol Sci* 98: 602–603, 2007.
72. Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, Cedergreen N, Cherian MG, Chiueh CC, Clarkson TW, Cook RR, Diamond DM, Doolittle DJ, Dorato MA, Duke SO, Feinendegen L, Gardner DE, Hart RW, Hastings KL, Hayes AW, Hoffmann GR, Ives JA, Jaworowski Z, Johnson TE, Jonas WB, Kaminski NE, Keller JG, Klaunig JE, Knudsen TB, Kozumbo WJ, Lettieri T, Liu SZ, Maisseu A, Maynard KI, Masoro EJ, McClellan RO, Mehendale HM, Mothersill C, Newlin DB, Nigg HN, Oehme FW, Phalen RF, Philbert MA, Rattan SI, Riviere JE, Rodricks J, Sapolsky RM, Scott BR, Seymour C, Sinclair DA, Smith-Sonneborn J, Snow ET, Spear L, Stevenson DE, Thomas Y, Tubiana M, Williams GM, and Mattson MP. Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. *Toxicol Appl Pharmacol* 222: 122–128, 2007.
73. Calabrese EJ. Neuroscience and hormesis: overview and general findings. *Crit Rev Toxicol* 38: 249–252, 2008.
74. Calabrese EJ. Dose-response features of neuroprotective agents: an integrative summary. *Crit Rev Toxicol* 38: 253–348, 2008.
75. Calabrese EJ. Pharmacological enhancement of neuronal survival. *Crit Rev Toxicol* 38: 349–391, 2008.
76. Calabrese EJ. Enhancing and regulating neurite outgrowth. *Crit Rev Toxicol* 38: 391–418, 2008.
77. Calabrese EJ. Alzheimer’s disease drugs: An application of the hormetic dose-response model. *Crit Rev Toxicol* 38: 419–452, 2008.
78. Calabrese EJ. Stress biology and hormesis: the Yerkes-Dodson law in psychology—a special case of the hormesis dose response. *Crit Rev Toxicol* 38: 453–462, 2008.
79. Calabrese EJ. Astrocytes: Adaptive responses to low doses of neurotoxins. *Crit Rev Toxicol* 38: 463–472, 2008.
80. Calabrese EJ. P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships. *Crit Rev Toxicol* 38: 473–487, 2008.
81. Calabrese EJ. An assessment of anxiolytic drug screening tests: Hormetic dose responses predominate. *Crit Rev Toxicol* 38: 489–542, 2008.
82. Calabrese EJ. Modulation of the epileptic seizure threshold: implications of biphasic dose responses. *Crit Rev Toxicol* 38: 543–556, 2008.
83. Calabrese EJ. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. *Crit Rev Toxicol* 38: 557–577, 2008.
84. Calabrese EJ. Pain and U-shaped dose responses: occurrence, mechanisms, and clinical implications. *Crit Rev Toxicol* 38: 579–590, 2008.
85. Calabrese EJ. U-shaped dose response in behavioral pharmacology: historical foundations. *Crit Rev Toxicol* 38: 591–598, 2008.
86. Calabrese EJ. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic

- dose responses are dominant. *Crit Rev Toxicol* 38: 599–618, 2008.
87. Calabrese EJ. Hormesis: why it is important to toxicology and toxicologists. *Environ Toxicol Chem* 27: 1451–1474, 2008.
  88. Calabrese EJ. Hormesis and medicine. *Brit J Clin Pharm* 66: 594–617 2008.
  89. Calabrese EJ. Hormesis. In: *Encyclopedia of Quantitative Risk Assessment and Analysis* Melnick E, Everitt B, eds. Chichester, United Kingdom: John Wiley & Sons Ltd., 838–844, 2008.
  90. Calabrese EJ, Stanek III EJ, Nascarella MA, and Hoffmann GR. Hormesis predicts low-dose responses better than threshold models. *Int J Toxicol* 27: 369–378, 2008.
  91. Calabrese EJ. The road to linearity: Shy linearity at low doses became the basis for carcinogen risk assessment. *Arch Toxicol* 83: 203–225, 2009.
  92. Calabrese EJ. Getting the dose-response wrong: why hormesis became marginalized and the threshold model accepted. *Arch Toxicol* 83: 227–247, 2009.
  93. Calabrese EJ and Blain RB. Hormesis and plant biology. *Environ Poll* 157: 42–48, 2009.
  94. Calabrese EJ and Ricci PF. Hormesis in environmental health: How hormesis will change the risk assessment process. In: *Encyclopedia of Environmental Health*, edited by Nriagu JO. Elsevier, 2010 (In press).
  95. Calabrese V, Giuffrida Stella AM, Butterfield DA, and Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. *Antioxid Redox Signal* 6: 895–913, 2004.
  96. Calabrese V, Butterfield DA, Scapagnini G, Stella AM, and Maines MD. Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurodegenerative disorders, and longevity. *Antioxid Redox Signal* 8: 444–477, 2006.
  97. Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafato S, Puleo E, Pennisi G, Mancuso C, Butterfield AD, and Giuffrida Stella AM. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. *Neurochem Research* 32: 757–773, 2007.
  98. Calabrese V, Mancuso C, Ravagna A, Perluigi M, Cini C, De Marco C, Butterfield D, and Giuffrida Stella AM. *In vivo* induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. *J Neurochem* 101: 709–717, 2007.
  99. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, and Giuffrida Stella AM. Nitric oxide in the CNS: neuroprotection versus neurotoxicity. *Nat Neurosci* 8: 766–775, 2007.
  100. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, and Rizzarelli E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. *Neurochem Res* 33: 2444–2471, 2008.
  101. Calabrese V, Signorile A, Cornelius C, Mancuso C, Scapagnini G, Ventimiglia B, Ragusa N, and Dinkova-Kostova A. Practical approaches to investigate redox regulation of heat shock protein expression and intracellular glutathione redox state. *Methods Enzymol* 441: 83–110, 2008.
  102. Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, Di Renzo L, De Lorenzo A, and Dinkova-Kostova AT. Curcumin and the cellular stress response in free radical-related diseases. *Mol Nutr Food Res* 52: 1062–1073, 2008.
  103. Calabrese V, Butterfield DA, and Stella AM. Aging and oxidative stress response in the CNS. In: *Development and Aging Changes in the Nervous System. Handbook of Neurochemistry and Molecular Neurobiology*, 3rd edition, edited by Abel L, Regino P-PJ, and Steffen R. New York: Springer, 2008, pp. 128–234.
  104. Calabrese V, Cornelius C, Mancuso C, Ientile R, Stella AM, and Butterfield DA. Redox homeostasis and cellular stress response in aging and neurodegeneration. *Methods Mol Biol* 610: 285–308, 2010.
  105. Calabrese V, Calafato S, Cornelius C, Mancuso C, and Dinkova-Kostova A. Heme oxygenase: a master vitagene involved in cellular stress response In: *Enzymes and the Cellular Fight Against Oxidation*. Eleuteri AM, ed., Research Signpost 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India, 2008.
  106. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, Rizzarelli E, and Dinkova-Kostova AT. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. *Front Biosci* 14: 376–397, 2009.
  107. Calabrese V, Cornelius C, Dinkova-Kostova AT, and Calabrese EJ. Vitagenes, cellular stress response and acetylcarmitine: relevance to hormesis. *Biofactors* 35: 146–160, 2009.
  108. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, and Butterfield DA. Nitric oxide in cell survival: a Janus molecule. *Antioxid Redox Signal* 11: 2717–2739, 2009.
  109. Calabrese V, Perluigi M, Cornelius C, Coccia R, Di Domenico F, Mancuso C, Pennini G, and Dinkova-Kostova AT. Phenolics in aging and neurodegenerative disorders. In: *Phenolic Compounds of Plant Origin and Health: The Biochemistry behind their Nutritional and Pharmacological Value*, edited by Fraga CG. New York: Wiley & Sons, 2009, pp. 427–451.
  110. Calderwood SK, Murshid A, and Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging—a mini-review. *Gerontology* 55: 550–558, 2009.
  111. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, and Johnson JA. Protection from mitochondrial complex II inhibition *in vitro* and *in vivo* by Nrf2-mediated transcription. *Proc Natl Acad Sci USA* 102: 244–249, 2005.
  112. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP, Kraft AD, Lee JM, Li J, and Johnson JA. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. *Antioxid Redox Signal* 11: 497–508, 2009.
  113. Calvert JW, Coetzee WA, and Lefer D. Novel Insights into Hydrogen Sulfide Mediated Cytoprotection. *Antioxid Redox Signal* 12: 1203–1217, 2010.
  114. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, and Lefer DJ. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. *Circ Res* 105, 365–374, 2009.
  115. Camandola S and Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. *J Neurosci Res* 61: 134–139, 2000.
  116. Cedergreen N, Streibig JC, Kudsk P, Mathiassen SK, and Duke SO. The occurrence of hormesis in plants and algae. *Dose Response* 5: 150–162, 2007.



117. Chan K, Lu R, Chang JC, and Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. *Proc Natl Acad Sci USA* 93: 13943–13948, 1996.
118. Chan SL, Fu W, Zhang P, Cheng A, Lee J, Kokame K, and Mattson MP. Herp stabilizes neuronal Ca<sup>2+</sup> homeostasis and mitochondrial function during endoplasmic reticulum stress. *J Biol Chem* 279: 28733–28743, 2004.
119. Chen C, Xin H, and Zhu Y. Hydrogen sulfide: third gaseous transmitter, but with great pharmacological potential. *Acta Pharmacol Sin* 1709–1716, 2007.
120. Chen L and Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a drosophila model of Parkinson's disease. *Nat Neurosci* 8: 657–663, 2005.
121. Chen P, Sun B, Chen H, Wang G, Pan S, Kong R, Bai X, and Wang S. Effects of carbon monoxide releasing molecule-liberated CO on severe acute pancreatitis in rats. *Cytokine* 49: 15–23, 2010.
122. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, and Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. *Proc Natl Acad Sci USA* 106: 2933–2938, 2009.
123. Cheng B and Mattson MP. IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. *J Neurosci* 12: 1558–1566, 1992.
124. Chigurupati S, Son TG, Hyun DH, Lathia JD, Mughal MR, Savell J, Li SC, Nagaraju GP, Chan SL, Arumugam TV, and Mattson MP. Lifelong running reduces oxidative stress and degenerative changes in the testes of mice. *J Endocrinol* 199: 333–341, 2008.
125. Chong ZZ, Lin SH, Li F, and Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways. *Curr Neurovasc Res* 2: 271–285, 2005.
126. Chou YH, Ho FM, Liu DZ, Lin SY, Tsai LH, Chen CH, Ho YS, Hung LF, and Liang YC. The possible role of heat shock factor-1 in the negative regulation of heme oxygenase-1. *Int J Biochem Cell Biol* 37: 604–615, 2005.
127. Chueh S-C, Guh J-H, Chen J, Lai M-K, and Teng C-M. Dual effects of ouabain on the regulation of proliferation and apoptosis in human prostatic smooth muscle cells. *J Urol* 166: 347–353, 2001.
128. Chung HT, Choi BM, Kwon YG, and Kim YM. Interactive relations between nitric oxide (NO) and carbon monoxide (CO): heme oxygenase-1/CO pathway is a key modulator in NO-mediated antiapoptosis and anti-inflammation. *Methods Enzymol* 441: 329–338, 2008.
129. Chung KC, Sung JY, Ahn W, Rhim H, Oh TH, Lee MG, and Ahn YS. Intracellular calcium mobilization induces immediate early gene pip92 via Src and mitogen-activated protein kinase in immortalized hippocampal cells. *J Biol Chem* 276: 2132–2138, 2001.
130. Clements CM, McNally RS, Conti BJ, Mak TW, and Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. *Proc Natl Acad Sci USA* 103: 15091–15096, 2006.
131. Cleren C, Calingasan NY, Chen J, and Beal MF. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. *J Neurochem* 94: 995–1004, 2005.
132. Cohen E and Dillin A. The insulin paradox: aging, proteotoxicity and neurodegeneration *Nat Rev Neurosci* 9: 759–767, 2008.
133. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Praticò D, Harrison DG, and Hsueh WA. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. *Circ Res* 104: e42–e54, 2009.
134. Conney AH, Miller EC, and Miller JA. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. *Cancer Res* 16: 450–459, 1956.
135. Cook RR and Calabrese EJ. The importance of hormesis to public health. *Environ Health Perspect* 114: 1631–1635, 2006. Reprinted in: *Cienc Saude Colet* 12: 955–963, 2007.
136. Corson TW and Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. *Cell* 130: 769–774, 2007.
137. Crabtree HG. Anti-carcinogenesis. *Br Med Bull* 4: 345–348, 1947.
138. Crabtree HG. Influence of unsaturated dibasic acids on the induction of skin tumors by chemical carcinogens. *Cancer Res* 5: 346–351, 1945.
139. Csermely P, Söti C, and Blatch GL. Chaperones as parts of cellular networks. *Adv Exp Med Biol* 594: 55–63, 2007.
140. Cutler RG and Mattson MP. Sphingomyelin and ceramide as regulators of development and lifespan. *Mech Ageing Dev* 122: 895–908, 2001.
141. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, and Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. *Ann Neurol* 52: 448–457, 2002.
142. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, and Mattson MP. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci USA* 101: 2070–2075, 2004.
143. Cuttler JM. What becomes of nuclear risk assessment in light of radiation hormesis? *Dose Response* 5: 80–90, 2007.
144. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, and Auwerx J. Sirtuins: the "magnificent seven," function, metabolism and longevity. *Ann Med* 39: 335–345, 2007.
145. De Long MJ, Prochaska HJ, and Talalay P. Tissue-specific induction patterns of cancer-protective enzymes in mice by tert-butyl-4-hydroxyanisole and related substituted phenols. *Cancer Res* 45: 546–551, 1985.
146. De Long MJ, Prochaska HJ, and Talalay P. Induction of NAD(P)H:quinone reductase in murine hepatoma cells by phenolic antioxidants, azo dyes, and other chemoprotectors: a model system for the study of anticarcinogens. *Proc Natl Acad Sci USA* 83: 787–791, 1986.
147. Delgado M, Varela N, and Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. *Glia* 56: 1091–1103, 2008.
148. Dennery PA. Regulation and role of heme oxygenase in oxidative injury. *Curr Top Cell Regul* 36: 181–199, 2000.
149. Der P, Cui J, and Das DK. Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. *J Mol Cell Cardiol* 40: 313–320, 2006.
150. Di Stasi AM, Mallozzi C, Macchia G, Maura G, Petrucci TC, and Minetti M. Peroxynitrite affects exocytosis and SNARE

- complex formation and induces tyrosine nitration of synaptic proteins. *J Neurochem* 82: 420–429, 2002.
151. Dinkova-Kostova AT and Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of phase 2 detoxification enzymes. *Carcinogenesis* 20: 911–914, 1999.
  152. Dinkova-Kostova AT and Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. *Free Radic Biol Med* 29: 231–240, 2000.
  153. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. *Proc Natl Acad Sci USA* 98: 3404–3409, 2001.
  154. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc Natl Acad Sci USA* 99: 11908–11913, 2002.
  155. Dinkova-Kostova AT, Fahey JW, and Talalay P. Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). *Methods Enzymol* 382: 423–448, 2004.
  156. Dinkova-Kostova AT, Holtzclaw WD, and Kensler TW. The role of Keap1 in cellular protective responses. *Chem Res Toxicol* 18: 1779–1791, 2005.
  157. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, and Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. *Proc Natl Acad Sci USA* 102: 4584–4589, 2005.
  158. Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, Stephenson KK, Wade KL, and Talalay P. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. *Cancer Lett* 240: 243–252, 2006.
  159. Dinkova-Kostova AT. The isothiocyanate sulforaphane induces the phase 2 response by signaling of the Keap1-Nrf2-ARE pathway: implications for dietary protection against cancer. In: *Dietary Modulation of Cell Signaling Pathways*, edited by Surh YJ, Dong Z, Cadenas E, and Packer L. Boca Raton, FL: CRC Press, 2008, pp. 205–229.
  160. Dinkova-Kostova AT and Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. *Mol Nutr Food Res* 52 Suppl 1: S128–S138, 2008.
  161. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, and Garcia JA. Regulation of hypoxia-inducible factor 2 $\alpha$  signaling by the stress-responsive deacetylase sirtuin 1. *Science* 324: 1289–1293, 2009.
  162. Dirnagl U and Meisel A. Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning? *Neuropharmacology* 55: 334–344, 2008.
  163. Doré S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, and Snyder SH. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. *Proc Natl Acad Sci USA* 96: 2445–2450, 1999.
  164. Douglas PM and Cyr DM. Interplay between protein homeostasis networks in protein aggregation and proteotoxicity. *Biopolymers* 93: 229–236, 2010.
  165. Du Y, Wooten MC, Gearing M, and Wooten MW. Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease. *Free Radic Biol Med* 46: 492–501, 2009.
  166. Duan W and Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. *J Neurosci Res* 57: 195–206, 1999.
  167. Eaton DL and Klaassen CD. Principles of toxicology. In: *Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th ed.*, edited by Klaassen CD. New York: McGraw-Hill, 2003, pp. 6–20.
  168. Ekdahl CT, Kokaia Z, and Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. *Neuroscience* 158: 1021–1029, 2009.
  169. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, and Dawson VL. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. *Nat Med* 3: 1089–1095, 1997.
  170. Fahey JW, Dinkova-Kostova AT, Stephenson KK, and Talalay P. The "Prochaska" microtiter plate bioassay for inducers of NQO1. *Methods Enzymol* 382: 243–258, 2004.
  171. Fang J, Lu J, and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. *J Biol Chem* 280: 25284–25290, 2005.
  172. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, and Curello S. Oxidative stress during myocardial ischaemia and heart failure. *Curr Pharm Des* 10: 1699–16711, 2004.
  173. Flood JF, Smith GE, and Cherkin A. Memory retention—enhancement by cholinergic drug-combinations in mice. *Gerontologist* 22: 230–231, 1982.
  174. Flood JF, Smith GE, and Cherkin A. Memory retention—potentiation of cholinergic drug-combinations in mice. *Neurobiol Aging* 4: 37–43, 1983.
  175. Flood JF, Smith GE, and Cherkin A. Memory retention—enhancement by synergistic oral cholinergic drug-combination in mice. *Gerontol* 24: 149, 1984.
  176. Flood JF, Smith GE, and Cherkin A. Memory enhancement—supra-additive effect of subcutaneous cholinergic drug-combinations in mice. *Psychopharmacology* 86: 61–67, 1985.
  177. Forquero I, Covian R, Bowman MK, Trumpower BL, and Kramer DM. Similar transition states mediate the Q-cycle and superoxide production by the cytochrome bc<sub>1</sub> complex. *J Biol Chem* 281: 38459–38465, 2006.
  178. Foster KA, Galeffi F, Gerich FJ, Turner DA, and Müller M. Optical and pharmacological tools to investigate the role of mitochondria during oxidative stress and neurodegeneration. *Prog Neurobiol* 79: 136–171, 2006.
  179. Foster MW, Hess DT, and Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. *Trends Mol Med* 15: 391–404, 2009.
  180. Frankfurt OS, Lipchina LP, Bunto TV, and Emanuel NM. Effect of 4-methyl-2,6-di-*tert*-butylphenol (Ionol) on induction of liver tumors in rats. *Byull Eksp Biol Med USSR* 64: 86–88, 1967.
  181. Friebe A and Koesling D. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. *Nitric Oxide* 21: 149–156, 2009.
  182. Friling RS, Bensimon A, Tichauer Y, and Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. *Proc Natl Acad Sci USA* 87: 6258–6262, 1990.
  183. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, and Puigserver P.

- Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1 $\alpha$ . *EMBO J* 26: 1913–1923, 2007.
184. Gerich FJ, Funke F, Hildebrandt B, Fasshauer M, and Müller M. H<sub>2</sub>O<sub>2</sub>-mediated modulation of cytosolic signaling and organelle function in rat hippocampus. *Pflugers Arch* 458: 937–952, 2009.
  185. Gidalevitz T, Kikis EA, and Morimoto RI. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. *Curr Opin Struct Biol* 20: 23–32, 2010.
  186. Glabe CG. Structural Classification of Toxic Amyloid Oligomers. *J Biol Chem* 283: 29639–29643, 2008.
  187. Glaum SR and Miller RJ. Zinc protoporphyrin-IX blocks the effects of metabotropic glutamate receptor activation in the rat nucleus tractus solitarius. *Mol Pharmacol* 43: 965–969, 1993.
  188. Glazner GW, Camandola S, Geiger JD, Mattson MP. Endoplasmic reticulum D-myo-inositol 1,4,5-trisphosphate-sensitive stores regulate nuclear factor-kappaB binding activity in a calcium-independent manner. *J Biol Chem* 276: 22461–22467, 2001.
  189. Goloubinoff P and De Los Rios P. The mechanism of Hsp70 chaperones: (entropic) pulling the models together. *Trends Biochem Sci* 32: 372–380, 2007.
  190. Gonzalez DR, Treuer A, Sun QA, Stamler JS, and Hare JM. S-nitrosylation of cardiac ion channels. *J Cardiovasc Pharmacol* 54: 188–195, 2009.
  191. Goodman Y and Mattson MP. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. *J Neurochem* 66: 869–872, 1996.
  192. Gopalakrishna R, Gundimeda U, Schiffman JE, and McNeill TH. A direct redox regulation of protein kinase C isoenzymes mediates oxidant-induced neurogenesis in PC12 cells. *J Biol Chem* 283: 14430–14444, 2008.
  193. Graser T, Vedernikov YP, and Li DS. Study on the mechanism of carbon monoxide induced endothelium-independent relaxation in porcine coronary artery and vein. *Biomed Biochim Acta* 49: 293–296, 1990.
  194. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, and LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. *J Neurosci* 28: 11500–11510, 2008.
  195. Grehant N. *Le gas du sang*. Paris, 1894.
  196. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, and Michel PP. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. *Mol Pharmacol* 74: 980–989, 2008.
  197. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, LaFerla FM, and Mattson MP. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. *Neurobiol Dis* 26: 212–220, 2007.
  198. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, and Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. *Mol Cell* 11: 619–633, 2003.
  199. Harting K and Knöll B. SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. *Eur J Cell Biol* 89: 262–269, 2010.
  200. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends Biochem Sci* 34: 176–188, 2009.
  201. Hipkiss AR. On why decreasing protein synthesis can increase lifespan. *Mech Ageing Dev* 128: 412–414, 2007.
  202. Hipkiss AR. NAD<sup>+</sup> availability and proteotoxicity. *Neuromol Med* 11: 97–100, 2009.
  203. Hishiyama A and Takayama S. Molecular chaperones as regulators of cell death. *Oncogene* 27: 6489–6506, 2008.
  204. Hoffmann GR. A perspective on the scientific, philosophical, and policy dimensions of hormesis. *Dose Response* 7: 1–51, 2009.
  205. Holtzclaw WD, Dinkova-Kostova AT, and Talalay P. Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers. *Adv Enzyme Regul* 44: 335–367, 2004.
  206. Hubbs AF, Benkovic SA, Miller DB, O'Callaghan JP, Battelli L, Schwegler-Berry D, and Ma Q. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. *Am J Pathol* 170: 2068–2076, 2007.
  207. Huddleston AT, Tang W, Takeshima H, Hamilton SL, and Klann E. Superoxide-induced potentiation in the hippocampus requires activation of ryanodine receptor type 3 and ERK. *J Neurophysiol* 99: 1565–1571, 2008.
  208. Huggins C and Fukunishi R. Induced protection of adrenal cortex against 7,12-dimethylbenz[*a*]anthracene. Influence of ethionine. Induction of menadione reductase. Incorporation of thymidine-H<sup>3</sup>. *J Exp Med* 119: 923–942, 1964.
  209. Huggins C and Pataki J. Aromatic azo derivatives preventing mammary cancer and adrenal injury from 7,12-dimethylbenz[*a*]anthracene. *Proc Natl Acad Sci USA* 53: 791–796, 1965.
  210. Hyun DH, Hernandez JO, Mattson MP, and de Cabo R. The plasma membrane redox system in aging. *Ageing Res Rev* 5: 209–220, 2006.
  211. Hyun DH, Emerson SS, Jo DG, Mattson MP, and de Cabo R. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. *Proc Natl Acad Sci USA* 103: 19908–19912, 2006.
  212. Hyun DH, Hunt ND, Emerson SS, Hernandez JO, Mattson MP, and de Cabo R. Up-regulation of plasma membrane-associated redox activities in neuronal cells lacking functional mitochondria. *J Neurochem* 100: 1364–1374, 2007.
  213. Innamorato NG, Rojo AI, García-Yagüe AJ, Yamamoto M, de Ceballos ML, and Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. *J Immunol* 181: 680–689, 2008.
  214. Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, and Kimura H. A source of hydrogen sulfide and a mechanism of its release in the brain. *Antioxid Redox Signal* 11: 205–214, 2009.
  215. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 236: 313–322, 1997.
  216. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through

- binding to the amino-terminal Neh2 domain. *Genes Dev* 13: 76–86, 1999.
217. Jiang F, Zhang ZG, Katakowski M, Robin AM, Faber M, Zhang F, and Chopp M. Angiogenesis induced by photodynamic therapy in normal rat brains. *Photochem Photobiol* 79: 494–498, 2004.
218. Jiao J, Huang X, Feit-Leithman RA, Neve RL, Snider W, Dartt DA, and Chen DF. Bcl-2 enhances Ca(2+) signaling to support the intrinsic regenerative capacity of CNS axons. *EMBO J* 24: 1068–1078, 2005.
219. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, and Chen PC. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. *Ann NY Acad Sci* 1147: 61–69, 2008.
220. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson M, Nassar M, Telljohann R, Maudsley S, Carlson O, John S, Laub DR, and Mattson MP. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. *Free Radic Biol Med* 42: 665–674, 2007.
221. Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, and Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. *FASEB J* 16: 601–603, 2002.
222. Kang YH and Pezzuto JM. Induction of quinone reductase as a primary screen for natural product anticarcinogens. *Methods Enzymol* 382: 380–414, 2004.
223. Kapitulnik J and Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. *Trends Pharmacol Sci* 30: 129–137, 2009.
224. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, and O'Neill GN. BG-12 phase IIb study investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet* 372: 1463–1472, 2008.
225. Keller JN, Kindy MS, Holtsberg FW, St. Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, and Mattson MP. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. *J Neurosci* 18: 687–697, 1998.
226. Keller JN and Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. *Rev Neurosci* 9: 105–116, 1998.
227. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol* 47: 89–116, 2007.
228. Kensler TW. Chemoprevention by inducers of carcinogen detoxication enzymes. *Environ Health Perspect* 105: 965–970, 1997.
229. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, and Tsai LH. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. *EMBO J* 26: 3169–3179, 2007.
230. Kimura H. Hydrogen sulfide as a neuromodulator. *Mol Neurobiol* 26: 13–19, 2002.
231. Kimura H. Hydrogen sulfide as a biological mediator. *Antioxid Redox Signal* 7: 778–780, 2005.
232. Kitamuro T, Takahashi K, Ogawa K, Udono-Fujimori R, Takeda K, Furuyama K, Nakayama M, Sun J, Fujita H, Hida W, Hattori T, Shirato K, Igarashi K, and Shibahara S. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. *J Biol Chem* 278: 9125–9133, 2003.
233. Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, Soda M, Nakimawa K, Kiyama H, Stern DM, Hori O, Wakamatsu K, Ito S, Itohara S, Takahashi R, and Ogawa S. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. *Hum Mol Genet* 16: 50–60, 2007.
234. Kitao Y, Ozawa K, Miyazaki M, Tamatani M, Kobayashi T, Yanagi H, Okabe M, Ikawa M, Yamashita T, Stern DM, Hori O, and Ogawa S. Expression of the endoplasmic reticulum molecular chaperone (ORP150) rescues hippocampal neurons from glutamate toxicity. *J Clin Invest* 108: 1439–1450, 2001.
235. Klucken J, Shin Y, Maslia E, Hyman BT, and Mclean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. *J Biol Chem* 279: 25497–25502, 2004.
236. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, and Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. *Mol Cell Biol* 26: 221–229, 2006.
237. Kobayashi M and Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. *Adv Enzyme Regul* 46: 113–140, 2006.
238. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, and Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* 12: 213–223, 2010.
239. Kosaka K and Yokoi T. Carnosic acid, a component of rosemary (*Rosmarinus officinalis* L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells. *Biol Pharm Bull* 26: 1620–1622, 2003.
240. Kraft AD, Johnson DA, and Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. *J Neurosci* 24: 1101–1112, 2004.
241. Kraft AD, Lee JM, Johnson DA, Kan YW, and Johnson JA. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. *J Neurochem* 98: 1852–1865, 2006.
242. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, and Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. *J Neurosci* 17: 5089–5100, 1997.
243. Kruman II and Mattson MP. Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. *J Neurochem* 72: 529–540, 1999.
244. Kuroda K and Takagi K. Physiologically active substance in *Capsella bursa-pastoris*. *Nature* 220: 707–708, 1968.
245. Kuroda K and Akao M. Reduction by fumaric acid of side effects of mitomycin C. *Biochem Pharmacol* 29: 2839–2844, 1980.

246. Lacassagne A, Buu-Hoi NP, and Rudali G. Induction of the carcinogenic action produced by a weakly carcinogenic hydrocarbon on a highly active carcinogenic hydrocarbon. *Br J Exp Pathol* 26: 5–12, 1945.
247. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 $\alpha$ . *Cell* 127: 1109–1122, 2006.
248. Lavu S, Boss O, Elliott PJ, and Lambert PD. Sirtuins—novel therapeutic targets to treat age-associated diseases. *Nat Rev Drug Discov* 7: 841–853, 2008.
249. Lee JM, Shih AY, Murphy TH, and Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. *J Biol Chem* 278: 37948–37956, 2003.
250. Lee SH and Blair IA. Oxidative DNA damage and cardiovascular disease. *Trends Cardiovasc Med* 11: 148–155, 2001.
251. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. *Neurobiol Aging* 30, 1523–1534, 2009.
252. Leonarduzzi G, Chiarpotto E, Biasi F, and Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. *Mol Nutr Food Res* 49: 1044–1049, 2005.
253. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zaroni G, Morrow JD, and Darley-Usmar VM. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. *Biochem J* 378: 373–382, 2004.
254. Lewén A, Matz P, and Chan PH. Free radical pathways in CNS injury. *J Neurotrauma* 17: 871–890, 2000.
255. Li A, Xi Q, Umstot ES, Bellner L, Schwartzman ML, Jaggar JH, and Leffler CW. Astrocyte-derived CO is a diffusible messenger that mediates glutamate-induced cerebral arteriolar dilation by activating smooth muscle cell KCa channels. *Circ Res* 102: 234–241, 2008.
256. Li L and Moore PK. Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? *Trends Pharmacol Sci* 29: 84–90, 2008.
257. Li X, Zhang D, Hannink M, and Beamer LJ. Crystal structure of the Kelch domain of human Keap1. *J Biol Chem* 279: 54750–54758, 2004.
258. Li Y, Xu W, McBurney MW, and Longo VD. SirT1 inhibition reduces IGF-1/IRS-2/Ras/ERK1/2 signaling and protects neurons. *Cell Metab* 8: 38–48, 2008.
259. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. *J Neurosci* 20: 5709–5714, 2000.
260. Lipton SA. Pathologically activated therapeutics for neuroprotection. *Nat Rev Neurosci* 8: 803–808, 2007.
261. Liu D, Chan SL, de Souza-Pinto NC, Slevin JR, Wersto RP, Zhan M, Mustafa K, de Cabo R, and Mattson MP. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. *Neuromol Med* 8: 389–414, 2006.
262. Liu D, Gharavi R, Pitta M, Gleichmann M, and Mattson MP. Nicotinamide prevents NAD<sup>+</sup> depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD<sup>+</sup> consumption by SIRT1 may endanger energetically compromised neurons. *Neuromol Med* 11: 28–42, 2009.
263. Liu D, Pitta M, and Mattson MP. Preventing NAD(+) depletion protects neurons against excitotoxicity: bioenergetic effects of mild mitochondrial uncoupling and caloric restriction. *Ann NY Acad Sci* 1147: 275–282, 2008.
264. Liu H, Dinkova-Kostova AT, and Talalay P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. *Proc Natl Acad Sci USA* 105: 15926–15931, 2008.
265. Lu M, Hu LF, Hu G, and Bian JS. Hydrogen sulfide protects astrocytes against H<sub>2</sub>O<sub>2</sub>-induced neural injury via enhancing glutamate uptake. *Free Rad Biol Med* 45: 1705–1713, 2008.
266. Lu M, Kim HE, Li CR, Kim S, Kwak IJ, Lee YJ, Kim SS, Moon JY, Kim CH, Kim DK, Kang HS, and Park JS. Two distinct disulfide bonds formed in human heat shock transcription factor 1 act in opposition to regulate its DNA binding activity. *Biochemistry* 47: 6007–6015, 2008.
267. Luckey TD. *Radiation Hormesis*. Boca Raton, FL: CRC Press, 1992.
268. Ma ZC, Hong Q, Wang YG, Tan HL, Xiao CR, Liang QD, Zhang BL, and Gao Y. Ferulic acid protects human umbilical vein endothelial cells from radiation induced oxidative stress by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. *Biol Pharm Bull* 33: 29–34, 2010.
269. Macario AJ and Conway de Macario E. Sick chaperones, cellular stress, and disease. *N Engl J Med* 353: 1489–1501, 2005.
270. Macario AJ and Conway de Macario E. Molecular chaperones: multiple functions, pathologies, and potential applications. *Front Biosci* 12: 2588–2600, 2007.
271. Macario AJ and Conway de Macario E. Chaperonopathies by defect, excess, or mistake. *Ann NY Acad Sci* 1113: 178–191, 2007.
272. Madhavan L, Ourednik V, and Ourednik J. Neural stem/progenitor cells initiate the formation of cellular networks that provide neuroprotection by growth factor-modulated antioxidant expression. *Stem Cells* 26: 254–265, 2008.
273. Maines MD and Gibbs PEM. 30 some years of heme oxygenase: From a “molecular wrecking ball” to a “mesmerizing” trigger of cellular events. *Biochem Biophys Res Commun* 338: 568–577, 2005.
274. Maines MD. The heme oxygenase system; a regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* 37: 517–554, 1997.
275. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, Chen L, Zhuang X, Hogg J, Pare P, Tuder RM, and Biswal S. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. *Am J Respir Crit Care Med* 178: 592–604, 2008.
276. Mancuso C, Pani G, and Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. *Redox Rep* 11: 207–213, 2006.
277. Mancuso C, Scapagnini G, Curro D, Giuffrida Stella AM, De Marco C, Butterfield DA, and Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Front Biosci* 12: 1107–1123, 2007.
278. Mark RJ, Hensley K, Butterfield DA, and Mattson MP. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca<sup>2+</sup> homeostasis and cell death. *J Neurosci* 15: 6239–6249, 1995.

279. Mark RJ, Pang Z, Geddes JW, Uchida K, and Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. *J Neurosci* 17: 1046–1054, 1997.
280. Masoro EJ. Role of hormesis in life extension by caloric restriction. *Dose Response* 5: 163–173, 2007.
281. Mattson MP, Goodman Y, Luo H, Fu W, and Furukawa K. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. *J Neurosci Res* 49: 681–697, 1997.
282. Mattson MP. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. *Trends Neurosci* 21: 53–57, 1998.
283. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, and Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. *Trends Neurosci* 23: 222–229, 2000.
284. Mattson MP and Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. *Neuromolecular Med* 2: 215–231, 2002.
285. Mattson MP. Methylation and acetylation in nervous system development and neurodegenerative disorders. *Ageing Res Rev* 2: 329–342, 2003.
286. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature* 430: 631–639, 2004.
287. Mattson MP and Magnus T. Ageing and neuronal vulnerability. *Nat Rev Neurosci* 7: 278–294, 2006.
288. Mattson MP and Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. *Cell Death Differ* 13: 852–860, 2006.
289. Mattson MP, Son TG, and Camandola S. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. *Dose Response* 5: 174–186, 2007.
290. Mattson MP. Calcium and neurodegeneration. *Ageing Cell* 6: 337–350, 2007.
291. Mattson MP and Calabrese EJ. Best in small doses. *The New Scientist* 199, 6 August 2008, pp. 36–39.
292. Mattson MP, Gleichmann M, and Cheng A. Mitochondria in neuroplasticity and neurological disorders. *Neuron* 60: 748–766, 2008.
293. Mattson MP. Awareness of hormesis will enhance future research in basic and applied neuroscience. *Crit Rev Toxicol* 38: 633–639, 2008.
294. Mattson MP. Dietary factors, hormesis and health. *Ageing Res Rev* 7: 43–48, 2008.
295. Maulik N and Das DK. Redox signaling in vascular angiogenesis. *Free Radic Biol Med* 33: 1047–1060, 2002.
296. McCord JM. Superoxide dismutase in aging and disease: an overview. *Methods Enzymol* 349: 331–341, 2002.
297. McCoubrey WK, Huang TJ, and Maines MD. Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. *J Biol Chem* 272: 12568–12574, 1997.
298. McMahan M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, Wolf CR, Cavin C, and Hayes JD. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. *Cancer Res* 61: 3299–3307, 2001.
299. McMahan M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Dimerization of substrate adaptors can facilitate Cullin-mediated ubiquitylation of proteins by a “tethering” mechanism: a two-site interaction model for the Nrf2-Keap1 complex. *J Biol Chem* 281: 24756–24768, 2006.
300. McNally SJ, Harrison EM, Ross JA, Garden OJ, and Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. *Int J Mol Med* 19: 165–172, 2007.
301. Mendes CS, Levet C, Chatelain G, Dourlen P, Fouillet A, Dichtel-Danjoy ML, Gambis A, Ryoo HD, Steller H, and Mollereau B. ER stress protects from retinal degeneration. *EMBO J* 28: 1296–1307, 2009.
302. Michalak M, Robert Parker JM, and Opas M. Ca<sup>2+</sup> signaling and calcium binding chaperones of the endoplasmic reticulum. *Cell Calcium* 32: 269–278, 2002.
303. Miller CA, Campbell SL, and Sweatt JD. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. *Neurobiol Learn Mem* 89: 599–603, 2008.
304. Miller JA and Miller EC. The carcinogenic aminoazo dyes. *Adv Cancer Res* 1: 339–396, 1953.
305. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israeili K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, and Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature* 450: 712–716, 2007.
306. Mitchel REJ. Low doses of radiation are protective *in vitro* and *in vivo*: Evolutionary origins. *Dose Response* 4: 75–90, 2006.
307. Mitchel REJ. Low doses of radiation reduce risk *in vivo*. *Dose Response* 5: 1–10, 2007.
308. Moi P, Chan K, Asunis I, Cao A, and Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proc Natl Acad Sci USA* 91: 9926–9930, 1994.
309. Morimoto RI and Santoro MG. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. *Nat Biotechnol* 16: 833–838, 1998.
310. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. *Genes Dev* 12: 3788–3796, 1998.
311. Morimoto RI. Stress, aging, and neurodegenerative disease. *New Engl J Med* 355: 2254–2255, 2006.
312. Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. *Genes Dev* 22: 1427–1438, 2008.
313. Mothersill C and Seymour CB. Radiation-induced bystander effects and the DNA paradigm: An “out of field” perspective. *Mutat Res* 597: 5–10, 2006.
314. Motohashi H, O'Connor T, Katsuoka F, Engel JD, and Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. *Gene* 294: 1–12, 2002.
315. Motohashi H and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. *Trends Mol Med* 10: 549–557, 2004.
316. Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, and Green CJ. Endothelial Heme oxygenase-1 induction by hypoxia: modulation by inducible nitric oxide synthase (iNOS) and S-nitrosothiols. *J Biol Chem* 275: 13613–13620, 2000.



317. Motterlini R, Foresti R, Bassi R, and Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. *Free Radic Biol Med* 28: 1303–1312, 2000.
318. Muller P, Hrstka R, Coomber D, Lane DP, and Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. *Oncogene* 27: 3371–3383, 2008.
319. Munday R and Munday CM. Induction of phase II enzymes by aliphatic sulfides derived from garlic and onions: an overview. *Methods Enzymol* 382: 449–456, 2004.
320. Naidoo N. ER and aging—protein folding and the ER stress response. *Ageing Res Rev* 8: 150–159, 2009.
321. Nakamura T and Lipton SA. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding. *Cell Death Differ* 14: 1305–1314, 2007.
322. Napoli C and Ignaro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. *Arch Pharm Res* 32: 1103–1108, 2009.
323. Navarro A and Boveris A. Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. *Adv Drug Deliv Rev* 60: 1534–1544, 2008.
324. Nguyen T, Nioi P, and Pickett CB. The nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J Biol Chem* 284: 13291–13295, 2009.
325. Nguyen T, Sherratt PJ, and Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu Rev Pharmacol Toxicol* 43: 233–260, 2003.
326. Ni M and Lee AS. ER chaperones in mammalian development and human diseases. *FEBS Lett* 581: 3641–3651, 2007.
327. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, and van Dijk E. Systemic therapy with fumaric acid derivatives: new possibilities in the treatment of psoriasis. *J Am Acad Dermatol* 20: 601–608, 1989.
328. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, and Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science* 299: 896–893, 2003.
329. Noyan-Ashraf MH, Sadeghinejad Z, and Juurlink BH. Dietary approach to decrease aging-related CNS inflammation. *Nutr Neurosci* 8: 101–110, 2005.
330. Noyan-Ashraf MH, Wu L, Wang R, and Juurlink BH. Dietary approaches to positively influence fetal determinants of adult health. *FASEB J* 20: 371–373, 2006.
331. Nystul TG and Roth MB. Carbon monoxide-induced suspended animation protects against hypoxic damage in *Caenorhabditis elegans*. *Proc Natl Acad Sci USA* 101: 9133–9136, 2004.
332. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, and Yamamoto M. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. *Am J Physiol Gastrointest Liver Physiol* 295: G735–G747, 2008.
333. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, and Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. *Biochem Biophys Res Commun* 339: 79–88, 2006.
334. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, and Arumugam TV. Toll-like receptors in neurodegeneration. *Brain Res Rev* 59: 278–292, 2009.
335. Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M and Nakashima M. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. *Parkinsonism Relat Disord* 15: 649–654, 2009.
336. Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, and Kensler TW. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. *Toxicol Sci* 104: 218–227, 2008.
337. Otterbein LE. Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule. *Antioxid Redox Signal* 4: 309–319, 2002.
338. Otterbein LE, Soares MP, Yamashita K, and Bach F. Heme oxygenase-1: unleashing the protective properties of heme. *Trends Immunol* 24: 449–466, 2003.
339. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, and Soares MP. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. *Nat Med* 9: 183–190, 2003.
340. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, and Kazantsev AG. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. *Science* 317: 516–519, 2007.
341. Outeiro TF, Marques O, and Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. *Biochim Biophys Acta* 1782: 363–369, 2008.
342. Pacchioni AM, Vallone J, Melendez RI, Shih A, Murphy TH, and Kalivas PW. Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity. *Brain Res* 1127: 26–35, 2007.
343. Padmanabhan B, Scharlock M, Tong KI, Nakamura Y, Kang MI, Kobayashi A, Matsumoto T, Tanaka A, Yamamoto M, and Yokoyama S. Purification, crystallization and preliminary X-ray diffraction analysis of the Kelch-like motif region of mouse Keap1. *Acta Crystallogr Sect F Struct Biol Crystalliz Commun* 61: 153–155, 2005.
344. Padmanabhan B, Tong KI, Kobayashi A, Yamamoto M, and Yokoyama S. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1. *J Synchrotron Radiat* 15: 273–276, 2008.
345. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuki M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. *Mol Cell* 21: 689–700, 2006.
346. Panahian N, Yoshiura M, and Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. *J Neurochem* 72: 1187–1203, 1999.
347. Park MK, Choi YM, Kang YK, and Petersen OH. The endoplasmic reticulum as an integrator of multiple dendritic events. *Neuroscientist* 14: 68–77, 2008.
348. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, and Néri C. Resveratrol rescues mutant

- polyglutamine cytotoxicity in nematode and mammalian neurons. *Nat Genet* 37: 349–350, 2005.
349. Parola M, Bellomo G, Robino G, Barrera G, and Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. *Antioxid Redox Signal* 1: 255–284, 1999.
350. Paterniti I, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Galuppo M, Bramanti P, and Cuzzocrea S. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. *J Neurochem* 112: 611–624, 2010.
351. Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Cini C, and Butterfield DA. *In vivo* protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress. *J Neurosci Res* 84: 418–426, 2006.
352. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev, EV, and Tudor RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. *Nat Med* 11: 491–498, 2005.
353. Pfister JA, Ma C, Morrison BE, and D'Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. *PLoS One* 3: e4090, 2008.
354. Piantadosi CA, Zhang J, Levin ED, Folz RJ, and Schmechel DE. Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat. *Exp Neurol* 147: 103–114, 1997.
355. Piantadosi CA. Carbon monoxide, reactive oxygen signaling, and oxidative stress. *Free Radic Biol Med* 45: 562–569, 2008.
356. Prestera T, Zhang Y, Spencer SR, Wilczak CA, and Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. *Adv Enzyme Regul* 33: 281–296, 1993.
357. Prochaska HJ and Santamaria AB. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. *Anal Biochem* 169: 328–336, 1988.
358. Prochaska HJ, Bregman HS, De Long MJ, and Talalay P. Specificity of induction of cancer protective enzymes by analogues of tert-butyl-4-hydroxyanisole (BHA). *Biochem Pharmacol* 34: 3909–3914, 1985.
359. Prochaska HJ, De Long MJ, and Talalay P. On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. *Proc Natl Acad Sci USA* 82: 8232–8236, 1985.
360. Prochaska HJ, Santamaria AB, and Talalay P. Rapid detection of inducers of enzymes that protect against carcinogens. *Proc Natl Acad Sci USA* 89: 2394–2398, 1992.
361. Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schröter F, Ninnemann O, Siegert E, Bendix I, Brüstle O, Nitsch R, Zipp F, and Aktas O. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. *Nat Cell Biol* 10: 385–394, 2008.
362. Przemyslaw W, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, and Kaasik A. PGC-1[alpha] AND PGC-1[beta] regulate mitochondrial density in neurons. *J Biol Chem* 284: 21379–21385, 2009.
363. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA and, Pasinetti GM. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. *J Biol Chem* 281: 21745–21754, 2006.
364. Qu K, Lee SW, Bian JS, Low CM, and Wong PT. Hydrogen sulfide: neurochemistry and neurobiology. *Neurochem Int* 52, 155–165, 2008.
365. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kempainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J, and Wooten MW. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. *J Neurochem* 106: 107–120, 2008.
366. Randall WA, Price CW, and Welch H. Demonstration of hormesis (increase in fatality rate) by penicillin. *Am J Pub Health* 37: 421–425, 1947.
367. Redpath JL. Suppression of neoplastic transformation *in vitro* by low doses of low LET radiation. *Dose Response* 4: 302–308, 2006.
368. Redpath JL and Elmore E. Radiation-induced neoplastic transformation *in vitro*, hormesis and risk assessment. *Dose Response* 5: 123–130, 2007.
369. Reisman SA, Yeager RL, Yamamoto M, and Klaassen CD. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. *Toxicol Sci* 108: 35–47, 2009.
370. Robertson CH, Griffin AC, and Richardson HL. The inhibitory action of p-hydroxypropiophenone on hepatic carcinoma induced by azo dye. *J Natl Cancer Inst* 15: 519–527, 1954.
371. Riegel B, Wartman WB, Hill WT, Reeb BB, Shubik P, and Stanger DW. Delay of methylcholanthrene skin carcinogenesis in mice by 1,2,5,6-dibenzofluorene. *Cancer Res* 11: 301–303, 1951.
372. Ristow M, Zarse K, Oberbach A, Klötting N, Birringer M, Kiehnopf M, Stumvoll M, Kahn CR, Blüher M. Antioxidants prevent health-promoting effects of physical exercise in humans. *Proc Natl Acad Sci USA* 106: 8665–8670, 2009.
373. Rossi A, Trotta E, Brandi R, Arisi I, Coccia, and Santoro MG. AIRAP: a new human Heat shock gene regulated by Heat shock factor 1. *J Biol Chem* 285: 13607–13615, 2010.
374. Roth MB and Nystul T. Buying time in suspended animation. *Sci Am* 292: 48–55, 2005.
375. Rushmore TH and Pickett CB. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. *J Biol Chem* 265: 14648–14653, 1990.
376. Rushmore TH, Morton MR, and Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. *J Biol Chem* 266: 11632–11639, 1991.
377. Sachdev S and Davies KJ. Production, detection, and adaptive responses to free radicals in exercise. *Free Radic Biol Med* 44: 215–223, 2008.
378. Sadruddin S and Arora R. Resveratrol: biologic and therapeutic implications. *J Cardiometa Syndr* 4: 102–106, 2009.
379. Sagan LA. On radiation, paradigms, and hormesis. *Science* 245: 574–621, 1989.
380. Saibil HR. Chaperone machines in action. *Curr Opin Struct Biol* 18: 35–42, 2008.
381. Sakai K, Nomura T, and Ina Y. Enhancement of bio-protective functions by low dose/dose-rate radiation. *Dose Response* 4: 327–332, 2006.
382. Salminen A, Kauppinen A, Suuronen T, and Kaarniranta K. SIRT1 longevity factor suppresses NF-kappaB -driven

- immune responses: regulation of aging via NF-kappaB acetylation? *Bioessays* 30: 939–942, 2008.
383. Salminen A and Kaarniranta K. SIRT1 regulates the ribosomal DNA locus: epigenetic candles twinkle longevity in the Christmas tree. *Biochem Biophys Res Commun* 378: 6–9, 2009.
384. Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB, and Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. *Int J Radiat Oncol Biol Phys* 75: 534–542, 2009.
385. Satoh T and Lipton SA. Redox regulation of neuronal survival mediated by electrophilic compounds. *Trends Neurosci* 30: 37–45, 2007.
386. Satoh T, Kosaka K, Itoh K, Kobayashi A, Yamamoto M, Shimajo Y, Kitajima C, Cui J, Kamins J, Okamoto S, Izumi M, Shirasawa T, and Lipton SA. Carnosic acid, a catechol-type electrophilic compound, protects neurons both *in vitro* and *in vivo* through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. *J Neurochem* 104: 1116–1131, 2008.
387. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K, and Lipton SA. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. *Proc Natl Acad Sci USA* 103: 768–773, 2006.
388. Satoh T, Saitoh S, Hosaka M, and Kosaka K. Simple ortho- and para-hydroquinones as compounds neuroprotective against oxidative stress in a manner associated with specific transcriptional activation. *Biochem Biophys Res Commun* 379: 537–541, 2009.
389. Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, and Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. *Antioxid Redox Signal* 6: 811–818, 2004.
390. Scapagnini G, Colombrita C, Amadio M, D'Agata V, Arcelli E, Sapienza M, Quattrone A, and Calabrese V. Curcumin activates defensive genes and protects neurons against oxidative stress. *Antioxid Redox Signal* 8: 395–403, 2006.
391. Schilling S, Goelz S, Linker R, Luehder F, and Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. *Clin Exp Immunol* 145: 101–107, 2006.
392. Schmirgk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, and Przuntek H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. *Eur J Neurol* 13: 604–610, 2006.
393. Schipper HM. Heme oxygenase-1: role in brain aging and neurodegeneration. *Exp Gerontol* 35: 821–830, 2000.
394. Schipper HM, Song W, Zukor H, Hascalovici JR, and Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. *J Neurochem* 110: 469–485, 2009.
395. Schmidt U, Holsboer F, and Rein T. Role of the hsp70 co-chaperone BAG1 in glucocorticoid receptor function and stress-related diseases. *Proc Natl Acad Sci USA* 105: E101, 2008.
396. Schulz H. Über Hefegifte. *Pfluger's Archiv Gesammte Physiol* 42: 517–541, 1888.
397. Scott BR and DiPalma J. Sparsely ionizing diagnostic and natural background radiations are likely preventing cancer and other genomic-instability-associated diseases. *Dose Response* 5: 230–255, 2006.
398. Scott BR. It's time for a new low-dose-radiation risk assessment paradigm—one that acknowledges hormesis. *Dose Response* 6: 333–351, 2008.
399. Sergent O, Griffon B, Morel I, Chevanne M, Dubos MP, Cillard P, and Cillard J. Effect of nitric oxide on iron-mediated oxidative stress in primary rat hepatocyte culture. *Hepatology* 25: 122–127, 1977.
400. Sethi G, Ahn KS, Pandey MK, and Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF- $\kappa$ B activation. *Blood* 109: 2727–2735, 2007.
401. Sethi JM, Otterbein LE, and Choi AM. Differential modulation of exogenous carbon monoxide of TNF-alpha stimulated mitogen-activated protein kinases in rat pulmonary artery endothelial cells. *Antioxid Redox Signal* 4: 241–248, 2002.
402. Shan X, Chi L, Ke Y, Luo C, Qian S, Gozal D, and Liu R. Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage. *Neurobiol Dis* 28: 206–215, 2007.
403. Sharma SK, Christen P, and Goloubinoff P. Disaggregating chaperones: an unfolding story. *Curr Protein Pept Sci* 10: 432–446, 2009.
404. Shibuya N, Mikami Y, Kimura Y, Nagahara N, and Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J Biochem* 146: 623–626, 2009.
405. Shih AY, Erb H, and Murphy TH. Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. *J Neurochem* 101: 109–119, 2007.
406. Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P, and Murphy TH. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress *in vivo*. *J Biol Chem* 280: 22925–22936, 2005.
407. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, and Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *J Neurosci* 23: 3394–33940, 2003.
408. Shih AY, Li P, and Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia *in vivo*. *J Neurosci* 25: 10321–10335, 2005.
409. Shimazu T, Horinouchi S, and Yoshida M. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3'-end processing. *J Biol Chem* 282: 4470–4478, 2007.
410. Siebert A, Desai V, Chandrasekaran K, Fiskum G, and Jafri MS. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. *J Neurosci Res* 87: 1659–1669, 2009.
411. Siems W, Carluccio F, Radenkovic S, Grune T, and Hampl H. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. *Kidney Blood Press Res* 28: 295–301, 2005.
412. Siow RC, Ishii T, and Mann GE. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. *Redox Rep* 12: 11–15, 2007.
413. Sirabella R, Secondo A, Pannaccione A, Scorziello A, Valsecchi V, Adornetto A, Bilo L, Di Renzo G, and Annunziato L. Anoxia-induced NF-kappaB-dependent upregulation of NCX1 contributes to Ca<sup>2+</sup> refilling into endoplasmic reticulum in cortical neurons. *Stroke* 40: 922–929, 2009.

414. Sjöstrand T. Endogenous formation of carbon monoxide in man under normal and pathological conditions. *Scand J Clin Lab Invest* 1: 201–214, 1949.
415. Smith EL and Schuchman EH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. *FASEB J* 22: 3419–3431, 2008.
416. Söti C and Csermely P. Aging cellular networks: chaperones as major participants. *Exp Gerontol* 42: 113–119, 2007.
417. Söti C and Csermely P. Protein stress and stress proteins: implications in aging and disease. *J Biosci* 32: 511–515, 2007.
418. Söti C, Nagy E, Giricz Z, Vigh L, Csermely P, and Ferdinandy P. Heat shock proteins as emerging therapeutic targets. *Br J Pharmacol* 146: 769–780, 2005.
419. Sporn VL, Barany G, and Wattenberg LW. Effects of organosulfur compounds from garlic and onions on benzo[a]pyrene-induced neoplasia and glutathione S-transferase activity in the mouse. *Carcinogenesis* 9: 131–134, 1988.
420. Spencer SR, Wilczak CA, and Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. *Cancer Res* 50: 7871–7875, 1990.
421. Spencer SR, Xue LA, Klenz EM, and Talalay P. The potency of inducers of NAD(P)H:(quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases. Structural and electronic correlations. *Biochem J* 1: 711–717, 1991.
422. Stanford SJ, Walters MJ, and Mitchell JA. Carbon monoxide inhibits endothelin-1 release by human pulmonary artery smooth muscle cells. *Eur J Pharmacol* 486: 349–352, 2004.
423. Stebbing ARD. Effects of low metal levels on a clonal hydroid. *J Marine Biol Assoc UK* 56: 977–994, 1976.
424. Stebbing ARD. Hormesis—the stimulation of growth by low-levels of inhibitors. *Sci Total Environ* 22: 213–234, 1982.
425. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, and Ames BN. Bilirubin is an antioxidant of possible physiological importance. *Science* 235: 1043–1046, 1987.
426. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, and Boersma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. *Br J Dermatol* 144: 1114–1120, 2001.
427. Suliman HB, Carraway MS, Tatro LG, and Piantadosi CA. A new activating role for CO in cardiac mitochondrial biogenesis. *J Cell Sci* 120: 299–308, 2007.
428. Summers SA. Ceramides in insulin resistance and lipotoxicity. *Prog Lipid Res* 45: 42–72, 2006.
429. Sun MM, Bu H, Li B, Yu JX, Guo YS, and Li CY. Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. *Neurol Res* 31: 23–27, 2009.
430. Suzuki K and Koike T. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (Wlds) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. *Biochem Biophys Res Commun* 359: 665–671, 2007.
431. Sykes PJ, Morley AA, and Hooker AM. The pKZ1 recombination mutation assay: a sensitive assay for low dose studies. *Dose Response* 4: 91–105, 2006.
432. Sykes PJ and Day TK. Requirements for identification of low dose and non-linear mutagenic responses to ionizing radiation. *Dose Response* 5: 308–314, 2007.
433. Szabadi E. Model of 2 functionally antagonistic receptor populations activated by same agonist. *J Theor Biol* 69: 101–112, 1977.
434. Szabó C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 6: 917–935, 2007.
435. Talalay P, Batzinger RP, Benson AM, Bueding E, and Cha YN. Biochemical studies on the mechanisms by which dietary antioxidants suppress mutagenic activity. *Adv Enzyme Regul* 17: 23–36, 1978.
436. Talalay P and Benson AM. Elevation of quinone reductase activity by anticarcinogenic antioxidants. *Adv Enzyme Regul* 20: 287–300, 1982.
437. Talalay P, De Long MJ, and Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. *Proc Natl Acad Sci USA* 85: 8261–8265, 1988.
438. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. *Biofactors* 12: 5–11, 2000.
439. Talalay P, Dinkova-Kostova AT, and Holtzclaw WD. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. *Adv Enzyme Regul* 43: 121–134, 2003.
440. Talalay P and Dinkova-Kostova AT. Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. *Methods Enzymol* 382: 355–364, 2004.
441. Talalay P, Fahey JW, Healy ZR, Wehage SL, Benedict AL, Min C, and Dinkova-Kostova AT. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. *Proc Natl Acad Sci USA* 104: 17500–17505, 2007.
442. Tan BH, Wong PT, and Bian JS. Hydrogen sulfide: a novel signaling molecule in the central nervous system. *Neurochem Int* 56: 3–10, 2010.
443. Tangerman A. Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices. *J Chromatogr B* 877: 3366–3377, 2009.
444. Teiten MH, Eifes S, Reuter S, Duvoix A, Dicato M, and Diederich M. Gene expression profiling related to anti-inflammatory properties of curcumin in K562 leukemia cells. *Ann NY Acad Sci* 1171: 391–398, 2009.
445. Tenhunen R, Marver HS, and Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. *J Biol Chem* 244: 6388–6394, 1969.
446. Terada LS. Specificity in reactive oxidant signaling: think globally, act locally. *J Cell Biol* 174: 615–623, 2006.
447. Thom ER, Fisher D, Xu YA, Notarfrancesco K, and Ischiropoulos H. Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide. *Proc Natl Acad Sci USA* 97: 1305–1310, 2000.
448. Thong H-Y and Maibach HI. Hormesis [biological effects of low level exposure (BELLE)] and dermatology. *Dose Response* 6: 1–15, 2008.
449. Tong KI, Kobayashi A, Katsuoka F, and Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. *Biol Chem* 387: 1311–1320, 2006.
450. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. *Mol Cell Biol* 26: 2887–2900, 2006.
451. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, and Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. *Mol Cell Biol* 27: 7511–7521, 2007.

452. Trott A, West JD, Klaić L, Westerheide SD, Silverman RB, Morimoto RI, and Morano KA. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. *Mol Biol Cell* 19: 1104–1112, 2008.
453. Turcanu V, Dhouib M, and Poindron P. Nitric oxide synthase inhibition by haem oxygenase decreases macrophagenitric-oxide-dependent cytotoxicity: a negative feedback mechanism for the regulation of nitric oxide production. *Res Immunol* 149: 741–744, 1998.
454. Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY, and Cho JY. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. *Int J Mol Med* 22: 529–539, 2008.
455. Umemura K and Kimura H. Hydrogen sulfide enhances reducing activity in neurons: neurotrophic role of H<sub>2</sub>S in the brain? *Antioxid Redox Signal* 9: 2035–2041, 2007.
456. Vargas MR, Johnson DA, Sirkis DW, Messing A, and Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. *J Neurosci* 28: 13574–13581, 2008.
457. Verkhatsky A. The endoplasmic reticulum and neuronal calcium signalling. *Cell Calcium* 32: 393–404, 2002.
458. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, and Snyder SH. Carbon monoxide: a putative neural messenger. *Science* 259: 381–384, 1993.
459. Violi F, Marino R, Milite MT, and Loffredo L. Nitric oxide and its role in lipid peroxidation. *Diabetes Metab Res Rev* 15: 283–288, 1999.
460. Wagner F, Asfar P, Calzia E, Radermacher P, and Szabó C. Bench-to-bedside review: Hydrogen sulfide—the third gaseous transmitter: applications for critical care. *Crit Care* 13: 213, 2009.
461. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW, and Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. *Proc Natl Acad Sci USA* 101: 2040–2045, 2004.
462. Wang W, Fang H, Groom L, Cheng A, Zhang W, Liu J, Wang X, Li K, Han P, Zheng M, Yin J, Wang W, Mattson MP, Kao JP, Lakatta EG, Sheu SS, Ouyang K, Chen J, Dirksen RT, and Cheng H. Superoxide flashes in single mitochondria. *Cell* 134: 279–290, 2008.
463. Wattenberg LW. Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin. *J Natl Cancer Inst* 48: 1425–1430, 1972.
464. Wattenberg LW, Coccia JB, and Lam LK. Inhibitory effects of phenolic compounds on benzo(a)pyrene-induced neoplasia. *Cancer Res* 40: 2820–2823, 1980.
465. Welch H, Price CW, and Randall WA. Increase in fatality rate of *E. Typhosa* for white mice by streptomycin. *J Am Pharm* 35: 155–158, 1946.
466. Westerheide SD, Anckar J, Stevens SM, Sistonen L Jr., and Morimoto RI. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. *Science* 323: 1063–1066, 2009.
467. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, Gu W, Devlin JP, Silverman RB, and Morimoto RI. Celastrols as inducers of the heat shock response and cytoprotection. *J Biol Chem* 279: 56053–56060, 2004.
468. Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, and Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. *J Neuroimmunol* 166: 132–143, 2005.
469. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kaye R, Glabe CG, Frautschy SA, and Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid *in vivo*. *J Biol Chem* 280: 5892–5901, 2005.
470. Yao CJ, Lin CW, and Lin-Shiau SY. Roles of thapsigargin-sensitive Ca<sup>2+</sup> stores in the survival of developing cultured neurons. *J Neurochem* 73: 457–465, 1999.
471. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, and Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid treated mice. *Carcinogenesis* 30: 1024–1031, 2009.
472. Yoshida T and Owens GK. Molecular determinants of vascular smooth muscle cell diversity. *Circ Res* 96: 280–291, 2005.
473. Young LJ and Caughey WS. Oxygenation of carbon monoxide by bovine heart cytochrome c oxidase. *Biochemistry* 25: 152–161, 1986.
474. Yu Z, Luo H, Fu W, and Mattson MP. The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. *Exp Neurol* 155: 302–314, 1999.
475. Yu ZF and Mattson MP. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. *J Neurosci Res* 57: 830–839, 1999.
476. Yu ZF, Nikolova-Karakashian M, Zhou D, Cheng G, Schuchman EH, and Mattson MP. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. *J Mol Neurosci* 15: 85–97, 2000.
477. Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. *Mol Cell Biol* 23: 8137–8151, 2003.
478. Zhang K and Kaufman RJ. Protein folding in the endoplasmic reticulum and the unfolded protein response. *Handb Exp Pharmacol* 172: 69–91, 2006.
479. Zhang K, Zhao T, Huang X, Liu ZH, Xiong L, Li MM, Wu LY, Zhao YQ, Zhu LL, and Fan M. Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. *Cell Stress Chaperones* 14: 407–415, 2009.
480. Zhang Y and Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. *Acta Pharmacol Sin* 28: 1343–1354, 2007.
481. Zhang Y, Talalay P, Cho CG, and Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. *Proc Natl Acad Sci USA* 89: 2399–2403, 1992.
482. Zhao J, Kobori N, Aronowski J, and Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. *Neurosci Lett* 393: 108–112, 2006.
483. Zhao J, Moore AN, Clifton GL, and Dash PK. Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. *J Neurosci Res* 82: 499–506, 2005.

484. Zhao J, Moore AN, Redell JB, and Dash PK. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. *J Neurosci* 27: 10240–10248, 2007.
485. Zhao X, Sun G, Zhang J, Strong R, Dash PK, Kan YW, Grotta JC, and Aronowski J. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. *Stroke* 38: 3280–3286, 2007.
486. Zhou P, Qian L, and Iadecola C. Nitric oxide inhibits caspase activation and apoptotic morphology but does not rescue neuronal death. *J Cereb Blood Flow Metab* 25: 348–357, 2005.
487. Zlotkin S. A new approach to control of anemia in “at risk” infants and children around the world. 2004 Ryley-Jeffs memorial lecture. *Can J Diet Pract Res* 65: 136–138, 2004.

Address correspondence to:

Prof. Vittorio Calabrese  
Department of Chemistry  
University of Catania  
Via Andrea Doria  
95100 Catania  
Italy

E-mail: calabres@unict.it

Date of first submission to ARS Central, December 23, 2009; date of final revised submission, April 27, 2010; date of acceptance, May 1, 2010.

#### Abbreviations Used

AD = Alzheimer's disease  
AMPK = AMP-activated protein kinase  
AOE = antioxidant enzyme  
ARE = antioxidant response element  
BDNF = brain-derived neurotrophic factor  
CBS = cystathionine  $\beta$ -synthase  
CO = carbon monoxide  
CoQ = coenzyme Q10  
CREB = cyclic AMP response element binding protein  
CSE = cystathionine  $\gamma$ -lyase  
cyclic GMP = cyclic guanosin monophosphate  
Cys = cysteine  
CytC = cytochrome c  
eNOS = endothelial NOS  
ER = endoplasmic reticulum  
ERR = estrogen-related receptor  
ETS = electron transport system  
FA = ferulic acid  
FH = forkhead transcription factor  
GFAP = glial fibrillary acidic protein  
GRP = glucose regulated protein  
GSH = reduced glutathione  
GST = glutathione S-transferase

H<sub>2</sub>S = hydrogen sulfide  
HD = Huntington's disease  
HDAC = histone deacetylase  
HIF-1 = hypoxia-inducible factor 1  
HMOX1 = *ho-1* gene  
HNE = 4-hydroxynonenal  
HO-1 = Heme oxygenase-1  
HSE = heat shock elements  
HSF = heat shock transcription factor  
Hsp = heat shock protein  
HSR = heat shock response  
IFN = interferon  
IL = interleukin  
iNOS = inducible NOS  
JNK = jun N-terminal kinase  
K<sub>ATP</sub> = ATP-dependent K<sup>+</sup>  
Keap1 = Kelch-like ECH-associated protein 1  
LPS = lipopolysaccharide  
MAPK = mitogen-activated protein kinase  
MPST = 3-mercaptopyruvate sulfur transferase  
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
NAD<sup>+</sup> = oxidized nicotinamide adenine dinucleotide  
NADPH = nicotinamide adenine dinucleotide phosphate  
NAD(P)H = reduced nicotinamide adenine dinucleotide phosphate  
NF $\kappa$ B = nuclear factor- $\kappa$ B  
NMDA = N-methyl-D-aspartate  
nNOS = neuronal NOS  
NO = nitric oxide  
NOS = NO synthase  
NQO1 = NAD(P)H quinone oxidoreductase 1  
Nrf2 = Nuclear factor-erythroid 2 p45-related factor 2  
PD = Parkinson's disease  
PDK = pyruvate dehydrogenase kinase  
PGC-1 $\alpha$  = peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$   
PI3K = phosphatidylinositol 3-kinase  
PMRS = plasma membrane redox system  
PPAR $\gamma$  = peroxisome proliferator-activated receptor  $\gamma$   
PTP = permeability transition pore  
R-FeS = Rieske-iron sulfur  
ROS = reactive oxygen species  
RSNO = S-nitrosothiols  
RyR = ryanodine receptor  
SERCA = sarco endoplasmic reticulum calcium ATPase  
SIRT = silent information regulator two  
SMase = sphingomyelinase  
SOD = superoxide dismutase  
SPT = serine palmitoyl CoA transferase  
tBHQ = tert-butyl hydroquinone  
TCA = tricarboxylic acid cycle  
TNF = tumor necrosis factor  
UCP = uncoupling protein  
UPR = unfolded protein response  
VDAC = voltage-dependent anion channel



